{
  "102-1.xlsx": {},
  "103-1.xlsx": {},
  "103-2.xlsx": {},
  "103-3.xlsx": {},
  "105-1.xlsx": {},
  "105-2.xlsx": {},
  "105-3.xlsx": {},
  "105-4.xlsx": {},
  "106-1.xlsx": {},
  "114-1.xlsx": {
    "离子阱": [
      "10-4000",
      "2000-4000",
      "中等",
      "一般较少单独使用"
    ],
    "四极杆": [
      "10-4000",
      "2000-4000",
      "较慢",
      "一般用三个四极杆串\n联使用（三重四极杆）"
    ],
    "飞行时间": [
      "无限制",
      "5000-60000",
      "快",
      "一般和四极杆联用\n（Q-TOF）"
    ],
    "轨道阱": [
      "<6000",
      "<960000",
      "较慢",
      "一般和四极杆联用"
    ]
  },
  "117-1.xlsx": {
    "蛋白质表达谱": [
      "主要目标是对蛋白质混合物进行分离、鉴定及图谱化，展现待\n测样品中的蛋白质的表达全貌（全谱）或者样品间蛋白质的表达\n差异，即蛋白质表达量在不同时间、不同条件下的动态变化"
    ],
    "蛋白质修饰谱": [
      "翻译后修饰是蛋白质在翻译后的化学修饰，可以调节蛋白质的活\n性、定位、结构以及蛋白质与大分子间的相互作用。蛋白质修饰\n组分析用于鉴定翻译后修饰的蛋白质，及其修饰位点，确定修饰\n的功能以及在细胞功能网络中修饰蛋白的相互作用"
    ],
    "蛋白质互作谱": [
      "蛋白质互作谱的测定是通过分离蛋白质复合物，系统地研究蛋白\n质间的相互作用，以建立细胞内信号转导通路的复杂网络图并揭\n示其功能线索，是蛋白质组研究中的重要环节，也是沟通生物大\n分子水平到细胞水平的桥梁研究"
    ],
    "空间蛋白质组学": [
      "蛋白质亚细胞定位受到严格控制，许多蛋白质响应刺激，扰动或\n疾病而改变定位。基于高通量成像、细胞器分离技术、亲和富集\n和质谱分析技术，空间蛋白质组学针对细胞内蛋白质的亚细胞定\n位来研究不同细胞环境对蛋白质功能的影响，有助于更全面了解\n细胞复杂性"
    ],
    "化学蛋白质组学": [
      "化学蛋白质组学主要是利用具有生物活性的小分子作为化学分\n子探针，探测与蛋白质组的相互作用，从而揭示小分子与靶标蛋\n白结合。其中应用最广的是基于活性的蛋白质组分析技术\n（activity-based protein profiling ABPP），利用活性探针共价连\n接位于靶点蛋白活性中心的某个氨基酸位点，再利用探针中的报\n告基团进行富集，用质谱分析对富集到的蛋白进行鉴定"
    ],
    "药物蛋白质组学": [
      "药物蛋白质组学是指在药物干预前后对细胞、组织或器官的蛋\n白质组进行分析，结合药物敏感数据，鉴定出可以预测药物疗\n效的蛋白质标签。在精准医学高速发展的大背景下，药物蛋白\n质组学对于合理用药和个性化医疗有关键的驱动作用"
    ],
    "单细胞蛋白质组学": [
      "临床样本，特别是肿瘤样本的异质性是组学分析的主要瓶颈之\n一，按照不同的细胞亚型将临床样本进行细分是精准医学的必\n然方向。近年来，单细胞蛋白质组学已经成为蛋白质组学最热\n门的方向之一，在 103到 104数量级的细胞水平上对蛋白质组进\n行有效分析，加深对不同种类细胞之间相互作用的理解"
    ]
  },
  "119-1_120-1.xlsx": {
    "药物靶点的发现": [
      "1、利用蛋白质组学比较分析病灶组织和正常组织的蛋白质表达谱，发现特\n异性异常表达的蛋白质，筛选潜在的药物靶点 \n2、通过分析敲除、敲低候选药物靶点的细胞模型中的蛋白质和翻译后修饰\n的表达量，理解该药物靶点蛋白在疾病发生发展中的作用和机理"
    ],
    "应用领域": [
      "具体应用"
    ],
    "药物开发": [
      "1、通过基于生物标志物发现的蛋白质组学研究，助力精准药物研发。借助\n大规模分析和临床试验样本中潜在的生物标志物，可以实现药物适应症患者\n群体的精准筛选、细分适应症的精准划分或新适应症的开发 \n2、另一方面，蛋白质组分析也可以对既有药物进行生产成分鉴定和质量控\n制，或者辅助探索药物剂型的改良和升级"
    ],
    "临床诊断": [
      "1、伴随诊断。利用蛋白质组学方法鉴定伴随诊断的生物标志物，随后开发\n诊断试剂盒用于临床辅助诊断、伴随诊断（POCT） \n2、精准疗效预判/病情监控。借助蛋白质组分析，针对不同患者的蛋白标志\n物进行药物治疗的疗效预判，或者监控治疗期间患者的蛋白标志物水平变化\n用于病情评估 \n3、精准疗效评估/预后评估。用药疗程后评估患者治疗效果或者预测患者的\n预后及复发概率"
    ]
  },
  "120-2.xlsx": {
    "精准药物研发": [
      "传统药物研发具有成本高、效率低、周期长的特点。蛋白质组学在药物研\n发过程中不仅可以进行药物结构鉴定和分析，还能够参与临床样本的分析，\n筛选出具有临床意义的生物标志物，帮助药物开发筛选和聚焦合适的病人\n群体和细分适应症，从而提升研发效率，实现精准药物研发"
    ],
    "精准疾病分型与诊断": [
      "疾病的精准分型与诊断在精准医疗中扮演着重要的角色，对患者进行分子\n分型和个性化的诊断已成为诸如肺癌等疾病不可或缺的环节。蛋白质组学\n能够通过临床样本分析进行患者亚群的精准分型，也可以通过开发体外诊\n断试剂盒应用于疾病的精准诊断，辅助医生进行用药决策"
    ],
    "精准治疗": [
      "疾病诊断后的精准治疗要求医生能够借助患者的诊断信息制定个性化的用\n药方案并且实时观测疗效、调整用药方案。蛋白质组分析能够通过检测临\n床样品从而分析在患者用药过程中体内生物标志物的整体变化水平，借助\n精准且高灵敏的方式辅助临床医生调整用药方案"
    ],
    "精准预后分析": [
      "精准医学中的精准预后分析包括在治疗前的预后预判和治疗后的随访分析\n两个方面。蛋白质组学能够通过高通量、高灵敏度、高重复性和高精准度\n的方式分析单个样本或结合大数据样本进行对比分析，从而能够实现疗效\n的预判或者针对接受治疗后的患者进行长期随访分析"
    ]
  },
  "127-1.xlsx": {
    "抗体产品类型": [
      "抗体科研试剂",
      "体外诊断抗体原料",
      "抗体药物"
    ],
    "概览": [
      "在科学研究中，科研抗\n体通常通过抗原-抗体\n的特异性反应，检测特\n定的蛋白，从而达到对\n于目标蛋白分子的定性\n和定量检测。",
      "在免疫诊断中，抗体作\n为关键的诊断原料，通\n过免疫反应检测血液或\n体液样本中的特定物\n质，提供病人的生理/\n病理状态信息。或通过\n对病理组织中疾病特异\n关联蛋白的免疫检测，\n进行准确的疾病诊断。",
      "作为较为新型的大分子\n靶向药物，可以激活、\n抑制或改变特定细胞或\n分子的内源性免疫反\n应，从而达到特定疾病\n的治疗作用。"
    ]
  },
  "129-1.xlsx": {
    "酶联免疫吸附测定（ELISA）": [
      "ELISA（Enzyme-Linked Immunosorbent Assay）的原理是基于抗体/抗原\n的特异性结合，它不仅能够对特定的蛋白进行定量分析，还可以研究分\n子之间的相互作用或其他特性。"
    ],
    "蛋白质免疫印迹 （WB）": [
      "WB（Western Blotting）原理是通过特异性抗体对凝胶电泳处理过的细胞\n或生物组织样品进行着色，通过分析着色的位置和着色深度获得特定蛋\n白质在所分析的细胞或组织中表达情况的信息。抗体是目前蛋白免疫印\n迹技术中最常用的标记探针。"
    ],
    "免疫组织化学（IHC）": [
      "IHC（Immunohistochemistry）是应用免疫学及组织化学原理，对组织切\n片或细胞标本中的某些化学成分，进行原位的定性、定位或定量的研究。\n免疫组化利用了抗体与抗原的结合具有高度特异性的特点。"
    ],
    "流式细胞术（FCM）": [
      "FCM（Flow Cytometry）流式细胞术是一种对快速直线流动状态中的单\n列细胞或生物颗粒进行逐个、多参数、快速的定性、定量分析或分选的\n技术，具有检测速度快、测量参数多、采集数据量大、分析全面、分选\n纯度高、方法灵活等特点。利用特异性的抗体对细胞或生物颗粒进行标\n记，从而实现对其检测、分选。"
    ],
    "免疫沉淀（IP）": [
      "IP（Immunoprecipitation）是利用抗体可与抗原特异性结合的特性，将抗\n原（常为靶蛋白）从混合体系沉淀下来，初步分离靶蛋白的一种方法。"
    ],
    "酶联免疫斑点 （ELISPOT）": [
      "ELISPOT（Enzyme-Linked Immunospot Assay）技术是利用预先包被好\n抗原或抗体的微量板从单细胞水平检测特异性抗体分泌细胞或特异性\n细胞因子（cytokineCK）分泌细胞的免疫学检测技术。"
    ],
    "染色质免疫共沉淀（ChIP）": [
      "ChIP（Chromatin ImmunoPrecipitation）染色质免疫共沉淀技术的原理是\n在活细胞状态下固定蛋白质－DNA复合物，并将其随机切断为一定长度\n范围内的染色质小片段，然后通过特异性的抗体特异性地富集目的蛋白\n结合的DNA片段，通过对目的片断的纯化与检测，从而获得蛋白质与\nDNA相互作用的信息。"
    ],
    "免疫斑点试验（DIBA）": [
      "免疫斑点试验（Dot Immunobinding Assay DIBA）是利用硝酸纤维素膜\n（N、C或醋酸纤维素膜作为固相支持物，进行抗原抗体反应的免疫学\n检测方法。该法具有微量、快速、经济、方便等特点，可用于检测抗体\n或抗原。近年来已较多地应用于医学基础研究和疾病的诊断。"
    ]
  },
  "13-1_14-1.xlsx": {
    "景杰有限": [
      "指",
      "杭州景杰生物科技股份有限公司前身，杭州景杰生物科技有限\n公司"
    ],
    "控股股东": [
      "指",
      "蒋旦如、程仲毅"
    ],
    "实际控制人": [
      "指",
      "Yingming Zhao、程仲毅、蒋旦如"
    ],
    "上海江村": [
      "指",
      "上海江村市隐投资发展有限公司，曾用名为上海绿谷道生中医\n文化传播有限公司（其于2015年10月12日改为目前名称）"
    ],
    "国投创业基金": [
      "指",
      "国投（上海）科技成果转化创业投资基金企业（有限合伙）"
    ],
    "杭州哲驰": [
      "指",
      "杭州哲驰科技合伙企业（有限合伙）"
    ],
    "珠海瑛杰": [
      "指",
      "珠海瑛杰管理咨询企业（有限合伙）"
    ],
    "成都博远": [
      "指",
      "成都博远嘉昱创业投资合伙企业（有限合伙）"
    ],
    "苏州隆门六号": [
      "指",
      "苏州隆门六号医药投资合伙企业（有限合伙）"
    ],
    "达晨创鸿": [
      "指",
      "深圳市达晨创鸿私募股权投资企业（有限合伙）"
    ],
    "福州泰弘": [
      "指",
      "福州泰弘景晖股权投资合伙企业（有限合伙）"
    ],
    "西藏数联": [
      "指",
      "西藏数联投资有限公司"
    ],
    "青岛正永": [
      "指",
      "青岛正永智麟创业投资合伙企业（有限合伙），曾用名为西藏\n鼎石投资创业管理合伙企业（有限合伙）"
    ],
    "浙江和信": [
      "指",
      "浙江和信投资管理有限公司"
    ],
    "珠海泰弘": [
      "指",
      "珠海泰弘景晖股权投资合伙企业（有限合伙）"
    ],
    "财智创赢": [
      "指",
      "深圳市财智创赢私募股权投资企业（有限合伙）"
    ],
    "海南华昆": [
      "指",
      "海南华昆创业投资合伙企业（有限合伙）"
    ],
    "翱鹰实业": [
      "指",
      "翱鹰实业投资有限公司"
    ],
    "杭州承鼎": [
      "指",
      "杭州承鼎企业管理有限公司"
    ],
    "杭州哲康": [
      "指",
      "杭州哲康科技合伙企业（有限合伙）"
    ],
    "杭州哲鼎": [
      "指",
      "杭州哲鼎生物科技有限公司"
    ],
    "景杰北京分公司": [
      "指",
      "杭州景杰生物科技有限公司北京分公司"
    ],
    "景杰医学": [
      "指",
      "杭州景杰医学检验实验室有限公司，系公司全资子公司"
    ],
    "臻至生物": [
      "指",
      "上海臻至生物科技有限公司，系公司全资子公司"
    ],
    "江苏弘晖": [
      "指",
      "江苏弘晖股权投资管理有限公司"
    ],
    "上海合弘景晖": [
      "指",
      "上海合弘景晖股权投资管理有限公司"
    ],
    "芝加哥大学": [
      "指",
      "The University of Chicago，一所位于美国芝加哥市的私立研究\n型大学"
    ],
    "辉瑞": [
      "指",
      "辉瑞制药有限公司（Pfizer Inc.），知名跨国药企（NYSE:PFE）"
    ],
    "葛兰素史克": [
      "指",
      "葛兰素史克（GSK，GlaxoSmithKline plc），以研发为基础的药\n品和保健品公司（（NYSE:GSK））"
    ],
    "诺华": [
      "指",
      "诺华（Novartis AG），全球医药健康行业的跨国企业诺华集团 \n（NYSE:NVS）"
    ],
    "赛默飞": [
      "指",
      "赛默飞世尔科技公司（Thermo Fisher Scientific），全球科学服\n务领域的领导者（NYSE：TMO），提供包括高端分析仪器、实\n验室装备、软件、服务、耗材和试剂在内的实验室综合解决方\n案"
    ],
    "布鲁克": [
      "指",
      "布鲁克公司（Bruker Corporation），行业领先的科学仪器制造\n商（NASDAQ:BRKR）"
    ],
    "ABCAM": [
      "指",
      "Abcam Plc，知名抗体试剂产品提供商 （NASDAQ:ABCM）"
    ],
    "CST": [
      "指",
      "Cell Signaling Technology Inc，知名抗体试剂产品提供商"
    ],
    "保荐人、保荐机构、中信证券": [
      "指",
      "中信证券股份有限公司"
    ],
    "发行人律师、君合律师": [
      "指",
      "北京市君合律师事务所"
    ],
    "发行人会计师、天健会计师、验资复核机构": [
      "指",
      "天健会计师事务所（特殊普通合伙）"
    ],
    "立信评估": [
      "指",
      "上海立信资产评估有限公司"
    ],
    "报告期": [
      "指",
      "2019年、2020年、2021年和2022年1-6月"
    ],
    "元、万元": [
      "指",
      "人民币元、万元"
    ]
  },
  "138-1.xlsx": {
    "中科新生命": [
      "科研、临床",
      "蛋白质组学",
      "未披露",
      "未披露",
      "未披露",
      "未披露"
    ],
    "华大基因": [
      "科研、临床",
      "基因组（含\n蛋白质组）",
      316133.37,
      60589.99,
      676613.73,
      146153.63
    ],
    "诺禾致源": [
      "科研",
      "基因组（含\n蛋白质组）",
      84972.06,
      5669.66,
      186639.63,
      22498.61
    ],
    "欧易生物": [
      "科研",
      "蛋白质组",
      "未披露",
      "未披露",
      "未披露",
      "未披露"
    ]
  },
  "14-2_15-1_16-1_17-1_18-1.xlsx": {
    "蛋白质组": [
      "指",
      "在给定时间，在给定条件下在给定类型的细胞或生物中表达的\n蛋白质的集合"
    ],
    "组学": [
      "指",
      "生物学中对各类研究象（一般为生物分子）的集合所进行的系\n统性研究，主要包括基因组学、蛋白组学、代谢组学、转录组\n学、脂类组学、免疫组学、糖组学和RNA组学等"
    ],
    "蛋白质组学": [
      "指",
      "一门致力于研究生物体中在特定条件、特定时间所表达的全部\n蛋白质的表达和功能全貌和图谱，分析细胞内动态变化的蛋白\n质成分、表达水平与修饰状态，了解其相互之间的作用与联系"
    ],
    "基因": [
      "指",
      "能够遗传且具功能性的一段DNA或RNA序列，详细来说，其\n为DNA或RNA大分子内一段编码基因产物（RNA或蛋白质）\n的核苷酸序列"
    ],
    "基因组学": [
      "指",
      "对生物体所有基因进行集体表征、定量研究及不同基因组比较\n研究的一门交叉生物学学科"
    ],
    "色谱分离": [
      "指",
      "基于不同物质在由固定相和流动相构成的体系中具有不同的分\n配系数，在采用流动相洗脱过程中呈现不同保留时间，从而实\n现分离"
    ],
    "质谱": [
      "指",
      "一种与光谱并列的谱学方法，通常意义上是指广泛应用于各个\n学科领域中通过制备、分离、检测气相离子来鉴定化合物的一\n种专门技术"
    ],
    "质谱仪": [
      "指",
      "分离和检测带电粒子的仪器，即根据带电粒子在电磁场中能够\n偏转的原理，按物质原子、分子或分子碎片的质量差异进行分\n离和检测物质组成的一类仪器"
    ],
    "抗体": [
      "指",
      "一种主要由浆细胞分泌，被免疫系统用来鉴别与中和外来物质\n如细菌、病毒等病原体的大型Y形蛋白质"
    ],
    "诊断抗体": [
      "指",
      "针对疾病标志物分子的抗体，如肿瘤、心肌损伤或炎症、肾损\n伤、细菌感染、传染病等标志物分子的抗体"
    ],
    "生物化学": [
      "指",
      "研究生物体中的化学进程的一门学科，主要用于研究细胞内各\n组分，如蛋白质、糖类、脂类、核酸等生物大分子的结构和功\n能"
    ],
    "免疫学": [
      "指",
      "研究生物体对抗原物质免疫应答性及其方法的学科"
    ],
    "分子生物学": [
      "指",
      "从分子水平研究生物大分子的结构与功能从而阐明生命现象本\n质的科学"
    ],
    "生物信息学": [
      "指",
      "利用数学、信息学、统计学和计算机科学的方法研究生物学的\n问题的学科。生物信息学以各类生物学数据为基础，其搜索（收\n集和筛选）、处理（编辑、整理、管理和显示）及利用（计算、\n模拟）。目前主要的研究方向有：序列比对、序列组装、基因识\n别、基因重组、蛋白质结构预测、基因表达、蛋白质反应的预\n测，以及创建进化模型"
    ],
    "抗体特异性": [
      "指",
      "专一性，即某一特定的抗体只能与唯一一种抗原结合"
    ],
    "蛋白质翻译后修饰": [
      "指",
      "蛋白质在翻译后的化学修饰，是调节蛋白质生物学功能的关键\n步骤之一，是蛋白质动态反应和相互作用的一个重要分子基础；\n同时，它也是细胞信号网络调控的重要靶点"
    ],
    "蛋白质修饰组学": [
      "指",
      "一门致力于研究识别那些翻译后修饰的蛋白质，及其修饰位点，\n确定修饰的功能以及在细胞功能网络中修饰蛋白的相互作用的\n学科"
    ],
    "组蛋白": [
      "指",
      "真核细胞染色质与原核细胞中的碱性蛋白质，和 DNA 共同组\n成核小体结构。组蛋白是染色质的主要蛋白质组分，在基因调\n控中发挥作用"
    ],
    "组蛋白密码": [
      "指",
      "组蛋白在翻译后的修饰中会发生改变，从而提供一种识别的标\n志，为其它蛋白与 DNA 的结合产生协同或拮抗效应，它是一\n种动态转录调控成分，称为组蛋白密码"
    ],
    "表观遗传": [
      "指",
      "一个生物体（或细胞）可以观察到的性状或特征，是特定的基\n因型与环境相互作用的结果"
    ],
    "富集": [
      "指",
      "一种提高检测方法的灵敏度和结果的可靠性的样本处理步骤。\n在化学分析中，样本除了含有待测物之外，往往还有其它众多\n成分，甚至是检测的干扰物。因此往往需要对样本进行处理，\n既可以去除检测的干扰物，同时对待测物进行浓缩"
    ],
    "修饰抗体": [
      "指",
      "能够识别、结合特定修饰基团或特定位点上的修饰基团的一类\n抗体"
    ],
    "蛋白质测序": [
      "指",
      "蛋白质的一级结构的测定，蛋白质的一级结构指的是蛋白质多\n肽链中氨基酸残基的排列顺序，是蛋白质最基本的结构"
    ],
    "蛋白酶": [
      "指",
      "水解蛋白质肽链的一类酶的统称"
    ],
    "二抗": [
      "指",
      "第二抗体；第一抗体就是平常所说的抗体即能和抗原特异性结\n合；第二抗体能和抗体结合，即抗体的抗体，主要用于检测抗\n体的存在"
    ],
    "亲和试剂": [
      "指",
      "具有特异的亲和性物质的试剂"
    ],
    "大队列样本": [
      "指",
      "进行队列研究时收集的临床样本；队列研究指特定的人群按照\n暴露、未暴露于某种因素分为两组，然后追踪一定的时间，比\n较两组发病或死亡的结局，从而研究暴露因素与结局的关联"
    ],
    "QC": [
      "指",
      "Quality Control，是质量控制的简称"
    ],
    "肽段": [
      "指",
      "氨基酸脱水缩合成的链状物质"
    ],
    "丰度": [
      "指",
      "质谱仪测得的离子的强度，一般以相对丰度即相对于基峰强度\n的百分比表示"
    ],
    "表征": [
      "指",
      "用物理或化学方法对物质进行化学性质的分析、测试或鉴定，\n并阐明物质的化学特性"
    ],
    "抗原": [
      "指",
      "能刺激机体产生抗体的物质，是任何可诱发免疫反应的物质"
    ],
    "多肽": [
      "指",
      "由三个或三个以上氨基酸分子组成的肽叫多肽"
    ],
    "泛抗体": [
      "指",
      "识别某一类含有某种修饰性氨基酸残基的蛋白质"
    ],
    "同位素": [
      "指",
      "质子数相同而中子数不同的同一元素的不同原子"
    ],
    "TMT": [
      "指",
      "Tandem Mass Tag技术，是由美国赛默飞公司研发的一种多肽体\n外标记技术。该技术采用2种、6种或10种同位素的标签，通\n过特异性标记多肽的氨基基团，然后进行串联质谱分析，可同\n时比较2组、6组或10组不同样品中蛋白质的相对含量"
    ],
    "靶点": [
      "指",
      "药物治疗针对的目标分子，通常在疾病的病理过程中扮演重要\n作用，药物通过抑制或激活该目标分子的生物活性产生临床药\n效"
    ],
    "杂交瘤": [
      "指",
      "骨髓瘤细胞和免疫淋巴细胞（免疫B淋巴细胞）融合，形成能\n分泌高度纯一单克隆抗体的杂交瘤细胞"
    ],
    "单克隆抗体": [
      "指",
      "由一纯系B淋巴细胞克隆经分化、增值后的浆细胞所产生的单\n一成分、单一特异性的免疫球蛋白分子"
    ],
    "重组单克隆抗体": [
      "指",
      "使用重组 DNA 技术产生的抗体"
    ],
    "液相色谱仪": [
      "指",
      "利用混合物在液-固或不互溶的两种液体之间分配比的差异，对\n混合物进行先分离，而后分析鉴定的仪器"
    ],
    "抗体纯化": [
      "指",
      "多种杂蛋白混杂中获得成分相对单一的抗体或将抗体用于特定\n的用途"
    ],
    "HPLC": [
      "指",
      "High Performance Liquid Chromatography （高效液相色谱法），\n是色谱法的一个重要分支，以液体为流动相，采用高压输液系\n统，将具有不同极性的单一溶剂或不同比例的混合溶剂、缓冲\n液等流动相泵入装有固定相的色谱柱，在柱内各成分被分离后，\n进入检测器进行检测，从而实现对试样的分析"
    ],
    "转录组": [
      "指",
      "某一生理条件下，细胞内所有转录产物的集合，包括信使RNA、\n核糖体 RNA、转运 RNA 及非编码 RNA；狭义上指所有信使\nRNA的集合"
    ],
    "代谢组": [
      "指",
      "生物体内源性代谢物质的动态整体"
    ],
    "ELISA": [
      "指",
      "Enzyme linked immunosorbent assay（酶联免疫吸附测定），是指\n将可溶性的抗原或抗体结合到聚苯乙烯等固相载体上，利用抗\n原抗体特异性结合进行免疫反应的定性和定量检测方法"
    ],
    "Western Blot": [
      "指",
      "蛋白质印迹法，是分子生物学、生物化学和免疫遗传学中常用\n的一种实验方法，将印迹技术与抗原-抗体反应的特异性相结合\n的检测技术，用于分离和检测生物标本中的某一特定蛋白"
    ],
    "实验动物": [
      "指",
      "经人工培育，对其携带的微生物和寄生虫实行控制，遗传背景\n明确或者来源清楚，用于科学研究、教学、生产、检定以及其\n他科学实验的动物"
    ],
    "IgG": [
      "指",
      "免疫球蛋白G，是血清中免疫球蛋白的主要成分"
    ],
    "转染": [
      "指",
      "细胞在一定条件下主动或被动导入外源 DNA 片段而获得新的\n表型的过程"
    ],
    "质粒": [
      "指",
      "细菌、酵母菌和放线菌等生物中染色体（或拟核）以外的DNA\n分子，存在于细胞质中，具有自主复制能力，使其在子代细胞\n中也能保持恒定的拷贝数，并表达所携带的遗传信息，是闭合\n环状的双链DNA分子"
    ],
    "PCR": [
      "指",
      "聚合酶链式反应，是一种用于放大扩增特定的 DNA 片段的分\n子生物学技术，它可看作是生物体外的特殊 DNA 复制，PCR\n的最大特点是能将微量的DNA大幅增加"
    ],
    "RT-PCR": [
      "指",
      "逆转录PCR，是聚合酶链式反应（PCR）的一种广泛应用的变\n形。在RT-PCR 中，一条RNA 链被逆转录成为互补DNA，再\n以此为模板通过PCR进行DNA扩增"
    ],
    "DNA": [
      "指",
      "脱氧核糖酸的英文缩写，一种生物大分子可组成遗传指令，引\n导生物发育与生命机能运作"
    ],
    "核酸": [
      "指",
      "脱氧核糖核酸（DNA）和核糖核酸（RNA）的总称，是由许多\n核苷酸单体聚合成的生物大分子化合物，为生命的最基本物质\n之一"
    ],
    "转录": [
      "指",
      "是遗传信息从DNA流向RNA的过程"
    ],
    "翻译": [
      "指",
      "蛋白质生物合成过程中的第二步，翻译是根据遗传密码的中心\n法则，将成熟的信使RNA分子（由DNA通过转录而生成）中\n“碱基的排列顺序”（核苷酸序列）解码，并生成对应的特定\n氨基酸序列的过程"
    ],
    "二代基因测序": [
      "指",
      "高通量测序，也称“下一代”测序技术，以能一次并行对几十\n万到几百万条 DNA 分子进行序列测定和一般读长较短等为标\n志"
    ],
    "MALDI": [
      "指",
      "Matrix-Assisted Laser Desorption Ionization，基质辅助激光脱附\n电离，是质谱仪中较为常用的一种离子化方式"
    ],
    "ESI": [
      "指",
      "Electron Spray Ionization，电喷雾离子源，是质谱仪中较为常用\n的一种离子化方式"
    ],
    "氨基酸": [
      "指",
      "含有碱性氨基和酸性羧基的有机化合物，是构成蛋白质的基本\n单位"
    ],
    "DDA": [
      "指",
      "Data dependent acuiqisition 数据依赖型采集模式，质谱仪采集\n数据的常见方式之一。质谱仪器进行全扫描，然后对从全扫描\n质谱中选择的母离子（强度依赖）列表进行二级扫描"
    ],
    "DIA": [
      "指",
      "Data independent acquisition，数据非依赖型采集模式，质谱仪\n采集数据的常见方式之一。将质谱整个全扫描范围分为若干个\n窗口区域，高速、循环地对每个窗口区域中的所有离子进行选\n择、碎裂、检测，从而无遗漏、无差异地获得样本中所有离子\n的全部碎片信息。相较于数据依赖型采集模式拥有不会造成低\n丰度蛋白信息的丢失、定量准确度高、数据重现性高等优势"
    ],
    "PRM": [
      "指",
      "Parallel reaction monitoring，平行反应监测，质谱仪采集数据的\n常见方式之一。能够对目标蛋白质、目标肽段（如发生翻译后\n修饰的肽段）进行选择性检测，从而实现对目标蛋白质/肽段的\n定量"
    ],
    "PD-1": [
      "指",
      "程序性死亡受体1，是一种重要的免疫抑制分子"
    ],
    "CAR-T": [
      "指",
      "Chimeric Antigen Receptor T-Cell Immunotherapy，即嵌合抗原受\n体T细胞免疫疗法，是一种治疗肿瘤的新型精准靶向疗法"
    ],
    "生物标志物": [
      "指",
      "可以标记系统、器官、组织、细胞及亚细胞结构或功能的改变\n或可能发生的改变的生化指标"
    ],
    "精准医学": [
      "指",
      "以个体化医疗为基础、本质是通过基因组、蛋白质组等组学技\n术和医学前沿技术，对于大样本人群与特定疾病类型进行生物\n标记物的分析与鉴定、验证与应用，从而精确寻找到疾病的原\n因和治疗的靶点，并对一种疾病不同状态和过程进行精确分类，\n最终实现对于疾病和特定患者进行个体化精准治疗的目的提\n高疾病诊治与预防的效益"
    ],
    "免疫诊断": [
      "指",
      "应用免疫学的理论、技术和方法诊断各种疾病和测定免疫状态"
    ],
    "靶向药": [
      "指",
      "被赋予了靶向能力的药物或其制剂。其目的是使药物或其载体\n能瞄准特定的病变部位，并在目标部位蓄积或释放有效成分"
    ],
    "病理诊断": [
      "指",
      "对手术切下或解剖取下之病理标本，固定染色后，在显微镜下\n进行组织学检查，以诊断疾病"
    ],
    "抗体亲和力": [
      "指",
      "一个完整抗体分子的抗原结合部位与若干相应抗原表位之间\n的结合强度"
    ],
    "核酸适配体": [
      "指",
      "一段寡核苷酸序列（DNA或RNA），核酸适配体能与多种目标物\n质高特异性、高选择性地结合"
    ],
    "转化医学": [
      "指",
      "将基础医学研究和临床治疗连接起来的一种新的思维方式"
    ],
    "基序抗体": [
      "指",
      "能够识别不同基序（即各种修饰所在位点及周围氨基酸各种排\n列组合）的抗体"
    ],
    "克隆": [
      "指",
      "生物体通过体细胞进行的无性繁殖，以及由无性繁殖形成的基\n因型完全相同的后代个体"
    ],
    "GB": [
      "指",
      "一种十进制的信息计量单位，1GB=1024MB"
    ],
    "μL": [
      "指",
      "微升，一种容积单位，1毫升=1000微升"
    ],
    "CRO": [
      "指",
      "Contract Research Organization，通过合同形式为制药企业、\n医疗机构、中小医药医疗器械研发企业、甚至各种政府基金等\n机构在基础医学和临床医学研发过程中提供专业化服务的一\n种学术性或商业性的科学机构"
    ],
    "CRISPR": [
      "指",
      "Clustered Regularly Interspaced Short Palindromic Repeats，\n是原核生物基因组内的一段重复序列。CRISPR 来自微生物的免疫\n系统，这种工程编辑系统利用一种酶，能把一段作为引导工具的小\nRNA切入DNA，就能在此处切断或做其他改变"
    ],
    "GMP": [
      "指",
      "Good Manufacture Practice of Medical Products，是药品\n生产和质量管理的基本准则，适用于药品制剂生产的全过程和\n原料药生产中影响成品质量的关键工序"
    ],
    "FFPE": [
      "指",
      "Formalin-Fixed and Parrffin-Embedded，即使用福尔马林固\n定石蜡包埋处理的样本，它可以在常温保留很久，以供切片后\n用于组织学诊断及研究使用"
    ],
    "热蛋白质组学分析": [
      "指",
      "thermal proteome profiling（TPP），是基于蛋白和活性分子\n的结合可以稳定蛋白，减少蛋白随温度升高产生的聚沉这一原\n理，发展出来的用于鉴定活性分子靶标蛋白的蛋白质组学方法"
    ]
  },
  "140-1.xlsx": {
    "Abcam": [
      "科研",
      "未披露",
      "未披露",
      "未披露",
      "未披露"
    ],
    "CST": [
      "科研",
      "未披露",
      "未披露",
      "未披露",
      "未披露"
    ],
    "爱博泰克": [
      "科研、诊断",
      "未披露",
      "未披露",
      "未披露",
      "未披露"
    ],
    "优宁维": [
      "科研",
      50262.43,
      4225.85,
      110966.79,
      10872.82
    ],
    "菲鹏生物": [
      "诊断",
      "未披露",
      "未披露",
      233189.16,
      147613.13
    ]
  },
  "146-1.xlsx": {
    "产能（GB）": [
      35100.0,
      68040.0,
      33930.0,
      20430.0
    ],
    "产量（GB）": [
      20713.84,
      46405.73,
      26392.17,
      19289.76
    ],
    "销量（GB）": [
      20752.69,
      45904.42,
      27888.62,
      18496.09
    ],
    "产能利用率": [
      "59.01%",
      "68.20%",
      "77.78%",
      "94.42%"
    ],
    "产销率": [
      "100.19%",
      "98.92%",
      "105.67%",
      "95.89%"
    ]
  },
  "147-1.xlsx": {
    "产量": [
      20115173.96,
      18289535.74,
      2089298.62,
      2367338.21
    ],
    "销量": [
      3758690.0,
      2695653.1,
      606555.0,
      473843.6
    ],
    "其中： 对外实现销售": [
      1083830.0,
      2324245.0,
      433770.0,
      218960.0
    ],
    "试用样品赠送": [
      2583900.0,
      143090.0,
      "",
      ""
    ],
    "组学技术服务领用": [
      90960.0,
      228318.1,
      172785.0,
      254883.6
    ],
    "产销率": [
      "18.69%",
      "14.74%",
      "29.03%",
      "20.02%"
    ]
  },
  "148-1.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "148-2_149-1.xlsx": {
    "": [
      "金额",
      "比例（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "境内": [
      8764.51,
      98.13,
      21816.9,
      98.7,
      15059.99,
      98.12,
      11416.8,
      98.46
    ],
    "东北": [
      548.41,
      6.14,
      1780.66,
      8.06,
      1046.28,
      6.82,
      848.77,
      7.32
    ],
    "华北": [
      2854.3,
      31.96,
      5899.03,
      26.69,
      3199.23,
      20.84,
      2800.5,
      24.15
    ],
    "客户区域": [
      "2022年1-6月",
      "",
      "2021年度",
      "",
      "2020年度",
      "",
      "2019年度",
      ""
    ],
    "华东": [
      2252.32,
      25.22,
      5577.54,
      25.23,
      4016.2,
      26.17,
      2909.64,
      25.09
    ],
    "华南": [
      1227.39,
      13.74,
      2973.96,
      13.45,
      2123.33,
      13.83,
      1175.26,
      10.14
    ],
    "华中": [
      617.33,
      6.91,
      1625.95,
      7.36,
      2143.49,
      13.97,
      1370.8,
      11.82
    ],
    "西北": [
      324.05,
      3.63,
      1391.3,
      6.29,
      721.05,
      4.7,
      775.54,
      6.69
    ],
    "西南": [
      940.71,
      10.53,
      2568.46,
      11.62,
      1810.4,
      11.8,
      1536.29,
      13.25
    ],
    "境外": [
      167.1,
      1.87,
      287.28,
      1.3,
      288.25,
      1.88,
      178.51,
      1.54
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "149-2.xlsx": {
    "": [
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）"
    ],
    "第一季度": [
      3718.34,
      41.63,
      3223.33,
      14.58,
      1729.24,
      11.27,
      1761.88,
      15.19
    ],
    "第二季度": [
      5213.27,
      58.37,
      4955.47,
      22.42,
      3380.8,
      22.03,
      2497.18,
      21.54
    ],
    "第三季度": [
      "不适用",
      "不适用",
      5663.82,
      25.62,
      4065.04,
      26.49,
      2621.79,
      22.61
    ],
    "第四季度": [
      "不适用",
      "不适用",
      8261.56,
      37.38,
      6173.16,
      40.22,
      4714.45,
      40.66
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "150-1.xlsx": {
    "": [
      "收入 \n（万元）",
      "占当期主营业\n务收入的比例",
      "收入 \n（万元）",
      "占当期主营业\n务收入的比例"
    ],
    "医院客户": [
      6075.22,
      "39.58%",
      3514.04,
      "30.31%"
    ],
    "基础科研客户": [
      8066.21,
      "52.55%",
      7690.57,
      "66.32%"
    ],
    "工业客户": [
      1206.82,
      "7.86%",
      390.7,
      "3.37%"
    ],
    "合计": [
      15348.24,
      "100.00%",
      11595.3,
      "100.00%"
    ],
    "客户类型": [
      "2020年",
      "",
      "2019年",
      ""
    ]
  },
  "150-2_151-1.xlsx": {
    "蛋白质修饰组": [
      "销量",
      "GB",
      3396.7,
      7387.55,
      4975.43,
      2791.58
    ],
    "业务": [
      "项目",
      "单位",
      "2022年\n1-6月",
      "2021年",
      "2020年",
      "2019年"
    ],
    "分析": [
      "销售单价",
      "元/GB",
      8828.87,
      10731.23,
      15415.6,
      18571.31
    ],
    "蛋白质组分析": [
      "销量",
      "GB",
      15252.27,
      35587.23,
      21148.89,
      14801.47
    ],
    "": [
      "销售单价",
      "元/GB",
      2005.63,
      2183.0,
      2522.37,
      3206.35
    ]
  },
  "151-2_152-1.xlsx": {
    "序号": [
      "名称",
      "主要销售内容",
      "金额",
      "占比"
    ],
    "1": [
      "华中农业大学",
      "蛋白质组学技术服务、抗体\n试剂产品",
      270.44,
      "2.33%"
    ],
    "2": [
      "河南农业大学",
      "蛋白质组学技术服务",
      203.84,
      "1.76%"
    ],
    "3": [
      "浙江大学",
      "蛋白质组学技术服务、抗体\n试剂产品",
      201.5,
      "1.74%"
    ],
    "4": [
      "上海市第一人民医院",
      "蛋白质组学技术服务、抗体\n试剂产品",
      197.55,
      "1.70%"
    ],
    "5": [
      "中国人民解放军海军军医大\n学第一附属医院",
      "蛋白质组学技术服务",
      185.69,
      "1.60%"
    ],
    "合计": [
      "",
      "",
      1059.02,
      "9.13%"
    ],
    "2021年": [
      "",
      "",
      "",
      ""
    ],
    "2020年": [
      "",
      "",
      "",
      ""
    ],
    "2019年": [
      "",
      "",
      "",
      ""
    ]
  },
  "153-1_154-1.xlsx": {
    "TMTsixplex标记试剂": [
      "用于组学业务中\n的标记定量",
      "盒",
      "",
      23207.08,
      23727.43,
      23420.61
    ],
    "TMT10PLEX标记试剂": [
      "用于组学业务中\n的标记定量",
      "盒",
      "",
      21338.05,
      26991.15,
      26991.15
    ],
    "TMTpro16plex标记试剂": [
      "用于组学业务中\n的标记定量",
      "盒",
      71669.47,
      69380.53,
      69380.53,
      ""
    ],
    "HighSelectTop14去高丰度蛋白试剂": [
      "用于组学业务中\n的蛋白提取",
      "盒",
      5251.24,
      4945.21,
      4734.07,
      ""
    ],
    "PierceTop12去高丰度蛋白试剂": [
      "用于组学业务中\n的蛋白提取",
      "盒",
      "",
      "",
      4612.99,
      4389.47
    ],
    "固相萃取小柱": [
      "用于组学业\n务中的蛋白提取",
      "盒\n（strata-X10mg\n/1ml）",
      983.1,
      919.43,
      774.31,
      894.34
    ],
    "": [
      "",
      "盒（1L）",
      "",
      "",
      60766.83,
      ""
    ],
    "名称": [
      "简介",
      "规格",
      "2022年\n1-6月",
      "2021年",
      "2020年",
      "2019年"
    ],
    "胰蛋白酶": [
      "用于组学业务中\n的蛋白提取",
      "瓶（100ug/ph）",
      70.8,
      70.8,
      70.8,
      86.21
    ],
    "ExpiFectamine293转染试剂": [
      "用于抗体业\n务中的细胞转染\n实验",
      "盒（50次）",
      "",
      6929.13,
      6840.53,
      ""
    ],
    "Expi293™ExpressionMediu培养基": [
      "用于抗体业务中\n的大量表达环节",
      "瓶",
      "",
      "",
      2443.54,
      2304.11
    ],
    "FectoPRO转染试剂": [
      "用于抗体业务中\n的细胞转染实验",
      "包（10x1ml）",
      9151.46,
      11152.24,
      15209.73,
      ""
    ],
    "超滤离心管": [
      "通用实验耗材",
      "个（0.5ML/10KD）",
      27.96,
      24.9,
      23.56,
      21.87
    ]
  },
  "154-2_155-1.xlsx": {
    "": [
      "小计",
      608.55,
      "24.08%",
      1355.12,
      "24.59%",
      870.66,
      "17.71%",
      544.06,
      "27.16%"
    ],
    "主要 原材料": [
      "组学业务原材料",
      279.08,
      "11.04%",
      624.55,
      "11.33%",
      365.03,
      "7.42%",
      387.84,
      "19.36%"
    ],
    "仪器设备": [
      "仪器设备",
      1120.42,
      "44.33%",
      1878.8,
      "34.09%",
      2803.72,
      "57.03%",
      971.84,
      "48.51%"
    ],
    "采购": [
      "外协服务",
      366.57,
      "14.50%",
      729.2,
      "13.23%",
      574.62,
      "11.69%",
      335.61,
      "16.75%"
    ],
    "采购情况 服务  质谱仪服务 小计": [
      "",
      "2022年1-6月",
      "",
      "2021年",
      "",
      "2020年",
      "",
      "2019年",
      ""
    ],
    "合计": [
      "",
      2527.5,
      "100.00%",
      5511.01,
      "100.00%",
      4916.43,
      "100.00%",
      2003.41,
      "100.00%"
    ]
  },
  "156-1.xlsx": {
    "电": [
      "采购数量（万度）",
      113.66,
      215.93,
      96.82,
      43.14
    ],
    "": [
      "采购单价（含固定电容费）（元/度）",
      1.03,
      0.99,
      1.36,
      1.38
    ]
  },
  "156-2_157-1.xlsx": {
    "2022年1-6月": [
      1.0,
      "布鲁克科学仪器香港有限公司/布\n鲁克（北京）科技有限公司",
      "质谱仪设备、数据库",
      879.92,
      "34.81%"
    ],
    "": [
      "合计",
      "",
      "",
      1231.58,
      "61.47%"
    ],
    "2021年": [
      1.0,
      "赛默飞世尔科技（中国）有限公司\n/英潍捷基（上海）贸易有限公司",
      "质谱仪设备、试剂耗材",
      1579.36,
      "28.66%"
    ],
    "年度": [
      "序号",
      "供应商名称",
      "主要采购产品",
      "采购金额",
      "占比"
    ],
    "2020年": [
      1.0,
      "赛默飞世尔科技（中国）有限公司\n/英潍捷基（上海）贸易有限公司",
      "质谱仪设备、质谱仪维修\n保养服务、试剂耗材",
      1364.13,
      "27.75%"
    ],
    "2019年": [
      1.0,
      "建发（上海）有限公司",
      "质谱仪设备",
      752.56,
      "37.56%"
    ]
  },
  "158-1.xlsx": {
    "1": [
      "浙江省病原微生物\n生物实验室（BSL-2\n级）备案",
      "浙备\nBSL20215710055",
      "杭州市卫生健康委",
      "2022年8月\n19日",
      "长期"
    ],
    "2": [
      "对外贸易经营者备\n案登记表",
      4404481.0,
      "杭州市 \n商务局",
      "2021年5月\n7日",
      "不适用"
    ],
    "3": [
      "出入境检验检疫备\n案",
      3333609602.0,
      "钱江海关驻下沙办事处",
      "2015年6月\n15日",
      "长期"
    ],
    "4": [
      "质量管理体系 \n认证（ISO9000）",
      "15/21Q0105R00",
      "中国质量认证中心",
      "2021年3月\n30日",
      "2024年 \n3月29日"
    ],
    "5": [
      "高新技术企业证书",
      "GR202133007413",
      "浙江省科学技术厅、浙\n江省财政厅、国家税务\n总局浙江省税务局",
      "2021年12\n月16日",
      "2024年 \n12月16日"
    ],
    "6": [
      "医疗机构执业许可\n证",
      "MA2KGT6G4330\n10416P1202",
      "杭州市钱塘区社会发展\n局",
      "2022年1月\n29日",
      "2027年1月\n28日"
    ],
    "7": [
      "出入境检验检疫备\n案",
      3333609602.0,
      "钱江海关驻下沙办事处",
      "2015年6月\n15日",
      "长期"
    ]
  },
  "158-2.xlsx": {
    "通用设备": [
      908.71,
      361.49,
      547.22,
      "60.22%"
    ],
    "专用设备": [
      7178.09,
      3583.72,
      3594.37,
      "50.07%"
    ],
    "运输设备": [
      19.05,
      18.48,
      0.57,
      "3.00%"
    ],
    "合计": [
      8105.85,
      3963.69,
      4142.16,
      "51.10%"
    ]
  },
  "159-1.xlsx": {
    "景杰生物": [
      "浙（2021）\n杭州市不\n动产权第\n0283192号",
      "杭州市钱塘区\n金乔街与规划\n松合路交叉口\n东北角",
      20020.0,
      "出让",
      "工业\n用地",
      "2021/11/22",
      "至\n2071/11/10\n止"
    ]
  },
  "160-1.xlsx": {
    "1": [
      "房屋租赁\n中介合同",
      "严进",
      "景杰生物",
      "杭州市滟澜园澜轩\n12幢1单元2201\n室",
      127.43,
      "2022年8月5日至\n2023年8月4日",
      "10000元/月",
      "居住",
      "杭房权证经移字\n第16316623号"
    ],
    "2": [
      "办公空间\n服务合同",
      "寰图（广州）商\n务发展有限公\n司第二分公司",
      "景杰生物",
      "广东省广州市天河\n区临江大道3号楼\n发展中心25楼\n25F-A10",
      63.81,
      "2022年8月1日\n-2023年7月31日",
      "24187.50元/月",
      "办公",
      "《广州市房地产\n权属证明书》\n（NO.B0002230）"
    ],
    "3": [
      "租赁续签 \n合同",
      "钱景熙、 \n谢楠",
      "景杰生物",
      "成都市高新区府城\n大道中段188号18\n幢1单元19层10\n号",
      117.55,
      "2022年4月24日\n-2024年4月23日",
      "10579元/月",
      "办公",
      "成房权证监证字\n第4055534号"
    ],
    "4": [
      "和科科技\n中心租赁\n合同",
      "杭州万海投资\n管理有限公司",
      "景杰生物",
      "杭州经济技术开发\n区下沙街道乔新路\n500号和科科技中\n心1幢",
      11026.57,
      "2020 年 4 月 1 日\n-2030 年 10 月 31\n日",
      "1层前36个月租金为\n3589.62元/天，后24个\n月租金为3781.0664元/\n天；2-4层前36个月租\n金为11223.537元/天，\n后24个月租金为\n11827.8813元/天；2025\n年4月1日至2030年10\n月31日的租金价格由双\n方于2025年4月1日前\n三个月内书面协商确\n定，租赁价格参照和达",
      "工业用\n地（标准 \n厂房）",
      "浙（2019）杭州市\n不动产权第\n0086635号、第\n0086641号、第\n0086632号、第\n0086644号"
    ]
  },
  "161-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "药谷园区同类型厂房租\n赁价格；",
      "",
      ""
    ],
    "5": [
      "上海房屋\n租赁合同",
      "世达志不动产\n投资顾问（上\n海）有限 \n公司",
      "景杰生物",
      "上海市徐汇区肇嘉\n浜路789号均瑶国\n际广场6楼601部\n位 \n-606/607室",
      49.3,
      "2022 年 1 月 20 日\n-2023年1月19日",
      "19000元/月",
      "办公",
      "沪房地徐字\n（2004）第031963\n号"
    ],
    "6": [
      "房屋租赁 \n合同",
      "陆留芳",
      "景杰生物",
      "南京市秦淮区太平\n南路168号2幢\n1213室",
      87.44,
      "2022 年 4 月 1 日\n-2023年3月31日",
      "11800元/月",
      "办公",
      "苏（2016）宁秦不\n动产权第0018760\n号"
    ],
    "7": [
      "北京市房\n屋租赁合\n同",
      "李玉华",
      "景杰生物",
      "北京市海淀区紫金\n数码园3号楼9层\n0903",
      180.98,
      "2022 年 1 月 10 日\n-2023年1月9日",
      "41286元/月",
      "办公",
      "X京房权证海字第\n091683号"
    ],
    "8": [
      "房屋租赁\n合同",
      "邵奎发",
      "景杰生物",
      "辽宁省沈阳市沈河\n区青年大街路173\n号1单元12楼02\n室（佳兆业中心）",
      98.52,
      "2022 年 2 月 7 日\n-2023年2月6日",
      "8333.00元/月",
      "办公",
      "辽（2020）沈阳市\n不动产权第\n0551087号"
    ],
    "9": [
      "商业地产\n租赁合同",
      "叶华泉",
      "景杰生物",
      "福建省福州市台江\n区宁化街道上浦路\n南侧福利中心C1\n栋926单元",
      66.85,
      "2021 年 2 月 18 日\n-2023年2月17日",
      "5500元/月",
      "办公",
      "榕房预FZ购字第\n15027718号"
    ],
    "10": [
      "群光中心\n预租合同",
      "百脑汇（武汉）\n实业有限公司",
      "景杰生物",
      "湖北省武汉市洪山\n区珞喻路10号12\n层01室",
      81.92,
      "2022 年 2 月 21 日\n-2023年2月27日",
      "8192元/月",
      "办公",
      "鄂（2020）武汉市\n洪山不动产权第\n0067826号"
    ],
    "11": [
      "房屋租赁\n合同",
      "刘腊初",
      "景杰生物",
      "西安市新城区长乐\n西路166号2栋\n11209",
      113.91,
      "2022 年 6 月 1 日\n-2023年5月31日",
      "5500元/月",
      "商业",
      "陕（2017）西安市\n不动产权第\n1285744号"
    ]
  },
  "162-1.xlsx": {
    "12": [
      "License \nAgreement",
      "The Board of \nTrustees of the \nUniversity of \nIllinois a body \ncorporate and \npolitical of the \nState of Illinois",
      "PTM Bio \nLLC",
      "Suite 305 2201 \nWest Campell Park \nDrive Chicago IL",
      "约19.94 \n（215 ft²）",
      "2022 年 5 月 1 日\n-2023年4月30日",
      "656.73美元/月",
      "办公",
      ""
    ]
  },
  "163-1.xlsx": {
    "1": [
      "赛默飞Orbitrap™质谱仪",
      8.0,
      "景杰生物",
      3463.68,
      "40.23%",
      "无"
    ],
    "2": [
      "布鲁克TOF质谱仪",
      6.0,
      "景杰生物",
      2266.25,
      "62.38%",
      "无"
    ],
    "3": [
      "流式细胞仪",
      1.0,
      "景杰生物",
      116.69,
      "78.98%",
      "无"
    ],
    "4": [
      "氮气发生器",
      4.0,
      "景杰生物",
      61.96,
      "60.89%",
      "无"
    ],
    "5": [
      "液相色谱仪",
      4.0,
      "景杰生物",
      59.02,
      "24.41%",
      "无"
    ],
    "6": [
      "冷冻离心机",
      16.0,
      "景杰生物",
      50.84,
      "63.84%",
      "无"
    ],
    "7": [
      "超低温冰箱",
      12.0,
      "景杰生物",
      48.58,
      "37.09%",
      "无"
    ],
    "8": [
      "CO2震荡培养箱",
      6.0,
      "景杰生物",
      48.5,
      "76.26%",
      "无"
    ],
    "9": [
      "Bio-Plex200",
      1.0,
      "景杰生物",
      39.31,
      "22.38%",
      "无"
    ],
    "10": [
      "自动化固相萃取仪",
      1.0,
      "景杰生物",
      32.65,
      "66.05%",
      "无"
    ],
    "11": [
      "显微镜",
      4.0,
      "景杰生物",
      32.39,
      "65.50%",
      "无"
    ],
    "12": [
      "冷冻研磨仪",
      1.0,
      "景杰生物",
      31.38,
      "32.07%",
      "无"
    ],
    "13": [
      "生物安全柜",
      10.0,
      "景杰生物",
      31.08,
      "58.76%",
      "无"
    ],
    "14": [
      "UPS稳压电源",
      9.0,
      "景杰生物",
      28.31,
      "66.78%",
      "无"
    ],
    "15": [
      "色谱柱温箱",
      10.0,
      "景杰生物",
      27.67,
      "52.58%",
      "无"
    ],
    "16": [
      "实时荧光定量PCR仪",
      1.0,
      "景杰生物",
      26.37,
      "75.75%",
      "无"
    ],
    "17": [
      "高精度色谱柱温箱",
      1.0,
      "景杰生物",
      22.93,
      "3.00%",
      "无"
    ],
    "18": [
      "微量分光光度计",
      3.0,
      "景杰生物",
      22.35,
      "88.38%",
      "无"
    ],
    "19": [
      "蛋白中压层析仪",
      1.0,
      "景杰生物",
      21.77,
      "69.28%",
      "无"
    ],
    "20": [
      "搜库服务器",
      3.0,
      "景杰生物",
      21.24,
      "91.57%",
      "无"
    ],
    "21": [
      "化学发光成像系统",
      2.0,
      "景杰生物",
      20.35,
      "69.28%",
      "无"
    ],
    "22": [
      "真空浓缩仪+70孔转子",
      3.0,
      "景杰生物",
      20.35,
      "55.74%",
      "无"
    ],
    "23": [
      "二氧化碳培养箱",
      7.0,
      "景杰生物",
      20.03,
      "3.00%",
      "无"
    ]
  },
  "164-1_165-1_166-1_167-1_168-1_169-1_170-1.xlsx": {
    "1": [
      "发行人",
      "",
      41536263.0,
      42.0,
      "技术研究；质量检测；\n化学研究；临床试验；\n计算机硬件设计和开\n发咨询；云计算；平\n台即服务（PaaS）；\n建筑学服务；包装设\n计；材料测试",
      "2020.08.07- \n2030.08.06",
      "原始\n取得",
      "无"
    ],
    "2": [
      "发行人",
      "",
      41533165.0,
      35.0,
      "兽药零售或批发服\n务；销售展示架出租",
      "2020.09.28- \n2030.09.27",
      "原始\n取得",
      "无"
    ],
    "3": [
      "发行人",
      "",
      41536253.0,
      35.0,
      "广告设计；广告策划；\n组织商业或广告展\n览；特许经营的商业\n管理；商业管理和组\n织咨询；为第三方进\n行商业贸易的谈判和\n缔约；替他人推销；\n替他人采购（替其他\n企业购买商品或服\n务）；兽药零售或批\n发服务；销售展示架\n出租",
      "2020.06.21- \n2030.06.20",
      "原始\n取得",
      "无"
    ],
    "4": [
      "发行人",
      "",
      41532406.0,
      1.0,
      "工业用同位素；工业\n用淀粉；工业淀粉酶；\n蛋白质（原料）；水\n软化剂；防水垢剂；\n生物化学催化剂；气\n体净化剂；肥料；糖\n精",
      "2020.08.07- \n2030.08.06",
      "原始\n取得",
      "无"
    ],
    "5": [
      "发行人",
      "",
      41524973.0,
      1.0,
      "工业用同位素；工业\n用淀粉；工业淀粉酶；\n蛋白质（原料）；水\n软化剂；防水垢剂；\n生物化学催化剂；气\n体净化剂；肥料；糖\n精",
      "2020.07.21- \n2030.07.20",
      "原始\n取得",
      "无"
    ],
    "6": [
      "发行人",
      "",
      41524490.0,
      1.0,
      "工业用同位素；工业\n用淀粉；工业淀粉酶；\n蛋白质（原料）；水\n软化剂；防水垢剂；\n生物化学催化剂；气\n体净化剂；肥料；糖\n精",
      "2020.07.21- \n2030.07.20",
      "原始\n取得",
      "无"
    ],
    "7": [
      "发行人",
      "",
      41522589.0,
      44.0,
      "医疗保健；医疗诊所；\n医疗咨询；医疗辅助；\n医疗按摩；医疗护理；\n卫生设备出租；物质\n滥用病人的康复；远\n程医学服务；疗养院",
      "2020.07.21- \n2030.07.20",
      "原始\n取得",
      "无"
    ],
    "序号": [
      "注册人",
      "商标",
      "注册号",
      "类\n别",
      "核定使用商品/服务",
      "注册有效 \n期限",
      "取得\n方式",
      "权利\n限制"
    ],
    "8": [
      "发行人",
      "",
      41522525.0,
      10.0,
      "医用放射设备；诊断\n和治疗期同位素设备\n和器械；医用诊断设\n备；牙科设备和仪器；\n医疗器械和仪器；医\n用手套；奶瓶；假肢；\n腹带；缝合材料",
      "2020.07.21- \n2030.07.20",
      "原始\n取得",
      "无"
    ],
    "9": [
      "发行人",
      "",
      41517580.0,
      10.0,
      "医用放射设备；诊断\n和治疗期同位素设备\n和器械；医用诊断设\n备；牙科设备和仪器；\n医疗器械和仪器；医\n用手套；奶瓶；假肢；\n腹带；缝合材料",
      "2020.06.21- \n2030.06.20",
      "原始\n取得",
      "无"
    ],
    "10": [
      "发行人",
      "",
      41516463.0,
      44.0,
      "医疗保健；医疗诊所；\n医疗咨询；医疗辅助；\n医疗按摩；医疗护理；\n卫生设备出租；物质\n滥用病人的康复；远\n程医学服务；疗养院",
      "2020.06.14- \n2030.06.13",
      "原始\n取得",
      "无"
    ],
    "11": [
      "发行人",
      "",
      41512925.0,
      42.0,
      "化学研究；临床试验；\n计算机硬件设计和开\n发咨询；云计算；平\n台即服务（PaaS）；\n包装设计",
      "2020.10.07- \n2030.10.06",
      "原始\n取得",
      "无"
    ],
    "12": [
      "发行人",
      "",
      41518385.0,
      5.0,
      "医用诊断制剂；医用\n填料；医用诊断试剂；\n兽医用药；医用气体；\n消毒剂；医用或兽医\n用微生物培养物；医\n用营养食物；假牙黏\n合剂",
      "2020.10.28- \n2030.10.27",
      "原始\n取得",
      "无"
    ],
    "13": [
      "发行人",
      "",
      41516417.0,
      35.0,
      "广告设计；广告策划；\n组织商业或广告展\n览；特许经营的商业\n管理；商业管理和组\n织咨询；为第三方进\n行商业贸易的谈判和\n缔约；替他人推销；\n替他人采购（替其他\n企业购买商品或服\n务）；兽药零售或批\n发服务；销售展示架\n出租",
      "2020.08.14- \n2030.08.13",
      "原始\n取得",
      "无"
    ],
    "14": [
      "发行人",
      "",
      16360752.0,
      42.0,
      "技术研究；技术项目\n研究；替他人研究和\n开发新产品；材料测\n试；计算机系统设计",
      "2016.07.28- \n2026.07.27",
      "原始\n取得",
      "无"
    ],
    "15": [
      "发行人",
      "",
      16360747.0,
      35.0,
      "市场营销；广告宣传；\n进出口代理；无线电\n广告；商业管理咨询；\n将信息编入计算机数\n据库；计算机数据库\n信息系统化；寻找赞\n助；商业研究；药用、\n兽医用、卫生用制剂\n和医疗用品的零售或\n批发服务",
      "2016.04.28- \n2026.04.27",
      "原始\n取得",
      "无"
    ],
    "16": [
      "发行人",
      "",
      16360704.0,
      10.0,
      "血球计；医用测试仪；\n医疗分析仪器；医用\n诊断设备；医用身体\n康复仪；电疗器械；\n医用激光器；医用放\n射设备；理疗设备；\n缝合材料",
      "2016.04.28- \n2026.04.27",
      "原始\n取得",
      "无"
    ],
    "17": [
      "发行人",
      "",
      16360681.0,
      5.0,
      "医用或兽医用微生物\n培养物",
      "2016.07.28- \n2026.07.27",
      "原始\n取得",
      "无"
    ],
    "18": [
      "发行人",
      "",
      16360675.0,
      1.0,
      "非医用、非兽医用化\n学试剂；科学用化学\n制剂（非医用、非兽\n医用）；生物化学催\n化剂；实验室分析用\n化学制剂（非医用、\n非兽医用）；蛋白质\n（原料）；工业用同\n位素；水软化剂；糖\n精；试纸（非医用、\n非兽医用）；低温实\n验制剂",
      "2016.04.28- \n2026.04.27",
      "原始\n取得",
      "无"
    ],
    "19": [
      "发行人",
      "",
      9668318.0,
      1.0,
      "蛋白（动植物原料）；\n蛋白质（原料）；动\n物蛋白（原料）",
      "2012.08.07- \n2022.08.06",
      "原始\n取得",
      "无"
    ],
    "20": [
      "发行人",
      "",
      41530429.0,
      5.0,
      "医用填料；兽医用药；\n医用气体；消毒剂；\n医用或兽医用微生物\n培养物；净化剂",
      "2021.06.28- \n2031.06.27",
      "原始\n取得",
      "无"
    ],
    "21": [
      "发行人",
      "",
      59346290.0,
      5.0,
      "医用诊断试剂；医用\n诊断制剂；兽医用药；\n医用气体；消毒剂；\n医用或兽医用微生物\n培养物；医用营养食\n物；净化剂；医用填",
      "2022.03.14- \n2032.03.13",
      "原始\n取得",
      "无"
    ],
    "": [
      "",
      "",
      "",
      "",
      "的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "",
      "",
      ""
    ],
    "22": [
      "发行人",
      "",
      41537584.0,
      5.0,
      "医用气体；消毒剂；\n医用或兽医用微生物\n培养物",
      "2021.06.28- \n2031.06.27",
      "原始\n取得",
      "无"
    ],
    "23": [
      "发行人",
      "",
      44866846.0,
      5.0,
      "医用诊断试剂；医用\n诊断制剂；兽医用药；\n医用气体；消毒剂；\n医用或兽医用微生物\n培养物；医用营养食\n物；净化剂；医用填\n料；假牙黏合剂",
      "2021.08.21- \n2031.08.20",
      "原始\n取得",
      "无"
    ],
    "24": [
      "发行人",
      "",
      53106716.0,
      1.0,
      "蛋白质（原料）；工\n业用同位素；水软化\n剂；生物化学催化剂；\n工业用淀粉；工业淀\n粉酶；气体净化剂；\n防水垢剂；肥料；糖\n精",
      "2021.09.21- \n2031.09.20",
      "原始\n取得",
      "无"
    ],
    "25": [
      "发行人",
      "",
      53119771.0,
      5.0,
      "医用诊断试剂；医用\n诊断制剂；兽医用药；\n医用气体；消毒剂；\n医用或兽医用微生物\n培养物；医用营养食\n物；医用填料；假牙\n黏合剂",
      "2021.12.07- \n2031.12.06",
      "原始\n取得",
      "无"
    ],
    "26": [
      "发行人",
      "",
      53115386.0,
      10.0,
      "医用诊断设备；诊断\n和治疗期同位素设备\n和器械；医疗器械和\n仪器；牙科设备和仪\n器；医用放射设备；\n医用手套；奶瓶；假\n肢；腹带；缝合材料",
      "2021.09.07- \n2031.09.06",
      "原始\n取得",
      "无"
    ],
    "27": [
      "发行人",
      "",
      53112954.0,
      44.0,
      "医疗诊所；卫生设备\n出租；医疗按摩；医\n疗保健；医疗辅助；\n医疗护理；医疗咨询；\n物质滥用病人的康\n复；远程医学服务；\n疗养院",
      "2021.10.21- \n2031.10.20",
      "原始\n取得",
      "无"
    ],
    "28": [
      "发行人",
      "",
      53096496.0,
      1.0,
      "蛋白质（原料）；工\n业用同位素；水软化\n剂；生物化学催化剂；\n工业用淀粉；工业淀\n粉酶；气体净化剂\n糖精",
      "2021.12.28- \n2031.12.27",
      "原始\n取得",
      "无"
    ],
    "29": [
      "发行人",
      "",
      53107157.0,
      44.0,
      "医疗诊所；卫生设备\n出租；医疗按摩；医\n疗保健；医疗辅助；\n医疗护理；医疗咨询；\n物质滥用病人的康\n复；远程医学服务；\n疗养院",
      "2021.09.28-\n2031.09.27",
      "原始\n取得",
      "无"
    ],
    "30": [
      "发行人",
      "",
      53587287.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.09.28- \n2031.09.27",
      "原始\n取得",
      "无"
    ],
    "31": [
      "发行人",
      "",
      52747760.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.08.21-\n2031.08.20",
      "原始\n取得",
      "无"
    ],
    "32": [
      "发行人",
      "",
      53582869.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.09.14- \n2031.09.13",
      "原始\n取得",
      "无"
    ],
    "33": [
      "发行人",
      "",
      53587295.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.09.14- \n2031.09.13",
      "原始\n取得",
      "无"
    ],
    "34": [
      "发行人",
      "",
      53611506.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目",
      "2021.09.14- \n2031.09.13",
      "原始\n取得",
      "无"
    ],
    "35": [
      "发行人",
      "",
      53593268.0,
      42.0,
      "药物研究服务科学研\n究和开发；生物技术\n研究；生物医学研究\n服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.09.14- \n2031.09.13",
      "原始\n取得",
      "无"
    ],
    "36": [
      "发行人",
      "",
      53587309.0,
      42.0,
      "药物研究服务；科学\n研究和开发；生物技\n术研究；生物医学研\n究服务；生物学研究；\n科学研究；为医疗目\n的进行癌症科学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.09.14- \n2031.09.13",
      "原始\n取得",
      "无"
    ],
    "37": [
      "发行人",
      "",
      53607070.0,
      42.0,
      "药物研究服务；生物\n技术研究；生物医学\n研究服务；生物学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.12.21- \n2031.12.20",
      "原始\n取得",
      "无"
    ],
    "38": [
      "发行人",
      "",
      53610229.0,
      42.0,
      "药物研究服务；生物\n技术研究；生物医学\n研究服务；生物学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.12.21- \n2031.12.20",
      "原始\n取得",
      "无"
    ],
    "39": [
      "发行人",
      "",
      53610231.0,
      42.0,
      "药物研究服务；生物\n技术研究；生物医学\n研究服务；生物学研\n究；医学研究服务；\n生物学研究和分析；\n医学研究",
      "2021.12.21- \n2031.12.20",
      "原始\n取得",
      "无"
    ],
    "40": [
      "发行人",
      "",
      53092450.0,
      35.0,
      "兽药零售或批发服\n务；销售展示架出租",
      "2022.4.28- \n2032.4.27",
      "原始\n取得",
      "无"
    ],
    "41": [
      "发行人",
      "",
      53101161.0,
      42.0,
      "计算机硬件设计和开\n发咨询；云计算；平\n台即服务（PaaS）",
      "2022.4.28- \n2032.4.27",
      "原始\n取得",
      "无"
    ],
    "42": [
      "发行人",
      "",
      62645816.0,
      5.0,
      "医用诊断试剂；医用\n或兽医用微生物培养\n物；兽医用药；医用\n气体；消毒剂；医用\n诊断制剂；医用营养\n食物；净化剂；医用\n填料；假牙黏合剂（截\n止）",
      "2022.08.07\n-2032.08.0\n6",
      "原始\n取得",
      "无"
    ],
    "43": [
      "发行人",
      "",
      62638255.0,
      10.0,
      "医用诊断设备；诊断\n和治疗期同位素设备\n和器械；医疗器械和\n仪器；牙科设备和仪\n器；医用:放射设备；\n医用手套；奶瓶；假\n肢；腹带；缝合材料\n（截止）",
      "2022.08.07\n-2032.08.0\n6",
      "原始\n取得",
      "无"
    ]
  },
  "170-2_171-1.xlsx": {
    "1": [
      "发明\n专利",
      2017105656025.0,
      "一种制备特异性的丙酰\n甲基化赖氨酸泛抗体方\n法",
      "景杰\n生物",
      "原始\n取得",
      "2014.7.25",
      "2020.12.15"
    ],
    "2": [
      "发明\n专利",
      2014103600623.0,
      "一种鉴定赖氨酸ε.氨基\n侧链单甲基化修饰的方\n法",
      "景杰\n生物",
      "原始\n取得",
      "2014.7.25",
      "2017.7.11"
    ],
    "3": [
      "发明\n专利",
      "201210215063X",
      "一种蛋白质赖氨酸巴豆\n酰化修饰的检测及亲和\n试剂开发的方法",
      "景杰\n生物",
      "继受\n取得",
      "2012.6.25",
      "2016.6.8"
    ],
    "4": [
      "发明\n专利",
      "201010103035X",
      "赖氨酸去丙酰化酶及去\n丁酰化酶的筛选及活性\n测定方法",
      "景杰\n生物",
      "继受\n取得",
      "2010.1.29",
      "2015.7.8"
    ],
    "5": [
      "发明\n专利",
      2010101030434.0,
      "真核细胞中高化学计量\n的非遗传性突变的鉴定\n方法",
      "景杰\n生物",
      "继受\n取得",
      "2010.1.29",
      "2015.1.14"
    ],
    "序号": [
      "专利\n类型",
      "专利号",
      "专利名称",
      "专利\n权人",
      "来源",
      "申请日",
      "授权日"
    ],
    "6": [
      "发明\n专利",
      2020113369363.0,
      "一种识别H3K18la兔单\n克隆抗体稳转细胞株及\n其构建方法",
      "景杰\n生物",
      "原始\n取得",
      "2020.11.25",
      "2021.5.20"
    ],
    "7": [
      "发明\n专利",
      2018800612659.0,
      "利用微混合和卡培他滨\n两亲性特性的卡培他滨\n的聚合物-脂质混杂纳\n米颗粒",
      "景杰\n生物",
      "原始\n取得",
      "2018.9.20",
      "2021.10.8"
    ],
    "8": [
      "发明\n专利",
      2014103598604.0,
      "一种赖氨酸单甲基化衍\n生化修饰的抗体及其制\n备方法",
      "景杰\n生物",
      "原始\n取得",
      "2014.7.2\n5",
      "2022.7.19"
    ]
  },
  "171-2.xlsx": {
    "1": [
      "发明专利",
      "US 13/117154 \n（US9625467）",
      "Agent and method for \nidentifying lysine \ncrotonylation in proteins",
      "继受\n取得",
      "PTM \nBIO \nLLC",
      "授权"
    ],
    "2": [
      "发明专利",
      "US 15/323873 \n（US10551390）",
      "Lysine monomethylated \nderivative and \ncorresponding antibody \nand use thereof",
      "原始\n取得",
      "景杰\n生物",
      "授权"
    ],
    "3": [
      "发明专利",
      "US16/249363 \n（US10908169）",
      "Reagents and methods \nfor detecting protein \ncrotonylation",
      "继受\n取得",
      "PTM \nBIO \nLLC",
      "授权"
    ],
    "4": [
      "发明专利",
      "US 16/251822 \n（US11204353）",
      "Reagents and methods \nfor detecting protein \nlysine \n2-hydroxyisobutyrylation",
      "继受\n取得",
      "景杰\n生物",
      "授权"
    ],
    "5": [
      "发明专利",
      "US16/454686 \n（US11385240）",
      "Reagents and Methods \nfor Detecting Protein \nLysine \n3-Hydroxybutyrylatio\nn",
      "继受\n取得",
      "PTM \nBIO \nLLC",
      "授权"
    ]
  },
  "171-3_172-1.xlsx": {
    "1": [
      "蛋白质组学数据分析自动\n化软件[简称：PTMQuant] \nV2.1",
      "2021SR0193624",
      "景杰 \n生物",
      "2020-02-10",
      "原始 \n取得"
    ],
    "2": [
      "蛋白质组功能注释自动化\n软件[简称：PA-PTM] V1.0",
      "2021SR0117733",
      "景杰 \n生物",
      "2020-04-01",
      "原始 \n取得"
    ],
    "序号": [
      "软件全称",
      "登记号",
      "著作 \n权人",
      "开发完成日期",
      "取得 \n方式"
    ],
    "3": [
      "景杰官网系统V1.0",
      "2021SR1701156",
      "景杰 \n生物",
      "2021-04-01",
      "原始 \n取得"
    ],
    "4": [
      "景杰抗体产业互联之生态\n经纪人服务系统[简称：\nPTMab小程序] V1.0",
      "2021SR1701201",
      "景杰 \n生物",
      "2021-04-01",
      "原始 \n取得"
    ],
    "5": [
      "景杰抗体服务标准化流程\n系统[简称：景杰抗体ITR\n支撑系统] V1.0",
      "2021SR1704423",
      "景杰 \n生物",
      "2021-04-01",
      "原始 \n取得"
    ],
    "6": [
      "景杰抗体一码通客户服务\n系统[简称：PTMab一码\n通] V1.0",
      "2021SR1702291",
      "景杰 \n生物",
      "2021-04-01",
      "原始 \n取得"
    ]
  },
  "172-2_173-1.xlsx": {
    "1": [
      "景杰生物",
      "ptmclub.com",
      "2021-04-06",
      "2026-04-06"
    ],
    "2": [
      "景杰生物",
      "ptmabclub.com",
      "2021-04-06",
      "2026-04-06"
    ],
    "3": [
      "景杰生物",
      "ptmab.com",
      "2020-09-03",
      "2025-09-03"
    ],
    "4": [
      "景杰生物",
      "ptmab.com.cn",
      "2020-09-03",
      "2025-09-03"
    ],
    "5": [
      "景杰生物",
      "ptmbiolab.cn",
      "2019-06-13",
      "2024-06-13"
    ],
    "6": [
      "景杰生物",
      "ptm-biolab.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "7": [
      "景杰生物",
      "ptmbiolab.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "8": [
      "景杰生物",
      "ptmbio.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "9": [
      "景杰生物",
      "景杰生物科技.com",
      "2019-06-13",
      "2024-06-13"
    ],
    "10": [
      "景杰生物",
      "景杰生物科技.cn",
      "2019-06-13",
      "2024-06-13"
    ],
    "11": [
      "景杰生物",
      "景杰生物科技.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "12": [
      "景杰生物",
      "杭州景杰生物科技.com",
      "2019-06-13",
      "2024-06-13"
    ],
    "13": [
      "景杰生物",
      "杭州景杰生物科技.cn",
      "2019-06-13",
      "2024-06-13"
    ],
    "14": [
      "景杰生物",
      "杭州景杰生物科技.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "15": [
      "景杰生物",
      "杭州景杰.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "16": [
      "景杰生物",
      "景杰.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "17": [
      "景杰生物",
      "景杰生物.net",
      "2019-06-13",
      "2024-06-13"
    ],
    "18": [
      "景杰生物",
      "ptmbiotech.com",
      "2016-02-18",
      "2026-02-18"
    ],
    "19": [
      "景杰生物",
      "ptmbio.cn",
      "2016-02-18",
      "2026-02-18"
    ],
    "20": [
      "景杰生物",
      "ptmbio.com",
      "2016-02-18",
      "2026-02-18"
    ],
    "21": [
      "景杰生物",
      "ptmbiotech.com.cn",
      "2016-02-25",
      "2026-02-25"
    ],
    "序号": [
      "域名所有者",
      "域名",
      "注册日期",
      "到期日期"
    ],
    "22": [
      "景杰生物",
      "ptmbio.com.cn",
      "2016-02-25",
      "2026-02-25"
    ],
    "23": [
      "景杰生物",
      "ptmbiotech.cn",
      "2016-02-18",
      "2026-02-18"
    ],
    "24": [
      "景杰生物",
      "ptm-biolab.com.cn",
      "2011-05-24",
      "2026-05-24"
    ],
    "25": [
      "景杰生物",
      "ptm-biolab.com",
      "2011-01-26",
      "2025-01-26"
    ],
    "26": [
      "景杰生物",
      "ptmbiolab.com",
      "2011-01-26",
      "2025-01-26"
    ],
    "27": [
      "景杰生物",
      "ptm-bio.com",
      "2011-01-26",
      "2025-01-26"
    ]
  },
  "182-1_183-1.xlsx": {
    "1": [
      "Global profiling of \ncrotonylation on non-histone \nproteins",
      "细胞生物学、\n蛋白质翻译\n后修饰",
      "Cell Research",
      "2017年\n4月",
      25.6
    ],
    "2": [
      "Phosphoproteomics reveals \ntherapeutic targets of \nesophageal squamous cell \ncarcinoma",
      "食管癌研究、\n蛋白质翻译\n后修饰",
      "Signal Transduction \nand Targeted Therapy",
      "2021年\n11月",
      18.2
    ],
    "3": [
      "Dynamic competing histone \nH4 K5K8 acetylation and \nbutyrylation are hallmarks of \nhighly active gene promoters",
      "表观遗传学、\n蛋白质翻译\n后修饰",
      "Molecular cell",
      "2016年\n4月",
      17.97
    ],
    "4": [
      "Chromodomain Protein \nCDYL Acts as a \nCrotonyl-CoA Hydratase to \nRegulate Histone \nCrotonylation and \nSpermatogenesis",
      "表观遗传学、\n生殖发育、蛋\n白质翻译后\n修饰",
      "Molecular Cell",
      "2017年\n9月",
      17.97
    ],
    "序号": [
      "题目",
      "专业领域",
      "发表杂志",
      "发表 \n时间",
      "影响 \n因子"
    ],
    "5": [
      "Acetylation of PHF5A \nModulates Stress Responses \nand Colorectal \nCarcinogenesis through \nAlternative \nSplicing-Mediated \nUpregulation of KDM3A",
      "结肠癌研究、\n蛋白质翻译\n后修饰",
      "Molecular Cell",
      "2019年\n6月",
      17.97
    ],
    "6": [
      "GLP-catalyzed H4K16me1 \npromotes 53BP1 recruitment \nto permit DNA damage \nrepair and cell survival",
      "表观遗传学、\n蛋白质翻译\n后修饰",
      "Nucleic Acids \nResearch",
      "2019年\n12月",
      16.971
    ],
    "7": [
      "Divergence and plasticity \nshape adaptive potential of \nthe Pacific oyster",
      "海洋生态学、\n蛋白质翻译\n后修饰",
      "Nature Ecology & \nEvolution",
      "2018年\n9月",
      15.46
    ],
    "8": [
      "SIRT7 is a histone \ndesuccinylase that \nfunctionally links to \nchromatin compaction and \ngenome stability",
      "表观遗传学、\n蛋白质翻译\n后修饰",
      "Nat Communication",
      "2016年\n7月",
      14.919
    ],
    "9": [
      "Global crotonylome reveals \nCDYL-regulated RPA1 \ncrotonylation in homologous \nrecombination-mediated \nDNA repair",
      "表观遗传学、\n蛋白质翻译\n后修饰",
      "Science Advances",
      "2020年\n3月",
      14.136
    ],
    "10": [
      "Dynamics and functional \ninterplay of histone lysine \nbutyrylation \ncrotonylationand acetylation \nin rice under starvation and \nsubmergence",
      "植物学、表观\n遗传学、蛋白\n质翻译后修\n饰",
      "Genome Biology",
      "2018年\n9月",
      13.583
    ]
  },
  "183-2_184-1.xlsx": {
    "1": [
      "一种制备特异性的丙酰甲\n基化赖氨酸泛抗体方法",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "所获得的泛抗体可用于蛋白质\n甲基化修饰组学的分析，用于富\n集发生赖氨酸甲基化修饰的肽\n段"
    ],
    "2": [
      "一种鉴定赖氨酸ε.氨基侧\n链单甲基化修饰的方法",
      "蛋白质修饰组学",
      "用于赖氨酸单甲基化蛋白质修\n饰组学的分析"
    ],
    "3": [
      "一种蛋白质赖氨酸巴豆酰\n化修饰的检测及亲和试剂\n开发的方法",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "所获得的抗体可用于赖氨酸巴\n豆酰化修饰组学的分析，用于富\n集发生赖氨酸巴豆酰化修饰的\n肽段"
    ],
    "序号": [
      "名称",
      "相关领域",
      "用途"
    ],
    "4": [
      "赖氨酸去丙酰化酶及去丁\n酰化酶的筛选及活性测定\n方法",
      "基于生物标志物的\n新药开发",
      "基于蛋白质组学的方法筛选、鉴\n定参与赖氨酸丙酰化和丁酰化\n调控蛋白，为开发靶向赖氨酸丙\n酰化和丁酰化的药物奠定基础"
    ],
    "5": [
      "真核细胞中高化学计量的\n非遗传性突变的鉴定方法",
      "基于生物标志物的\n新药开发",
      "基于蛋白质组学的方法鉴定蛋\n白质在非遗传水平的突变"
    ],
    "6": [
      "一种识别H3K18la兔单克\n隆抗体稳转细胞株及其构\n建方法",
      "蛋白质修饰抗体",
      "建立特异性兔单克隆抗体的稳\n定表达细胞株，用于对应抗体的\n大规模、稳定生产。"
    ],
    "7": [
      "一种赖氨酸单甲基化衍生\n化修饰的抗体及其制备方\n法",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "所获得的泛抗体可用于蛋白质\n赖氨酸单甲基化组学分析，富集\n发生赖氨酸单甲基化的肽段"
    ],
    "8": [
      "Agent and method for \nidentifying lysine \ncrotonylation in proteins",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "开发的试剂既可以用于赖氨酸\n巴豆酰化修饰的分析。也可以作\n为产品服务客户，用于检测蛋白\n质发生巴豆酰化修饰的水平"
    ],
    "9": [
      "Lysine monomethylated \nderivative and \ncorresponding antibody \nand use thereof",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "所获得的抗体用于赖氨酸单甲\n基化蛋白质修饰组学的分析 ，\n也可以作为产品服务客户，用于\n检测蛋白质发生单甲基化修饰\n的水平"
    ],
    "10": [
      "Reagent and method for \ndetecting protein \ncrotonylation",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "开发的试剂既可以用于赖氨酸\n巴豆酰化修饰的分析。也可以作\n为产品服务客户，用于检测蛋白\n质发生巴豆酰化修饰的水平"
    ],
    "11": [
      "Reagents and methods for \ndetecting protein lysine \n2-hydroxyisobutyrylation",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "开发的试剂既可以用于赖氨2-\n羟基异丁酰化修饰的分析。也可\n以作为产品服务客户，用于检测\n蛋白质发生赖氨2-羟基异丁酰\n化修饰的水平"
    ],
    "12": [
      "Reagents and Methods \nfor Detecting Protein \nLysine \n3-Hydroxybutyrylation",
      "蛋白质修饰组学 \n蛋白质修饰抗体",
      "开发的试剂既可以用于3-羟基\n丁酰化修饰的分析。也可以作为\n产品服务客户，用于检测蛋白质\n发生3-羟基丁酰化修饰修饰的\n水平"
    ]
  },
  "184-2.xlsx": {
    "1": [
      "精准医学\n国家重大\n专项",
      "临床定量蛋\n白质组的质\n谱仪及配套\n试剂的研发",
      "蛋白质组临\n床级定量和\n创新试剂研\n发",
      "北京蛋白质组研\n究中心、景杰生物\n等",
      "国家科技部\n和国家卫计\n委",
      "已结题"
    ]
  },
  "185-1.xlsx": {
    "1": [
      "开发区首批博士后科研工作站",
      "2014年"
    ],
    "2": [
      "第四届中国创新创业大赛第三名",
      "2015年"
    ],
    "3": [
      "杭州市企业高新技术研发中心",
      "2015年"
    ],
    "4": [
      "杭州市专利示范企业",
      "2019年"
    ],
    "5": [
      "省级高新技术企业研究开发中心",
      "2020年"
    ],
    "6": [
      "浙江省科技型中小型企业证书",
      "2020年"
    ],
    "7": [
      "钱塘新区雨燕企业",
      "2019年"
    ],
    "8": [
      "浙江省景杰蛋白质组学研究院",
      "2020年"
    ],
    "9": [
      "《快公司Fast Company》2020中国最佳创新公司50榜单",
      "2020年"
    ],
    "10": [
      "蛋白质组学与精准医疗浙江省工程研究中心",
      "2021年"
    ],
    "11": [
      "国家高新技术企业证书",
      "2021年"
    ]
  },
  "186-1.xlsx": {
    "程仲毅": [
      "董事、总经\n理、抗体业\n务总裁",
      "细胞生物学博士，长\n期从事蛋白质修饰\n组学、蛋白质修饰抗\n体的研究和开发",
      "1、建立公司蛋白质修饰抗体、表观遗传修\n饰抗体业务线，领导开发了 20 余种蛋白质\n修饰抗体以及近300种表观遗传密码抗体 \n2、将抗体和蛋白质组学技术服务进行整合，\n开发适合蛋白质组学分析的配套试剂，极大\n推动蛋白质组学业务的发展"
    ],
    "朱俊": [
      "监 事 会 主\n席、蛋白质\n组学总监",
      "分析化学博士，从事\n蛋白质组学方法开\n发工作",
      "1、建立公司蛋白质组学分析部门 \n2、搭建质谱平台并开发了20余种蛋白质修\n饰组分析技术 \n3、主导与布鲁克公司合作事项，推出 4D\n蛋白质组学技术服务"
    ],
    "高翔": [
      "研发总监",
      "遗传学博士，博士期\n间从事蛋白质修饰\n及其活性调控；博士\n后从事病毒的分子\n病理研究；目前从事\n临床蛋白质组学方\n法开发及应用",
      "1、建立临床蛋白质组学分析和基于质谱的\n生物标志物分析流程，涵盖从样本采集、样\n本处理、质谱分析、生物信息学发掘、后期\n验证 \n2、和国内知名医院就肿瘤的生物标志物发\n掘进行合作"
    ]
  },
  "187-1.xlsx": {
    "研发费用": [
      1281.96,
      3563.65,
      2223.38,
      1230.59
    ],
    "营业收入": [
      8932.54,
      22105.09,
      15348.24,
      11595.3
    ],
    "占营业收入比例": [
      "14.35%",
      "16.12%",
      "14.49%",
      "10.61%"
    ]
  },
  "187-2_188-1.xlsx": {
    "1": [
      "临床蛋白\n质组学分\n析",
      "基于蛋白质组\n学方法的局部\n进展期胃腺癌\n的药敏生物标\n志物的鉴定",
      "以胃癌为代表，建立病理组织、血液、尿\n液样本的临床蛋白组组学分析流程，并扩\n展到其它疾病类型，实现对各类临床样本\n的蛋白质组分析、微量临床样本空间蛋白\n质组分析以及单细胞样本的蛋白质组分\n析，同时利用机器学习算法辅助大队列临\n床试验中各适应症生物标志物的发现与验\n证： \n（1）血液样本去除高丰度蛋白污染后非标\n质谱分析，2小时内鉴定蛋白数从450提升\n到超1000种蛋白 \n（2）尿液的非标质谱分析，45分钟内能鉴\n定超1500种蛋白 \n（3）对细胞中不同的细胞器等亚细胞结构\n中蛋白质组成和含量变化进行蛋白质组分\n析；研究不同的组织结构中蛋白质组成和\n含量变化进行蛋白质组分析 \n（4）建立自动化的单细胞分离、筛选体系\n以及蛋白质提取和质谱前处理平台；实现\n从单个 HeLa 细胞中提取蛋白质并进行前\n处理，利用非标质谱分析，鉴定超过1000\n个蛋白质；对单个或50个细胞进行蛋白质\n磷酸化修饰分析，鉴定超过 200 个高可信\n磷酸化位点 \n（5）构建前沿生信特征选择和机器学习算\n法在 1000+例的大队列样本中鉴定药敏标\n志物，构建最优模型组合交叉验证",
      "进行中"
    ],
    "2": [
      "基于蛋白",
      "用于临床组织",
      "建立基于蛋白质组学的药物筛选、评价平",
      "进行中"
    ],
    "序号": [
      "领域",
      "名称",
      "拟达到的目标",
      "所处 \n阶段"
    ],
    "": [
      "质组学的\n药 物 筛\n选、评价",
      "中翻译后修饰\n位点精准靶向\n定量的 PRM\n修饰组学技术\n方法开发",
      "台： \n（1）建立构建类器官培养体系、筛选潜在\n的候选活性分子，并且对类器官样本进行\n蛋白质组分析 \n（2）建立热蛋白质组学分析平台，利用高\n深度蛋白质组学鉴定活性分子靶标蛋白、\n构建类器官培养并筛选潜在的候选活性分\n子 \n（3）建立临床样本中蛋白质修饰位点的靶\n向蛋白质修饰组学方法，对药物靶点相关\n的磷酸化、乙酰化、巴豆酰化等蛋白质翻\n译后修饰进行靶向定量分析。在此基础上，\n针对靶向蛋白质的精准药物开发建立基于\n蛋白质组学的筛选、评价体系",
      ""
    ],
    "3": [
      "临床蛋白\n质修饰组\n学分析",
      "用于临床组织\n和体液样本中\n完整 N-糖基\n化修饰鉴定和\n定量的技术方\n法开发",
      "针对蛋白质 N-糖基化修饰的蛋白开发高特\n异性富集试剂，并且对该修饰肽段富集条\n件、肽段的质谱检测方法进行优化，实现\n在细胞样本中鉴定超 1000 个 N-糖基化修\n饰位点，并同时对位点进行定量",
      "进行中"
    ],
    "4": [
      "临床蛋白\n质修饰组\n学分析",
      "用于组织和细\n胞中大规模\nSUMO化修饰\n位点鉴定和定\n量的新技术开\n发",
      "针对SUMO 修饰的蛋白开发高特异性富集\n抗体，并且对 SUMO 修饰肽段富集条件、\n肽段的质谱检测方法进行优化，实现在细\n胞样本中鉴定超 1000 个 SUMO 化修饰位\n点，并同时对位点进行定量分析",
      "进行中"
    ],
    "5": [
      "肠道微生\n物蛋白质\n宏修饰组\n学分析",
      "用于肠道微生\n物中大规模修\n饰位点鉴定的\n宏修饰组学技\n术方法开发",
      "开发肠道微生物的蛋白质组学以及和疾病\n相关的蛋白质修饰组分析方法，建立针对\n上述蛋白质组分析的前沿生信特征选择和\n机器学习算法，同时开发基于蛋白质组学、\n代谢组学等微生物多组学关联分析方法和\n策略",
      "进行中"
    ]
  },
  "188-2.xlsx": {
    "1": [
      "病 理 抗 体\n和 伴 随 诊\n断 抗 体 原\n料",
      "肿瘤早期发\n现标志物伴\n随诊断抗体\n开发",
      "开发400个高质量的肿瘤病理诊断和伴随\n诊断的高灵敏性、高特异性抗体",
      "进行中"
    ],
    "2": [
      "新 型 蛋 白\n质 修 饰 抗\n体开发",
      "调控癌症和\n炎症等疾病\n的全新组蛋\n白乳酸化修\n饰兔单抗及\n试剂盒的开\n发和鉴定",
      "鉴于乳酸化修饰在癌症发生、炎症调控中\n的重要作用，开发全新的和上述重要生理\n功能相关的组蛋白乳酸化修饰的兔单克\n隆抗体，并开发基于该抗体的检测试剂盒\n产品，用于对上述修饰位点的快速、准确\n检测",
      "进行中"
    ]
  },
  "19-1.xlsx": {
    "有限公司成立日期": [
      "2010年12月30日"
    ],
    "股份公司设立日期": [
      "2020年12月25日"
    ],
    "注册资本": [
      "人民币36000.00万元"
    ],
    "注册地址": [
      "浙江省杭州市钱塘新区杭州经济技术开发区乔新路 500 号和科\n科技中心1幢一层"
    ],
    "主要生产经营地址": [
      "浙江省杭州市钱塘新区杭州经济技术开发区乔新路 500 号和科\n科技中心1幢一层"
    ],
    "法定代表人": [
      "程仲毅"
    ],
    "控股股东": [
      "蒋旦如、程仲毅"
    ],
    "实际控制人": [
      "Yingming Zhao、程仲毅、蒋旦如"
    ],
    "行业分类": [
      "科学研究和技术服务业（M74）"
    ],
    "在其他交易场所（申请）挂牌或上市的情况": [
      "无"
    ]
  },
  "19-2.xlsx": {
    "发行人律师": [
      "北京市君合律师事务所"
    ],
    "审计机构": [
      "天健会计师事务所（特殊普通合伙）"
    ],
    "评估机构": [
      "上海立信资产评估有限公司"
    ]
  },
  "19-3_20-1_21-1.xlsx": {
    "股票种类": [
      "人民币普通股（A股）",
      "",
      "",
      "",
      ""
    ],
    "每股面值": [
      "人民币1.00元",
      "",
      "",
      "",
      ""
    ],
    "发行股数": [
      "不超过4010万股",
      "占发行后总\n股本比例",
      "不低于10%",
      "",
      ""
    ],
    "其中：发行新股数量": [
      "不超过4010万股",
      "",
      "占发行后总\n股本比例",
      "",
      "不低于10%"
    ],
    "股东公开发售股份数量": [
      "",
      "",
      "占发行后总\n股本比例",
      "",
      ""
    ],
    "发行后总股本": [
      "不超过40010万股",
      "",
      "",
      "",
      ""
    ],
    "每股发行价格": [
      "【】元",
      "",
      "",
      "",
      ""
    ],
    "发行人高管、员工拟 参与战略配售情况": [
      "若公司决定实施高管及员工战略配售，则在本次公开发行股票注册 \n后、发行前，履行内部程序审议该事项具体方案，并依法进行披露",
      "",
      "",
      "",
      ""
    ],
    "保荐人相关子公司 拟参与战略配售情 况": [
      "保荐机构及相关子公司将根据深交所的相关规定确定是否参与本次\n发行战略配售",
      "",
      "",
      "",
      ""
    ],
    "发行市盈率": [
      "【】倍",
      "",
      "",
      "",
      ""
    ],
    "发行前每股净资产": [
      "1.57元（按2022年6月30\n日经审计的归属于母公司\n所有者权益除以本次发行\n前总股本计算）",
      "发行前每\n股收益",
      "",
      "0.15元（按2021年度经审\n计扣除非经常性损益后的\n归属于母公司股东的净利\n润除以本次发行前总股本\n计算）",
      ""
    ],
    "发行后每股净资产": [
      "【】元",
      "发行后每\n股收益",
      "",
      "【】元",
      ""
    ],
    "发行市净率": [
      "【】倍（按每股发行价格除以发行后每股净资产计算）",
      "",
      "",
      "",
      ""
    ],
    "发行方式": [
      "本次发行采用网下向询价对象询价配售与网上向社会公众投资者定\n价发行相结合的方式 ，或采用中国证监会、深圳证券交易所认可的\n其他发行方式（包括但不限于直接定价发行、向战略投资者配售股\n票等）",
      "",
      "",
      "",
      ""
    ],
    "发行对象": [
      "符合资格的询价对象和在深圳证券交易所开户的符合资格的创业板\n市场投资者（国家法律、法规禁止购买者除外）或中国证监会、深\n圳证券交易所规定的其他对象",
      "",
      "",
      "",
      ""
    ],
    "承销方式": [
      "余额包销",
      "",
      "",
      "",
      ""
    ],
    "拟公开发售股份股东名称": [
      "本次发行无公开发售股份",
      "",
      "",
      "",
      ""
    ],
    "发行费用的分摊原则": [
      "不适用",
      "",
      "",
      "",
      ""
    ],
    "募集资金总额": [
      "【】万元",
      "",
      "",
      "",
      ""
    ],
    "募集资金净额": [
      "【】万元",
      "",
      "",
      "",
      ""
    ],
    "募集资金投资项目": [
      "蛋白质组学科技服务平台升级项目、高端科研及诊断抗体试剂生产\n项目、基于蛋白质组学技术的综合研发平台项目",
      "",
      "",
      "",
      ""
    ],
    "发行费用概算": [
      "本次新股发行费用总额为【】万元，其中： \n承销费及保荐费【】万元 \n审计费【】万元 \n律师费【】万元 \n用于本次发行的信息披露费【】万元 \n发行手续费【】万元",
      "",
      "",
      "",
      ""
    ],
    "（二）本次发行上市的重要日期": [
      "",
      "",
      "",
      "",
      ""
    ],
    "刊登发行公告日期": [
      "【】",
      "",
      "",
      "",
      ""
    ],
    "开始询价推介日期": [
      "【】",
      "",
      "",
      "",
      ""
    ],
    "刊登定价公告日期": [
      "【】",
      "",
      "",
      "",
      ""
    ],
    "申购日期和缴款日期": [
      "【】",
      "",
      "",
      "",
      ""
    ],
    "股票上市日期": [
      "【】",
      "",
      "",
      "",
      ""
    ]
  },
  "196-1.xlsx": {
    "1": [
      "杭州承鼎",
      "Yingming Zhao持股100%， \n担任执行董事兼总经理",
      "服务：企业管理咨询，经济信\n息咨询（除商品中介），企业\n形象策划，商务信息咨询（除\n商品中介），市场营销策划，\n图文设计（涉及国家规定实施\n准入特别管理措施的除外）。"
    ],
    "2": [
      "杭州哲驰",
      "间接持有1%的股份，杭州承鼎担任其\n执行事务合伙人，Yingming Zhao通过\n杭州承鼎对其控制。",
      "发行人员工持股平台"
    ],
    "3": [
      "杭州哲康",
      "间接持有1%的股份，杭州承鼎担任其\n执行事务合伙人，Yingming Zhao通过\n杭州承鼎对其控制。",
      "技术开发、技术服务、技术咨\n询、成果转让：网络信息技术，\n计算机软硬件，生物技术。（涉\n及国家规定实施准入特别管理\n措施的除外）。（依法须经批\n准的项目，经相关部门批准后\n方可开展经营活动）"
    ]
  },
  "197-1.xlsx": {
    "": [
      3.0,
      "",
      "",
      "蒋旦如",
      "",
      "",
      "公司控股股东、实际控制人、董事"
    ]
  },
  "197-2.xlsx": {
    "1": [
      "杭州承鼎",
      "实际控制人Yingming Zhao持有其100%的股份，并担任其执行董\n事、总经理"
    ],
    "2": [
      "杭州哲驰",
      "实际控制人Yingming Zhao控制的杭州承鼎担任其执行事务合伙人"
    ],
    "3": [
      "杭州哲康",
      "实际控制人Yingming Zhao控制的杭州承鼎担任其执行事务合伙人"
    ]
  },
  "198-1.xlsx": {
    "1": [
      "上海江村",
      "直接持有发行人24.65%的股份"
    ],
    "2": [
      "吕松涛",
      "间接持有发行人22.18%的股份、董事"
    ],
    "3": [
      "国投创业基金",
      "直接持有发行人10.39%的股份"
    ],
    "4": [
      "杭州哲驰",
      "直接持有发行人9.68%的股份"
    ],
    "5": [
      "珠海瑛杰",
      "直接持有发行人7.14%的股份"
    ],
    "6": [
      "深圳和谐成长三期科技发展股权\n投资基金合伙企业（有限合伙）",
      "间接持有发行人7.11%的股份"
    ],
    "7": [
      "北京和谐恒源科技有限公司",
      "间接持有发行人5.01%的股份"
    ],
    "8": [
      "北京泰坦通源天然气资源技术有\n限公司",
      "间接持有发行人5.00%的股份"
    ]
  },
  "198-2_199-1_200-1_201-1_202-1_203-1.xlsx": {
    "1": [
      "Maponos Therapeutics Inc.",
      "发行人董事长Yingming Zhao担任董事的\n公司"
    ],
    "序号": [
      "关联方名称",
      "关联关系"
    ],
    "2": [
      "Maponos Inc.",
      "发行人董事长Yingming Zhao担任董事的\n公司"
    ],
    "3": [
      "上海顾隐脉磨瑞生命科技有限公司",
      "发行人董事吕松涛持股83%并担任执行董\n事兼总经理的公司"
    ],
    "4": [
      "上海泽赫管理咨询中心（有限合伙）",
      "发行人董事吕松涛担任执行事务合伙人且\n持有20%份额、吕松涛之妻刘梅英持有80%\n份额的有限合伙企业"
    ],
    "5": [
      "上海悬壶管理咨询中心（有限合伙）",
      "发行人董事吕松涛通过上海顾隐脉磨瑞生\n命科技有限公司控制的有限合伙企业"
    ],
    "6": [
      "上海子芥管理咨询中心（有限合伙）",
      "发行人董事吕松涛通过上海顾隐脉磨瑞生\n命科技有限公司控制的有限合伙企业"
    ],
    "7": [
      "上海闪翼管理咨询中心（有限合伙）",
      "发行人董事吕松涛通过上海顾隐脉磨瑞生\n命科技有限公司控制的有限合伙企业"
    ],
    "8": [
      "上海义泉管理咨询中心（有限合伙）",
      "发行人董事吕松涛通过上海顾隐脉磨瑞生\n命科技有限公司控制的有限合伙企业"
    ],
    "9": [
      "北京中青未来国际文化交流中心",
      "发行人董事吕松涛持股73.33%并担任总经\n理的公司"
    ],
    "10": [
      "天下明德（北京）文化发展有限公司",
      "发行人董事吕松涛持股40%并担任董事的\n公司"
    ],
    "11": [
      "绿谷（集团）有限公司",
      "发行人董事吕松涛持股18%并担任董事长、\n吕松涛之妻刘梅英持股76.12%并担任总经\n理的公司"
    ],
    "12": [
      "上海绿谷医院投资管理有限公司",
      "发行人董事吕松涛持股80%、吕松涛之妻\n刘梅英持股20%并担任执行董事的公司"
    ],
    "13": [
      "上海汲清堂医药科技有限公司",
      "发行人董事吕松涛间接持有其80%股权的\n公司"
    ],
    "14": [
      "上海汲清堂中医诊所有限责任公司",
      "发行人董事吕松涛间接持有其80%股权的\n公司"
    ],
    "15": [
      "成都成中医互联网医馆有限公司",
      "发行人董事吕松涛间接持有其40.8%股权\n的公司"
    ],
    "16": [
      "上海泰坤堂东馆中西医结合门诊部有\n限公司",
      "发行人董事吕松涛间接持有其51.30%股权\n的公司"
    ],
    "17": [
      "上海泰坤堂中医医院有限公司",
      "发行人董事吕松涛间接持有其54%股权的\n公司，并担任董事"
    ],
    "18": [
      "上海泰坤堂大药房有限公司",
      "发行人董事吕松涛间接持有其51.30%股权\n并担任董事的公司"
    ],
    "19": [
      "广州泰坤堂中医门诊部有限公司",
      "发行人董事吕松涛间接持有其43.20%股权\n的公司"
    ],
    "20": [
      "十堰武当丹道国际养生有限公司",
      "发行人董事吕松涛间接持有其49.47%股\n权，吕松涛之妻刘梅英间接持有其35.82%\n股权的公司"
    ],
    "21": [
      "岐黄在线（上海）智能科技有限公司",
      "发行人董事吕松涛间接持有其66.60%股权\n的公司"
    ],
    "22": [
      "上海道生（本溪）医疗科技有限公司",
      "发行人董事吕松涛间接持有其66.60%股权\n的公司"
    ],
    "23": [
      "上海绿谷（本溪）制药有限公司",
      "发行人董事吕松涛间接持有其27.12%股权\n并担任董事长、吕松涛之妻刘梅英间接持有\n其45.54%股权的公司"
    ],
    "24": [
      "上海道生堂健康信息咨询有限公司",
      "发行人董事吕松涛间接持有其66.60%股权\n并担任执行董事兼总经理的公司"
    ],
    "25": [
      "上海环科建筑科技有限公司",
      "发行人董事吕松涛担任董事长的公司"
    ],
    "26": [
      "北京道生合和生物医药科技研究有限\n公司",
      "发行人董事吕松涛担任董事长、吕松涛之妻\n间接持有其47.30%股权的公司"
    ],
    "27": [
      "上海绿谷药物开发有限公司",
      "发行人董事吕松涛担任董事长的公司"
    ],
    "28": [
      "上海耀期九生命科技有限公司",
      "发行人董事吕松涛间接持有其15.81%股权\n并担任董事长、吕松涛之妻间接持有其\n63.25%股权的公司"
    ],
    "29": [
      "绿谷（上海）医药科技有限公司",
      "发行人董事吕松涛间接持有其27.12%股权\n并担任执行董事、吕松涛之妻刘梅英间接持\n有其45.54%股权的公司"
    ],
    "30": [
      "中科绿谷（深圳）医疗科技有限公司",
      "发行人董事吕松涛担任董事长、吕松涛之妻\n刘梅英间接持有其42.63%股权的公司"
    ],
    "31": [
      "上海绿谷制药有限公司",
      "发行人董事吕松涛间接持有其15.12%股权\n并担任董事长、吕松涛之妻刘梅英间接持有\n其63.94%股权的公司"
    ],
    "32": [
      "绿谷（上海）医药产业投资有限公司",
      "发行人董事吕松涛间接持有其32.10%股\n权、吕松涛之妻刘梅英间接持有其51.15%\n股权的公司"
    ],
    "33": [
      "绿谷林杏（上海）医疗科技有限公司",
      "发行人董事吕松涛间接持有其32.10%股\n权、吕松涛之妻刘梅英间接持有其51.15%\n股权的公司"
    ],
    "34": [
      "期康（海南）医疗科技有限公司",
      "发行人董事吕松涛间接持有其32.10%股\n权、吕松涛之妻刘梅英间接持有其51.15%\n股权的公司"
    ],
    "35": [
      "银川林杏互联网医院有限公司",
      "发行人董事吕松涛间接持有其32.10%股\n权、吕松涛之妻刘梅英间接持有其51.15%\n股权的公司"
    ],
    "36": [
      "杭州期康诊所有限公司",
      "发行人董事吕松涛间接持有其32.10%股\n权、吕松涛之妻刘梅英间接持有其51.15%\n股权的公司"
    ],
    "37": [
      "北京江村市隐教育科技有限公司",
      "发行人董事吕松涛担任董事长、经理的公司"
    ],
    "38": [
      "上海江村市隐智能科技有限公司",
      "发行人董事吕松涛间接持有其90%股权并\n担任董事的公司"
    ],
    "39": [
      "苏州江村市隐管理咨询有限公司",
      "发行人董事吕松涛间接持有其90%股权的\n公司"
    ],
    "40": [
      "上海道生医疗科技有限公司",
      "发行人董事吕松涛间接持有其66.60%股权\n并担任董事长的公司"
    ],
    "41": [
      "青岛海洋生物医药研究院股份有限公\n司",
      "发行人董事吕松涛担任董事的公司"
    ],
    "42": [
      "上海绿谷泰坤堂投资有限公司",
      "发行人董事吕松涛间接持有其48%股权并\n担任董事的公司"
    ],
    "43": [
      "成都泰坤堂中医门诊部（普通合伙）",
      "发行人董事间接持有其43.2%份额的企业"
    ],
    "44": [
      "上海芯灯咨询管理合伙企业（有限合\n伙）",
      "发行人董事吕松涛通过上海顾隐脉磨瑞生\n命科技有限公司控制的有限合伙企业"
    ],
    "45": [
      "燧人（珠海）医疗科技有限公司",
      "发行人董事吕松涛间接持有其53.95%股权\n的公司"
    ],
    "46": [
      "上海小橘本草电子商务有限公司",
      "发行人董事吕松涛间接持有其48.6%股权\n的公司"
    ],
    "47": [
      "上海泰一楠东中医门诊部有限公司",
      "发行人董事吕松涛间接持有其35.91%股权\n的公司"
    ],
    "48": [
      "福州绿谷生物药业技术研究所（普通合\n伙）",
      "发行人董事吕松涛持有70%份额的企业"
    ],
    "49": [
      "上海天颐养生文化咨询有限公司",
      "发行人董事吕松涛持股70%的公司，已吊\n销"
    ],
    "50": [
      "上海光华生物技术有限公司",
      "发行人董事吕松涛持股50%的公司，已吊\n销"
    ],
    "51": [
      "上海黄山发展有限公司",
      "发行人董事吕松涛担任董事长的公司，已吊\n销"
    ],
    "52": [
      "宁夏绿谷国药有限公司",
      "发行人董事吕松涛担任副总经理的公司，已\n吊销"
    ],
    "53": [
      "上海绿谷食品有限公司",
      "发行人董事吕松涛担任董事长的公司，已吊\n销"
    ],
    "54": [
      "上海绿谷房产有限公司",
      "发行人董事吕松涛担任董事长的公司，已吊\n销"
    ],
    "55": [
      "北京宏拓经络科技有限公司",
      "发行人董事吕松涛担任董事的公司，已吊销"
    ],
    "56": [
      "北京天下文化发展有限责任公司",
      "发行人董事吕松涛担任董事的公司，已吊销"
    ],
    "57": [
      "北京古华天然药物研究开发有限责任\n公司",
      "发行人董事吕松涛担任董事的公司，已吊销"
    ],
    "58": [
      "西安道隆实业有限公司",
      "发行人董事吕松涛担任董事的公司，已吊销"
    ],
    "59": [
      "上海绿谷生命园医药有限公司",
      "发行人董事吕松涛之妻刘梅英持股78.84%\n的公司"
    ],
    "60": [
      "北京燧康医药科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n45.54%的公司"
    ],
    "61": [
      "上海丰袤医疗科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n45.54%的公司"
    ],
    "62": [
      "哈尔滨德杜医药科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n63.94%的公司"
    ],
    "63": [
      "南京绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司，已吊销"
    ],
    "64": [
      "上海绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司，已吊销"
    ],
    "65": [
      "成都天佑人和保健产品有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司，已吊销"
    ],
    "66": [
      "济南绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司"
    ],
    "67": [
      "郑州绿谷保健产品有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司，已吊销"
    ],
    "68": [
      "上海绿谷（本溪）医药有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n58.19%的公司"
    ],
    "69": [
      "上海绿谷（本溪）生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n51.15%的公司"
    ],
    "70": [
      "上海绿谷农业种植专业合作社",
      "发行人董事吕松涛之妻刘梅英间接持股\n50.75%的公司"
    ],
    "71": [
      "上海绿谷沪东医院管理有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n52.63%并担任执行董事的公司"
    ],
    "72": [
      "上海沪东医院检测有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n52.63%并担任董事长兼总经理的公司"
    ],
    "73": [
      "上海雷允上（北区）绿谷药业有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n45.67%并担任董事的公司"
    ],
    "74": [
      "长春绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n44.76%的公司"
    ],
    "75": [
      "上海妙世医疗科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n58.19%的公司"
    ],
    "76": [
      "上海林哲生物技术有限公司",
      "发行人董事吕松涛之关系密切家庭成员吕\n林涛持股50%的公司"
    ],
    "77": [
      "上海拓能医疗设备有限公司",
      "发行人董事吕松涛之关系密切家庭成员吕\n林涛持股51%的公司"
    ],
    "78": [
      "上海拓能医疗器械有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股75.5%的公司"
    ],
    "79": [
      "上海国杏生命科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股100%的公司"
    ],
    "80": [
      "上海谷仁堂医院管理有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股69%的公司"
    ],
    "81": [
      "四川阿可贝尔科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股95%的公司"
    ],
    "82": [
      "上海方拓医疗科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股55%的公司"
    ],
    "83": [
      "上海拓能生物医学有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股73.99%的公司"
    ],
    "84": [
      "上海拓能医疗技术有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股73.99%的公司"
    ],
    "85": [
      "上海上拓医疗科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股73.99%的公司"
    ],
    "86": [
      "南京谷仁堂中医门诊有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股48.3%的公司"
    ],
    "87": [
      "上海拓能医疗科技发展有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股73.99%的公司"
    ],
    "88": [
      "成都司徒天际科技有限责任公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股71.73%的公司，已吊销"
    ],
    "89": [
      "拓能（成都）软件科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股56.63%的公司，已吊销"
    ],
    "90": [
      "上海国大中达大药房",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股100%的公司"
    ],
    "91": [
      "黄山如心温泉大酒店有限公司",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股97.5%的公司"
    ],
    "92": [
      "黄山九龙溪原生态农业专业合作社",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股60%的公司"
    ],
    "93": [
      "上海如心酒店有限公司",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股100%的公司"
    ],
    "94": [
      "黄山市黄山区亚胜旅游文化发展有限\n公司",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股97.5%的公司"
    ],
    "95": [
      "黄山市黄山区甘棠明瑞汽车服务有限\n公司",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯持股40%的公司"
    ],
    "96": [
      "上海聚仁投资有限公司",
      "发行人董事吕松涛之关系密切家庭成员刘\n亚凯担任董事长的公司，已吊销"
    ],
    "97": [
      "北京元昇咨询管理有限公司",
      "发行人董事万津持股99%并担任执行董事、\n经理的公司"
    ],
    "98": [
      "北京贝昇咨询管理有限公司",
      "发行人董事万津担任经理、执行董事、财务\n负责人的公司"
    ],
    "99": [
      "上海睿纳基因科技有限公司",
      "发行人董事万津持股100%并担任执行董事\n的公司"
    ],
    "100": [
      "上海源晟万纳企业管理咨询合伙企业\n（有限合伙）",
      "发行人董事万津持有97.5%合伙企业份额\n并担任执行事务合伙人的企业"
    ],
    "101": [
      "上海源津禾润私募基金管理有限公司",
      "发行人董事万津持股80%并担任执行董事\n的公司"
    ],
    "102": [
      "博雅辑因（北京）生物科技有限公司",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "103": [
      "上海天泽云泰生物医药有限公司",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "104": [
      "Analytical Biosciences",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "105": [
      "百仑生物科技（江苏）有限公司",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "106": [
      "Nikegen Inc.",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "107": [
      "上海泰楚生物技术有限公司",
      "发行人董事庞紫璇担任董事的公司"
    ],
    "108": [
      "西湖制药（杭州）有限公司",
      "发行人独立董事Hongtao Yu担任董事长的\n公司"
    ],
    "109": [
      "杭州四时餐饮管理有限公司",
      "发行人独立董事郭坤坤持股90.25%并担任\n执行董事兼总经理的公司"
    ]
  },
  "2-1.xlsx": {
    "发行股数": [
      "公司本次公开发行股票的数量不超过 4010 万股，占发行后股本比\n例不低于10%； \n具体数量由公司董事会和主承销商根据本次发行定价情况以及中\n国证监会的相关要求在上述发行数量上限内协商确定；本次发行原\n股东不进行公开发售股份。"
    ],
    "每股面值": [
      "人民币1.00元"
    ],
    "每股发行价格": [
      "【】元/股"
    ],
    "预计发行日期": [
      "【】年【】月【】日"
    ],
    "拟上市的证券交易所和板块": [
      "深圳证券交易所创业板"
    ],
    "发行后总股本": [
      "不超过40010万股"
    ],
    "保荐人（主承销商）": [
      "中信证券股份有限公司"
    ],
    "招股说明书签署日期": [
      "【】年【】月【】日"
    ]
  },
  "203-2.xlsx": {
    "1": [
      "PTM BIO LLC",
      "公司全资子公司"
    ],
    "2": [
      "杭州景杰医学检验实验室有限公司",
      "发行人全资子公司"
    ],
    "3": [
      "上海臻至生物科技有限公司",
      "发行人全资子公司"
    ]
  },
  "203-3_204-1_205-1_206-1.xlsx": {
    "1": [
      "杭州哲鼎",
      "发行人曾持股10%的企业，发行人实际控制\n人Yingming Zhao曾经持股71%的公司，已\n于2020年4月注销"
    ],
    "2": [
      "山东亨利医药科技有限责任公司",
      "发行人董事万津曾担任董事的公司，已于\n2021年3月离任"
    ],
    "序号": [
      "关联方名称",
      "关联关系"
    ],
    "3": [
      "苏州艾博生物科技有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2021年5月离任"
    ],
    "4": [
      "苏州欧米尼医药有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "5": [
      "北京纳百生物科技有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "6": [
      "恺佧生物科技（上海）有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "7": [
      "杭州汇健科技有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "8": [
      "上海斯迈康生物科技有限公司",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "9": [
      "Abogen Therapeutics Limited",
      "发行人董事万津曾担任董事的公司，已于\n2022年4月离任"
    ],
    "10": [
      "北京鹤年堂科技发展有限公司",
      "发行人董事吕松涛持有其90%股权的公司\n已注销"
    ],
    "11": [
      "上海阿特门计算机技术有限公司",
      "发行人董事吕松涛曾持有其75%股权的公\n司已注销"
    ],
    "12": [
      "杭州阿来也信息科技有限公司",
      "发行人董事吕松涛持有其65%股权的公司\n已注销"
    ],
    "13": [
      "成都泰坤堂大药房有限公司",
      "发行人董事吕松涛间接持有其40.67%股权\n的公司，已注销"
    ],
    "14": [
      "上海绿谷（集团）有限公司",
      "发行人董事吕松涛曾担任其执行董事的公\n司已注销"
    ],
    "15": [
      "北京燧人脑科学研究院有限公司",
      "发行人董事吕松涛曾担任其经理、执行董事\n的公司已注销"
    ],
    "16": [
      "绿谷生命生物工程（苏州）有限公司",
      "发行人董事吕松涛曾担任其执行董事的公\n司已注销"
    ],
    "17": [
      "上海绿谷生命系统工程有限公司",
      "发行人董事吕松涛曾担任其董事长的公司\n已注销"
    ],
    "18": [
      "燧人（深圳）医疗科技有限公司",
      "发行人董事吕松涛曾担任其董事长的公司\n已注销"
    ],
    "19": [
      "绿谷国际贸易（上海）有限公司",
      "发行人董事吕松涛曾担任其执行董事的公\n司已注销"
    ],
    "20": [
      "北京绿谷泰和中医药研究院有限公司",
      "发行人董事吕松涛曾担任其董事的公司已\n注销"
    ],
    "21": [
      "岱山中科绿谷生命科学有限公司",
      "发行人董事吕松涛曾担任其董事的公司已\n注销"
    ],
    "22": [
      "上海绿谷金山制药有限公司",
      "发行人董事吕松涛曾担任其董事长的公司\n已注销"
    ],
    "23": [
      "上海道芯周行计算机科技开发有限公司",
      "发行人董事吕松涛曾持股53%并担任其董\n事长兼总经理的公司已注销"
    ],
    "24": [
      "泰赢传媒（北京）有限公司",
      "发行人董事吕松涛曾担任其董事的公司已\n注销"
    ],
    "25": [
      "安徽省绿谷九华养生园有限公司",
      "发行人董事吕松涛曾担任其董事长的公司\n已注销"
    ],
    "26": [
      "上海绿谷基业制药有限公司",
      "发行人董事吕松涛曾担任其执行董事兼总\n经理的公司已注销"
    ],
    "27": [
      "绿谷（菏泽）医药有限公司",
      "发行人董事吕松涛曾间接持有31.63%股权\n的公司，已于2021年2月1日转让全部股\n权"
    ],
    "28": [
      "宁波博晟利康医药投资有限公司",
      "发行人董事吕松涛曾间接持有32.10%股权\n的公司，已于2021年3月10日注销"
    ],
    "29": [
      "斯内华管理咨询（上海）有限公司",
      "发行人董事吕松涛曾担任其执行董事兼总\n经理且间接持股25.3%的公司，已于2021\n年6月离任"
    ],
    "30": [
      "上海东西智荟生物医药有限公司",
      "发行人董事吕松涛曾担任其执行董事的公\n司，已于2021年8月离任"
    ],
    "31": [
      "北京天颐慧生文化信息咨询有限公司",
      "发行人董事吕松涛曾持股55%并担任董事\n的公司，已注销"
    ],
    "32": [
      "上海阿特门医疗科技有限公司",
      "发行人董事吕松涛间接持有其54.22%股权\n的公司，已于2022年6月退出"
    ],
    "33": [
      "江村市隐教育咨询（苏州）有限公司",
      "发行人董事吕松涛间接持有其67.78%股权\n的公司，已注销"
    ],
    "34": [
      "上海绿谷礼品有限公司",
      "发行人董事吕松涛间接持有其59.86%股权\n的公司，已注销"
    ],
    "35": [
      "上海绿谷文化传播有限公司",
      "发行人董事吕松涛间接持有其59.86%股权\n的公司，已注销"
    ],
    "36": [
      "无锡泰坤堂中西医结合医院有限公司",
      "发行人董事吕松涛间接持有其40.67%股权\n的公司，已注销"
    ],
    "37": [
      "十堰武当大学堂教育有限公司",
      "发行人董事吕松涛曾担任其执行董事的公\n司，已于2019年1月离任"
    ],
    "38": [
      "燧人（上海）医疗科技有限公司",
      "发行人董事吕松涛曾间接持有其53.95%股\n权并担任执行董事的公司，已于2022年8\n月退出并离任"
    ],
    "39": [
      "上海翳道医疗科技咨询有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳担任其执行董事兼总经理的公司，已注销"
    ],
    "40": [
      "武汉国杏医疗投资管理有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳持股36%的公司，已注销"
    ],
    "41": [
      "北京广济福德中医研究院",
      "发行人董事吕松涛之关系密切家庭成员张\n琳曾持股100%的公司，已于2018年12月\n28日退出"
    ],
    "42": [
      "厦门阳泉商贸有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳曾持股70%的公司，已于2022年2月25\n日退出"
    ],
    "43": [
      "厦门九典源商贸有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳曾持股70%的公司，已于2022年3月29\n日退出"
    ],
    "44": [
      "上海拓能医用光电技术有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股75.5%的公司，已注销"
    ],
    "45": [
      "西安谷仁堂医院管理有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股69%的公司，已注销"
    ],
    "46": [
      "郑州谷仁堂网络科技有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股69%的公司，已注销"
    ],
    "47": [
      "无锡谷仁堂综合门诊有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股48.3%的公司，已注销"
    ],
    "48": [
      "常州谷仁堂中医门诊部有限公司",
      "发行人董事吕松涛之关系密切家庭成员张\n琳间接持股48.3%的公司，已注销"
    ],
    "49": [
      "上海绿谷生物研究所有限公司",
      "发行人董事吕松涛之妻刘梅英担任其执行\n董事的公司，已注销"
    ],
    "50": [
      "上海绿谷智慧医疗科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n51.15%的公司，已注销"
    ],
    "51": [
      "宁波博晟利康医药投资有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n51.15%的公司，已注销"
    ],
    "52": [
      "上海鑫钰园林景观设计有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n51.86%的公司，已注销"
    ],
    "53": [
      "北京泰坤堂中医研究院有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n74.37%的公司，已注销"
    ],
    "54": [
      "广东绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.90%的公司，已注销"
    ],
    "55": [
      "上海绿谷双灵固本散医学科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n76.84%的公司，已注销"
    ],
    "56": [
      "长沙绿谷生物科技有限公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n64.72%的公司，已注销"
    ],
    "57": [
      "绿谷（北京）临床医学研究中心有限责\n任公司",
      "发行人董事吕松涛之妻刘梅英间接持股\n45.67%的公司，已注销"
    ]
  },
  "206-2.xlsx": {
    "1": [
      "哲鼎生物科技（杭州）有限公司\n（下称“哲鼎生物”）",
      "实际控制人Yingming Zhao担任董事的公司\nMaponos Inc. 通过搭建VIE架构进行控制"
    ]
  },
  "207-1.xlsx": {
    "哲鼎生物科技（杭州）有限公司": [
      "房屋建筑物",
      0.93,
      0.9,
      "",
      ""
    ]
  },
  "207-2.xlsx": {
    "上海绿谷制药有限公司": [
      "蛋白质组学\n技术服务",
      "",
      27.51,
      96.6,
      ""
    ],
    "青岛海洋生物医药研究院股份有限公司": [
      "蛋白质组学\n技术服务",
      8.6,
      0.98,
      "",
      ""
    ],
    "杭州汇健科技有限公司": [
      "蛋白质组学\n技术服务",
      "",
      1.27,
      "",
      0.75
    ],
    "合计": [
      "",
      8.6,
      29.76,
      96.6,
      0.75
    ]
  },
  "207-3.xlsx": {
    "恺佧生物科技（上海）有限公司": [
      "原材料",
      "",
      "",
      3.9,
      ""
    ]
  },
  "208-1.xlsx": {
    "上海江村市隐投资发展有限公司": [
      800.0,
      "2014.12.10",
      "2019.10.31"
    ]
  },
  "208-2.xlsx": {
    "1": [
      "上海江村",
      615.0,
      41.0,
      78.59375
    ],
    "2": [
      "蒋旦如",
      600.0,
      40.0,
      68.75
    ],
    "3": [
      "程仲毅",
      195.0,
      13.0,
      22.34375
    ],
    "4": [
      "丁健",
      75.0,
      5.0,
      8.59375
    ],
    "5": [
      "赵雷杰",
      15.0,
      1.0,
      1.71875
    ],
    "合计": [
      "",
      1500.0,
      100.0,
      180.0
    ]
  },
  "209-1.xlsx": {
    "上海绿谷制药有限公司": [
      "从关联方借入\n一名人员",
      "",
      "",
      21.23,
      20.39
    ]
  },
  "209-2_210-1.xlsx": {
    "": [
      "",
      "账面 \n余额",
      "坏账 \n准备",
      "账面 \n余额",
      "坏账 \n准备",
      "账面 \n余额",
      "坏账 \n准备",
      "账面 \n余额",
      "坏账 \n准备"
    ],
    "上海绿谷制药有限公司": [
      "应收账\n款",
      "",
      "",
      "",
      "",
      101.24,
      5.06,
      "",
      ""
    ],
    "交易 关联方": [
      "项目",
      "2022.6.30",
      "",
      "2021.12.31",
      "",
      "2020.12.31",
      "",
      "2019.12.31",
      ""
    ],
    "青岛海洋生物医药研究院股份有限公司": [
      "应收账\n款",
      5.11,
      0.26,
      0.42,
      0.02,
      "",
      "",
      "",
      ""
    ],
    "哲鼎生物科技（杭州）有限公司": [
      "其他应\n收款",
      "",
      "",
      0.98,
      0.05,
      "",
      "",
      "",
      ""
    ],
    "金洪元": [
      "其他应\n收款",
      "",
      "",
      "",
      "",
      "",
      "",
      85.52,
      4.28
    ],
    "Yingming Zhao": [
      "其他应\n收款",
      "",
      "",
      "",
      "",
      "",
      "",
      0.33,
      0.02
    ],
    "小计": [
      "",
      5.11,
      0.26,
      1.4,
      0.07,
      101.24,
      5.06,
      85.84,
      4.29
    ]
  },
  "21-2.xlsx": {
    "资产总额（万元）": [
      67661.97,
      67398.46,
      55622.15,
      18299.44
    ],
    "负债总额（万元）": [
      11005.84,
      11809.98,
      10237.38,
      15444.79
    ],
    "归属于母公司股东所有者权益 （万元）": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ],
    "资产负债率（母公司）（%）": [
      15.98,
      17.17,
      18.34,
      84.0
    ],
    "营业收入（万元）": [
      8932.54,
      22105.09,
      15348.24,
      11595.3
    ],
    "净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "归属于母公司股东净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "扣除非经常性损益后归属于母公司股东净利润（万元）": [
      828.58,
      5277.79,
      3320.39,
      2130.23
    ],
    "基本每股收益（元）": [
      0.03,
      0.19,
      0.11,
      "/"
    ],
    "稀释每股收益（元）": [
      0.03,
      0.19,
      0.11,
      "/"
    ],
    "加权平均净资产收益率（%）": [
      1.68,
      13.59,
      40.1,
      138.04
    ],
    "经营活动产生的现金流量净额（万元）": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "现金分红（万元）": [
      "",
      900.0,
      "",
      ""
    ],
    "研发投入占营业收入的比例（%）": [
      14.35,
      16.12,
      14.49,
      10.61
    ]
  },
  "210-2.xlsx": {
    "青岛海洋生物医药研究院股份有限公司": [
      "合同负债",
      "",
      3.92,
      4.91,
      ""
    ],
    "程仲毅": [
      "其他应付款",
      "",
      "",
      "",
      5.4
    ],
    "小计": [
      "",
      "",
      3.92,
      4.91,
      5.4
    ]
  },
  "213-1_214-1.xlsx": {
    "流动资产：": [
      "",
      "",
      "",
      ""
    ],
    "货币资金": [
      361099986.12,
      434467421.19,
      134161194.4,
      55078936.4
    ],
    "交易性金融资产": [
      "",
      "",
      295488530.03,
      80012931.51
    ],
    "应收账款": [
      95189027.03,
      72417146.38,
      41416893.28,
      14585081.11
    ],
    "预付款项": [
      1948312.28,
      1864371.01,
      2777324.36,
      334720.59
    ],
    "其他应收款": [
      1974582.83,
      1785838.49,
      2041696.08,
      2417750.52
    ],
    "存货": [
      27429585.66,
      23120634.41,
      7134398.3,
      4253707.1
    ],
    "其他流动资产": [
      14235376.22,
      5297583.2,
      9496305.13,
      6461343.9
    ],
    "流动资产合计": [
      501876870.14,
      538952994.68,
      492516341.58,
      163144471.13
    ],
    "非流动资产：": [
      "",
      "",
      "",
      ""
    ],
    "固定资产": [
      41421636.72,
      37392553.33,
      40139584.9,
      14811604.88
    ],
    "在建工程": [
      48064120.54,
      8576716.51,
      "",
      765252.83
    ],
    "使用权资产": [
      36350075.25,
      37240274.66,
      "",
      ""
    ],
    "无形资产": [
      22378815.87,
      21973959.76,
      1826538.31,
      900273.33
    ],
    "长期待摊费用": [
      20628124.25,
      19434195.56,
      18322965.23,
      ""
    ],
    "递延所得税资产": [
      3669727.87,
      2810709.81,
      1768500.1,
      3372839.94
    ],
    "其他非流动资产": [
      2230345.21,
      7603174.08,
      1647527.14,
      ""
    ],
    "非流动资产合计": [
      174742845.71,
      135031583.71,
      63705115.68,
      19849970.98
    ],
    "资产总计": [
      676619715.85,
      673984578.39,
      556221457.26,
      182994442.11
    ],
    "项目": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ],
    "流动负债：": [
      "",
      "",
      "",
      ""
    ],
    "短期借款": [
      "",
      "",
      "",
      ""
    ],
    "应付账款": [
      13736113.42,
      9297892.3,
      17820944.68,
      4522167.92
    ],
    "预收款项": [
      "",
      "",
      "",
      57336985.76
    ],
    "合同负债": [
      41290390.63,
      48213939.61,
      65045074.19,
      ""
    ],
    "应付职工薪酬": [
      13209151.91,
      18458114.03,
      14146125.11,
      9856382.37
    ],
    "应交税费": [
      448607.44,
      316188.89,
      401115.58,
      1648273.11
    ],
    "其他应付款": [
      2315469.19,
      1492629.5,
      1485714.24,
      81084083.15
    ],
    "一年内到期的非流动负债": [
      4165426.09,
      3596360.01,
      "",
      ""
    ],
    "流动负债合计": [
      75165158.68,
      81375124.34,
      98898973.8,
      154447892.31
    ],
    "租赁负债": [
      33307429.91,
      34509219.5,
      "",
      ""
    ],
    "递延收益": [
      1585850.54,
      2215503.09,
      3474808.19,
      ""
    ],
    "递延所得税负债": [
      "",
      "",
      "",
      ""
    ],
    "非流动负债合计": [
      34893280.45,
      36724722.59,
      3474808.19,
      ""
    ],
    "负债合计": [
      110058439.13,
      118099846.93,
      102373781.99,
      154447892.31
    ],
    "所有者权益：": [
      "",
      "",
      "",
      ""
    ],
    "股本": [
      360000000.0,
      360000000.0,
      360000000.0,
      15000000.0
    ],
    "资本公积": [
      123609958.57,
      122235118.81,
      79398840.66,
      9507352.18
    ],
    "其他综合收益": [
      -219415.36,
      -74016.84,
      -120342.9,
      -200183.39
    ],
    "盈余公积": [
      8496796.52,
      8496796.52,
      1563731.34,
      486888.33
    ],
    "未分配利润": [
      74673936.99,
      65226832.97,
      13005446.17,
      3752492.68
    ],
    "归属于母公司所有者权益合计": [
      566561276.72,
      555884731.46,
      453847675.27,
      28546549.8
    ],
    "所有者权益合计": [
      566561276.72,
      555884731.46,
      453847675.27,
      28546549.8
    ],
    "负债和所有者权益总计": [
      676619715.85,
      673984578.39,
      556221457.26,
      182994442.11
    ]
  },
  "214-2_215-1_216-1.xlsx": {
    "一、营业总收入": [
      89325414.31,
      221050862.97,
      153482443.2,
      115953044.27
    ],
    "二、营业总成本": [
      73943545.16,
      155167854.31,
      113324770.12,
      91302312.42
    ],
    "其中：营业成本": [
      20654942.28,
      37118644.96,
      27430988.93,
      23591897.33
    ],
    "税金及附加": [
      72449.41,
      615408.21,
      270193.36,
      810015.68
    ],
    "项目": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "销售费用": [
      19237353.54,
      41072379.36,
      32219354.21,
      34313275.0
    ],
    "管理费用": [
      24086943.37,
      46192044.97,
      31318872.68,
      19483144.94
    ],
    "研发费用": [
      12819627.64,
      35636501.85,
      22233792.62,
      12305948.07
    ],
    "财务费用": [
      -2927771.08,
      -5467125.04,
      -148431.68,
      798031.4
    ],
    "其中：利息费用": [
      877077.86,
      1352374.74,
      "",
      847158.84
    ],
    "利息收入": [
      3519041.58,
      7068569.68,
      580178.27,
      158128.25
    ],
    "加：其他收益": [
      1435967.62,
      17064437.26,
      6741390.96,
      2100329.89
    ],
    "投资收益（损失以“-”号填列）": [
      "",
      475766.46,
      2223313.96,
      200438.36
    ],
    "公允价值变动收益（损失以“-”号填列）": [
      "",
      "",
      475598.52,
      12931.51
    ],
    "信用减值损失（损失以“-”号填列）": [
      -4986921.2,
      -3411707.9,
      -1833943.88,
      -592952.85
    ],
    "资产减值损失（损失以“-”号填列）": [
      -1641876.08,
      -1864797.63,
      -1083983.29,
      -131916.51
    ],
    "资产处置收益（损失以“-”号填列）": [
      "",
      622795.96,
      75471.7,
      ""
    ],
    "三、营业利润（亏损总额以“-”号填列）": [
      10189039.49,
      78769502.81,
      46755521.05,
      26239562.25
    ],
    "加：营业外收入": [
      34008.47,
      39000.0,
      48021.05,
      41641.37
    ],
    "减：营业外支出": [
      103764.56,
      104415.33,
      6202.71,
      150105.0
    ],
    "四、利润总额（亏损总额以“-”号填列）": [
      10119283.4,
      78704087.48,
      46797339.39,
      26131098.62
    ],
    "减：所得税费用": [
      672179.38,
      10549635.5,
      5469507.6,
      2954390.81
    ],
    "五、净利润（净亏损以“-”号填列）": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "（一）按经营持续性分类：": [
      "",
      "",
      "",
      ""
    ],
    "其中：持续经营净利润（净亏损以“-”号填列": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "终止经营净利润": [
      "",
      "",
      "",
      ""
    ],
    "（二）按所有权归属分类：": [
      "",
      "",
      "",
      ""
    ],
    "其中：归属于母公司股东的净利润（净亏损以“-”号填列）": [
      9447104.02,
      68154451.98,
      41327831.79,
      23176707.81
    ],
    "少数股东损益": [
      "",
      "",
      "",
      ""
    ],
    "六、其他综合收益的税后净额": [
      -145398.52,
      46326.06,
      79840.49,
      11720.08
    ],
    "七、综合收益总额": [
      9301705.5,
      68200778.04,
      41407672.28,
      23188427.89
    ],
    "归属于母公司股东的综合收益总额": [
      9301705.5,
      68200778.04,
      41407672.28,
      23188427.89
    ],
    "归属于少数股东的综合收益总额": [
      "",
      "",
      "",
      ""
    ],
    "八、每股收益": [
      "",
      "",
      "",
      ""
    ],
    "（一）基本每股收益": [
      0.03,
      0.19,
      0.11,
      "/"
    ],
    "（二）稀释每股收益": [
      0.03,
      0.19,
      0.11,
      "/"
    ]
  },
  "216-2_217-1.xlsx": {
    "一、经营活动产生的现金流量：": [
      "",
      "",
      "",
      ""
    ],
    "销售商品、提供劳务收到的现金": [
      58908222.48,
      185121246.73,
      141513791.57,
      135939710.05
    ],
    "收到的税费返还": [
      1274976.54,
      238991.67,
      "",
      ""
    ],
    "收到其他与经营活动有关的现金": [
      4978434.98,
      21791076.37,
      11968667.96,
      2143617.91
    ],
    "经营活动现金流入小计": [
      65161634.0,
      207151314.77,
      153482459.53,
      138083327.96
    ],
    "购买商品、接受劳务支付的现金": [
      12878525.17,
      33749808.86,
      20868182.93,
      10994376.64
    ],
    "支付给职工以及为职工支付的现金": [
      53814221.29,
      88296891.19,
      60183222.43,
      56717050.01
    ],
    "支付的各项税费": [
      2674934.0,
      16304006.56,
      9140871.04,
      10353504.33
    ],
    "支付其他与经营活动有关的现金": [
      10122067.03,
      29690223.8,
      22007331.99,
      16805915.83
    ],
    "经营活动现金流出小计": [
      79489747.49,
      168040930.41,
      112199608.39,
      94870846.81
    ],
    "经营活动产生的现金流量净额": [
      -14328113.49,
      39110384.36,
      41282851.14,
      43212481.15
    ],
    "二、投资活动产生的现金流量：": [
      "",
      "",
      "",
      ""
    ],
    "收回投资收到的现金": [
      "",
      295000000.0,
      560000000.0,
      80000000.0
    ],
    "取得投资收益收到的现金": [
      "",
      964296.49,
      2223313.96,
      200438.36
    ],
    "处置固定资产、无形资产和其他长期资产收回的现金净额": [
      610.0,
      800440.04,
      75471.7,
      ""
    ],
    "收到其他与投资活动有关的现金": [
      8670000.0,
      "",
      3000000.0,
      ""
    ],
    "项目": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "投资活动现金流入小计": [
      8670610.0,
      296764736.53,
      565298785.66,
      80200438.36
    ],
    "购置固定资产、无形资产和其他长期资产支付的现金": [
      49221989.14,
      54886580.35,
      49476087.97,
      11976874.02
    ],
    "投资支付的现金": [
      "",
      "",
      775000000.0,
      160000000.0
    ],
    "支付其他与投资活动有关的现金": [
      "",
      7600000.0,
      1500000.0,
      3000000.0
    ],
    "投资活动现金流出小计": [
      49221989.14,
      62486580.35,
      825976087.97,
      174976874.02
    ],
    "投资活动产生的现金流量净额": [
      -40551379.14,
      234278156.18,
      -260677302.31,
      -94776435.66
    ],
    "三、筹资活动产生的现金流量：": [
      "",
      "",
      "",
      ""
    ],
    "吸收投资收到的现金": [
      "",
      "",
      300000000.0,
      80000000.0
    ],
    "取得借款收到的现金": [
      "",
      "",
      "",
      ""
    ],
    "收到其他与筹资活动有关的现金": [
      "",
      35197716.79,
      "",
      ""
    ],
    "筹资活动现金流入小计": [
      "",
      35197716.79,
      300000000.0,
      80000000.0
    ],
    "偿还债务支付的现金": [
      "",
      "",
      "",
      5000000.0
    ],
    "分配股利、利润或偿付利息支付的现金": [
      "",
      9000000.0,
      "",
      361050.0
    ],
    "支付其他与筹资活动有关的现金": [
      9994499.18,
      6793168.26,
      "",
      8500000.0
    ],
    "筹资活动现金流出小计": [
      9994499.18,
      15793168.26,
      "",
      13861050.0
    ],
    "筹资活动产生的现金流量净额": [
      -9994499.18,
      19404548.53,
      300000000.0,
      66138950.0
    ],
    "四、汇率变动对现金及现金等价物的影响": [
      171756.74,
      -70742.28,
      -171770.83,
      42025.18
    ],
    "五、现金及现金等价物净增加额": [
      -64702235.07,
      292722346.79,
      80433778.0,
      14617020.67
    ],
    "加：期初现金及现金等价物余额": [
      425235061.19,
      132512714.4,
      52078936.4,
      37461915.73
    ],
    "六、期末现金及现金等价物余额": [
      360532826.12,
      425235061.19,
      132512714.4,
      52078936.4
    ]
  },
  "218-2.xlsx": {
    "服务及抗体试剂产品销售收入。2019年度、": [],
    "2020年度、2021年度及2022 年1-6月，景": [],
    "杰生物主营业务收入分别为 115,953,044.27": [],
    "元、153,482,443.20 元、221,041,835.72 元和": [],
    "89,316,162.25元，销售增长较快。": [],
    "由于营业收入是景杰生物关键业绩指标之": [],
    "一，可能存在景杰生物管理层（以下简称管": [],
    "理层）通过不恰当的收入确认以达到特定目": [],
    "标或预期的固有风险，且收入确认涉及复杂": [],
    "的信息系统，因此，天健会计师将收入确认": [],
    "确定为关键审计事项。": []
  },
  "219-1.xlsx": {
    "（一）收入确认": [
      "",
      "",
      ""
    ],
    "景杰生物的营业收入主要为蛋白质组学技术服务及抗体试剂产品销售收入。2019年度、2020年度、2021年度及2022 年1-6月，景杰生物主营业务收入分别为 115,953,044.27元、153,482,443.20 元、221,041,835.72 元和89,316,162.25元，销售增长较快。 由于营业收入是景杰生物关键业绩指标之一，可能存在景杰生物管理层（以下简称管理层）通过不恰当的收入确认以达到特定目标或预期的固有风险，且收入确认涉及复杂的信息系统，因此，天健会计师将收入确认确定为关键审计事项。": [
      "",
      "天健会计师在审计过程中执行以下审计程",
      ""
    ],
    "": [
      "账款减值确定为关键审计事项。",
      "",
      ""
    ],
    "关键审计事项": [
      "",
      "该事项在审计中是如何应对的",
      ""
    ],
    "（二）应收账款减值": [
      "",
      "",
      ""
    ]
  },
  "219-2.xlsx": {
    "序：": [],
    "1、了解与应收账款减值相关的关键内部控": [],
    "制，评价这些控制的设计，确定其是否得到": [],
    "执行，并测试相关内部控制的运行有效性；": [],
    "2、复核以前年度已计提坏账准备的应收账款": [],
    "的后续实际核销或转回情况，评价管理层过": [],
    "往预测的准确性；": [],
    "3、复核管理层对应收账款进行减值测试的相": [],
    "关考虑和客观证据，评价管理层是否充分识": [],
    "别已发生减值的应收账款；": [],
    "4、对于以组合为基础计量预期信用损失的应": [],
    "收账款，评价管理层按信用风险特征划分组": [],
    "合的合理性；评价管理层根据历史信用损失": [],
    "经验及前瞻性估计确定的应收账款账龄与预": [],
    "期信用损失率对照表的合理性；测试管理层": [],
    "使用数据（包括应收账款账龄等）的准确性": [],
    "和完整性以及对坏账准备的计算是否准确；": [],
    "5、结合应收账款的函证和期后回款情况，评": [],
    "价管理层计提应收账款坏账准备的合理性；": [],
    "6、检查与应收账款减值相关的信息是否已在": [],
    "财务报表中作出恰当列报。": []
  },
  "223-1.xlsx": {
    "": [
      "",
      "",
      "2022年\n1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "景杰医学": [
      "设立",
      100.0,
      "是",
      "是",
      "",
      ""
    ],
    "臻至生物": [
      "设立",
      100.0,
      "是",
      "是",
      "",
      ""
    ],
    "PTM BIO LLC": [
      "设立",
      100.0,
      "是",
      "是",
      "是",
      "是"
    ]
  },
  "229-1.xlsx": {
    "其他应收款——应收押金保证金组合": [
      "款项性质",
      "参考历史信用损失经验，结合当前状况以及对\n未来经济状况的预测，通过违约风险敞口和未\n来12个月内或整个存续期预期信用损失率，\n计算预期信用损失。"
    ],
    "其他应收款——账龄组合": [
      "账龄",
      ""
    ]
  },
  "229-2.xlsx": {
    "应收账款——账龄组合": [
      "账龄",
      "参考历史信用损失经验，结合当\n前状况以及对未来经济状况的预\n测，编制应收账款账龄与整个存\n续期预期信用损失率对照表，计\n算预期信用损失。"
    ]
  },
  "229-3.xlsx": {
    "1年以内（含，下同）": [
      5.0
    ],
    "1-2年": [
      20.0
    ],
    "2-3年": [
      40.0
    ],
    "3年以上": [
      100.0
    ]
  },
  "234-1.xlsx": {
    "通用设备": [
      "年限平均法",
      "3-10",
      3.0,
      "9.70-32.33"
    ],
    "专用设备": [
      "年限平均法",
      "3-5",
      3.0,
      "19.40-32.33"
    ],
    "运输工具": [
      "年限平均法",
      4.0,
      3.0,
      24.25
    ]
  },
  "234-2.xlsx": {
    "土地使用权": [
      50.0
    ],
    "办公软件": [
      "3-5"
    ]
  },
  "244-1.xlsx": {
    "": [
      "2019年12月31日",
      "新收入准则调整影响",
      "2020年1月1日"
    ],
    "预收款项": [
      5733.7,
      -5733.7,
      ""
    ],
    "合同负债": [
      "",
      5733.7,
      5733.7
    ]
  },
  "245-1.xlsx": {
    "": [
      "2020年12月31日",
      "新租赁准则调整影响",
      "2021年1月1日"
    ],
    "使用权资产": [
      "",
      4070.55,
      4070.55
    ],
    "一年内到期的非流动负债": [
      "",
      344.49,
      344.49
    ],
    "租赁负债": [
      "",
      3726.07,
      3726.07
    ]
  },
  "245-2.xlsx": {
    "": [
      "",
      "2022年 \n1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "增值税": [
      "以按税法规定计算的销\n售货物和应税劳务收入\n为基础计算销项税额，\n扣除当期允许抵扣的进\n项税额后，差额部分为\n应交增值税",
      "13%、6%",
      "13%、6%",
      "13%、6%",
      "16%、13%、\n6%"
    ],
    "城市维护建设税": [
      "实际缴纳的流转税税额",
      "7%",
      "7%",
      "7%",
      "7%"
    ],
    "教育费附加": [
      "实际缴纳的流转税税额",
      "3%",
      "3%",
      "3%",
      "3%"
    ],
    "地方教育附加": [
      "实际缴纳的流转税税额",
      "2%",
      "2%",
      "2%",
      "2%"
    ],
    "企业所得税": [
      "按应纳税所得额计缴",
      "15%、20%",
      "15%、20%",
      "15%",
      "15%"
    ]
  },
  "245-3.xlsx": {
    "": [
      "2022年 \n1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "景杰生物": [
      "15%",
      "15%",
      "15%",
      "15%"
    ],
    "景杰检验": [
      "20%",
      "20%",
      "不适用",
      "不适用"
    ],
    "臻至生物": [
      "20%",
      "20%",
      "不适用",
      "不适用"
    ],
    "PTM BIO LLC注": [
      "适用注册地所在地税率",
      "",
      "",
      ""
    ]
  },
  "247-1.xlsx": {
    "所得税优惠金额": [
      102.08,
      773.82,
      358.5,
      179.91
    ],
    "利润总额": [
      1011.93,
      7870.41,
      4679.73,
      2613.11
    ],
    "税收优惠/利润总额": [
      "10.09%",
      "9.83%",
      "7.66%",
      "6.89%"
    ]
  },
  "247-2.xlsx": {
    "母公司利润总额": [
      1096.62,
      7966.17,
      4714.36,
      2486.58
    ],
    "纳税调整": [
      -75.82,
      -239.1,
      -1129.35,
      -687.44
    ],
    "应纳税所得额": [
      1020.8,
      7727.07,
      3585.0,
      1799.13
    ],
    "税收优惠金额": [
      102.08,
      772.71,
      358.5,
      179.91
    ]
  },
  "247-3_248-1.xlsx": {
    "非流动资产处置损益，包括已计提资产减值准备的冲": [
      -0.21,
      62.02,
      6.93,
      -0.01
    ],
    "项目": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "销部分": [
      "",
      "",
      "",
      ""
    ],
    "计入当期损益的政府补助（与公司正常经营业务密切相关，符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外）": [
      103.4,
      1556.39,
      651.71,
      184.16
    ],
    "除同公司正常经营业务相关的有效套期保值业务外，持有以公允价值计量且其变动计入当期损益的金融资产、金融负债产生的公允价值变动收益，以及处置以公允价值计量且其变动计入当期损益的金融资产、金融负债和可供出售金融资产取得的投资收益": [
      "",
      47.58,
      269.89,
      21.34
    ],
    "除上述各项之外的其他营业外收入和支出": [
      -6.76,
      -6.28,
      4.8,
      -10.84
    ],
    "其他符合非经常性损益定义的损益项目": [
      40.19,
      150.05,
      22.43,
      25.87
    ],
    "非经常性损益总额": [
      136.62,
      1809.76,
      955.76,
      220.52
    ],
    "减：所得税费用（所得税费用减少以“-” 表示）": [
      20.49,
      272.11,
      143.36,
      33.08
    ],
    "少数股东损益": [
      "",
      "",
      "",
      ""
    ],
    "归属于母公司股东的非经常性损益净额": [
      116.13,
      1537.65,
      812.4,
      187.45
    ]
  },
  "248-2_249-1.xlsx": {
    "流动比率（倍）": [
      6.68,
      6.62,
      4.98,
      1.06
    ],
    "速动比率（倍）": [
      6.31,
      6.34,
      4.91,
      1.03
    ],
    "资产负债率（母公司）": [
      "15.98%",
      "17.17%",
      "18.34%",
      "84.00%"
    ],
    "资产负债率（合并）": [
      "16.27%",
      "17.52%",
      "18.41%",
      "84.40%"
    ],
    "应收账款周转率（次/年）": [
      1.07,
      3.88,
      5.48,
      10.85
    ],
    "存货周转率（次/年）": [
      0.82,
      2.45,
      4.82,
      4.73
    ],
    "主要财务指标": [
      "2022年1-6月\n/2022年6月30日",
      "2021年度/2021\n年12月31日",
      "2020年度/2020\n年12月31日",
      "2019年度/2019\n年12月31日"
    ],
    "息税折旧摊销前利润（万元）": [
      2238.44,
      9875.12,
      5378.21,
      3171.57
    ],
    "利息保障倍数（倍）": [
      12.54,
      59.2,
      "/",
      31.85
    ],
    "归属于公司普通股东的每股净资产（元）": [
      1.57,
      1.54,
      1.26,
      1.9
    ],
    "每股经营活动产生的现金流量净额（元）": [
      -0.04,
      0.11,
      0.11,
      2.88
    ],
    "每股净现金流量（元）": [
      -0.18,
      0.81,
      0.22,
      0.97
    ],
    "归属于母公司股东的净利润（万元）": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "扣除非经常性损益后归属于母公司股东的净利润（万元）": [
      828.58,
      5277.79,
      3320.39,
      2130.23
    ],
    "研发投入占营业收入的比例": [
      "14.35%",
      "16.12%",
      "14.49%",
      "10.61%"
    ]
  },
  "249-2_250-1.xlsx": {
    "": [
      "",
      "基本",
      "稀释"
    ],
    "2022年1-6月": [
      "",
      "",
      ""
    ],
    "归属于公司普通股股东的净利润": [
      138.04,
      "/",
      "/"
    ],
    "扣除非经常性损益后归属于公司普通股股东的净利润": [
      126.87,
      "/",
      "/"
    ],
    "2021年度": [
      "",
      "",
      ""
    ],
    "2020年度": [
      "",
      "",
      ""
    ],
    "项目": [
      "加权平均 \n净资产收益率\n（%）",
      "每股收益（元）",
      ""
    ],
    "2019年度": [
      "",
      "",
      ""
    ]
  },
  "25-1.xlsx": {
    "1": [
      "蛋白质组学科技服务\n平台升级项目",
      20229.41,
      20229.41,
      "杭政工出\n[2021]37\n号",
      "杭环钱环\n评批\n[2022]27\n号"
    ],
    "2": [
      "高端科研及诊断抗体\n试剂生产项目",
      13430.19,
      13430.19,
      "",
      ""
    ],
    "3": [
      "基于蛋白质组学技术\n的综合研发平台项目",
      17785.57,
      17785.57,
      "",
      ""
    ],
    "合计": [
      "",
      51445.17,
      51445.17,
      "",
      ""
    ]
  },
  "251-1.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "主营业务收入": [
      8931.62,
      99.99,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ],
    "其他业务收入": [
      0.93,
      0.01,
      0.9,
      0.0,
      "",
      "",
      "",
      ""
    ],
    "营业收入": [
      8932.54,
      100.0,
      22105.09,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "252-1.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "252-2.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "合计": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ]
  },
  "254-1.xlsx": {
    "蛋白质修饰组分析": [
      "销量",
      "GB",
      3396.7,
      7387.55,
      4975.43,
      2791.58
    ],
    "": [
      "销售单价",
      "元/GB",
      2005.63,
      2183.0,
      2522.37,
      3206.35
    ],
    "蛋白质组分析": [
      "销量",
      "GB",
      15252.27,
      35587.23,
      21148.89,
      14801.47
    ]
  },
  "255-1.xlsx": {
    "抗体试剂产品": [
      "收入",
      "万元",
      2177.06,
      4966.32,
      1040.18,
      566.52
    ],
    "": [
      "销售单价",
      "元/μl",
      20.09,
      21.37,
      23.98,
      25.87
    ]
  },
  "255-2_256-1.xlsx": {
    "": [
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）"
    ],
    "境内": [
      8764.51,
      98.13,
      21816.9,
      98.7,
      15059.99,
      98.12,
      11416.8,
      98.46
    ],
    "东北": [
      548.41,
      6.14,
      1780.66,
      8.06,
      1046.28,
      6.82,
      848.77,
      7.32
    ],
    "华北": [
      2854.3,
      31.96,
      5899.03,
      26.69,
      3199.23,
      20.84,
      2800.5,
      24.15
    ],
    "华东": [
      2252.32,
      25.22,
      5577.54,
      25.23,
      4016.2,
      26.17,
      2909.64,
      25.09
    ],
    "华南": [
      1227.39,
      13.74,
      2973.96,
      13.45,
      2123.33,
      13.83,
      1175.26,
      10.14
    ],
    "客户区域": [
      "2022年1-6月",
      "",
      "2021年度",
      "",
      "2020年度",
      "",
      "2019年度",
      ""
    ],
    "华中": [
      617.33,
      6.91,
      1625.95,
      7.36,
      2143.49,
      13.97,
      1370.8,
      11.82
    ],
    "西北": [
      324.05,
      3.63,
      1391.3,
      6.29,
      721.05,
      4.7,
      775.54,
      6.69
    ],
    "西南": [
      940.71,
      10.53,
      2568.46,
      11.62,
      1810.4,
      11.8,
      1536.29,
      13.25
    ],
    "境外": [
      167.1,
      1.87,
      287.28,
      1.3,
      288.25,
      1.88,
      178.51,
      1.54
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "256-2.xlsx": {
    "": [
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）",
      "金额",
      "比例 \n（%）"
    ],
    "第一季度": [
      3718.34,
      41.63,
      3223.33,
      14.58,
      1729.24,
      11.27,
      1761.88,
      15.19
    ],
    "第二季度": [
      5213.27,
      58.37,
      4955.47,
      22.42,
      3380.8,
      22.03,
      2497.18,
      21.54
    ],
    "第三季度": [
      "不适用",
      "不适用",
      5663.82,
      25.62,
      4065.04,
      26.49,
      2621.79,
      22.61
    ],
    "第四季度": [
      "不适用",
      "不适用",
      8261.56,
      37.38,
      6173.16,
      40.22,
      4714.45,
      40.66
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "257-1.xlsx": {
    "": [
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "主营业务成本": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ]
  },
  "257-2_258-1.xlsx": {
    "": [
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "蛋白质组学技术服务": [
      1960.2,
      94.9,
      3494.31,
      94.14,
      2690.74,
      98.09,
      2319.72,
      98.33
    ],
    "抗体试剂产品": [
      105.29,
      5.1,
      217.56,
      5.86,
      52.36,
      1.91,
      39.47,
      1.67
    ],
    "项目": [
      "2022年1-6月",
      "",
      "2021年度",
      "",
      "2020年度",
      "",
      "2019年度",
      ""
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ]
  },
  "258-2.xlsx": {
    "": [
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "直接材料": [
      280.44,
      13.58,
      571.2,
      15.39,
      404.19,
      14.73,
      342.04,
      14.5
    ],
    "直接人工": [
      852.0,
      41.25,
      1547.38,
      41.69,
      1228.0,
      44.77,
      1222.66,
      51.83
    ],
    "制造费用": [
      933.05,
      45.17,
      1593.28,
      42.92,
      1110.91,
      40.5,
      794.5,
      33.68
    ],
    "合计": [
      2065.49,
      100.0,
      3711.86,
      100.0,
      2743.1,
      100.0,
      2359.19,
      100.0
    ]
  },
  "26-1.xlsx": {
    "每股面值：": [
      "1.00元"
    ],
    "发行股数：": [
      "不超过4010万股"
    ],
    "占发行后总股本的比例：": [
      "不低于10%"
    ],
    "每股发行价格：": [
      "【】元（由发行人和主承销商通过向询价对象询价的方式或者中\n国证监会认可的其他方式确定）"
    ],
    "发行市盈率：": [
      "【】倍（按询价确定的每股发行价格除以发行后每股收益计算）"
    ],
    "发行人高级管理人员、员工拟参与战略配售情况：": [
      "若公司决定实施高管及员工战略配售，则在本次公开发行股票注\n册后、发行前，履行内部程序审议该事项具体方案，并依法进行\n披露"
    ],
    "保荐人相关子公司拟参与战略配售情况：": [
      "保荐机构及相关子公司将根据深交所的相关规定确定是否参与\n本次发行战略配售"
    ],
    "发行前每股净资产：": [
      "1.57 元（按2022 年 6 月 30 日经审计的归属于母公司所有者权\n益除以本次发行前总股本计算）"
    ],
    "发行后每股净资产：": [
      "【】元（按【】年【】月【】日经审计的归属于母公司净资产和\n实际募集资金合计额与发行后股本计算）"
    ],
    "发行市净率：": [
      "【】倍（按每股发行价格除以发行后每股净资产计算）"
    ],
    "发行方式：": [
      "本次发行采用网下向询价对象询价配售与网上向社会公众投资\n者定价发行相结合的方式 ，或采用中国证监会、深圳证券交易\n认可的其他发行方式（包括但不限于直接定价发行、向战略投资\n者配售股票等）"
    ],
    "发行对象：": [
      "符合资格的询价对象和在深圳证券交易所开户的符合资格的创\n业板市场投资者（国家法律、法规禁止购买者除外）或中国证监\n会、深圳证券交易所规定的其他对象"
    ],
    "承销方式：": [
      "余额包销"
    ],
    "募集资金总额：": [
      "【】万元"
    ],
    "募集资金净额：": [
      "【】万元"
    ],
    "发行费用概算：": [
      "本次新股发行费用总额为【】万元，其中： \n承销费及保荐费【】万元 \n审计及评估费【】万元 \n律师费【】万元 \n发行手续费【】万元"
    ]
  },
  "260-1.xlsx": {
    "": [
      "毛利",
      "占比 \n（%）",
      "毛利",
      "占比 \n（%）",
      "毛利",
      "占比 \n（%）",
      "毛利",
      "占比 \n（%）"
    ],
    "主营业务": [
      6866.12,
      99.99,
      18392.32,
      100.0,
      12605.15,
      100.0,
      9236.11,
      100.0
    ],
    "其他业务": [
      0.93,
      0.01,
      0.9,
      0.0,
      "",
      "",
      "",
      ""
    ],
    "合计": [
      6867.05,
      100.0,
      18393.22,
      100.0,
      12605.15,
      100.0,
      9236.11,
      100.0
    ]
  },
  "260-2.xlsx": {
    "": [
      "",
      "毛利\n率（%）",
      "占收入\n比例\n（%）",
      "毛利\n率（%）",
      "占收入\n比例\n（%）",
      "毛利\n率（%）",
      "占收入\n比例\n（%）",
      "毛利\n率（%）",
      "占收\n入比\n例（%）"
    ],
    "1": [
      "蛋白质组学技\n术服务",
      70.98,
      75.63,
      79.61,
      77.53,
      81.19,
      93.22,
      78.97,
      95.11
    ],
    "2": [
      "抗体试剂产品",
      95.16,
      24.37,
      95.62,
      22.47,
      94.97,
      6.78,
      93.03,
      4.89
    ],
    "-": [
      "合计",
      76.87,
      100.0,
      83.21,
      100.0,
      82.13,
      100.0,
      79.65,
      100.0
    ]
  },
  "261-1.xlsx": {
    "": [
      "",
      "毛利率\n（%）",
      "占收入\n比例（%）",
      "毛利\n率（%）",
      "占收\n入比\n例（%）",
      "毛利\n率（%）",
      "占收\n入比\n例（%）",
      "毛利\n率（%）",
      "占收\n入比\n例（%）"
    ],
    "1": [
      "蛋白质\n组学技\n术服务",
      70.98,
      75.63,
      79.61,
      77.53,
      81.19,
      93.22,
      78.97,
      95.11
    ],
    "1.1": [
      "蛋白质\n组分析",
      64.32,
      41.24,
      75.33,
      40.5,
      76.2,
      42.09,
      76.36,
      48.62
    ],
    "1.2": [
      "蛋白质\n修饰组\n分析",
      78.96,
      34.38,
      84.29,
      37.03,
      85.3,
      51.14,
      81.69,
      46.49
    ],
    "2": [
      "抗体试\n剂产品",
      95.16,
      24.37,
      95.62,
      22.47,
      94.97,
      6.78,
      93.03,
      4.89
    ],
    "-": [
      "合计",
      76.87,
      100.0,
      83.21,
      100.0,
      82.13,
      100.0,
      79.65,
      100.0
    ]
  },
  "263-1.xlsx": {
    "诺禾致源": [
      "688315.SH",
      "2021年4月",
      "生命科学基础科研服务、医\n学研究与技术服务、建库测\n序平台服务",
      "2021年、2022年\n1-6月营业收入\n18.66亿元、8.50\n亿元，净利润2.29\n亿元、0.58亿元"
    ],
    "华大基因": [
      "300676.SZ",
      "2017年7月",
      "生育健康基础研究和临床应\n用服务、肿瘤防控及转化医\n学类服务、感染防控基础研\n究和临床应用服务、多组学\n大数据服务与合成业务、精\n准医学检测综合解决方案",
      "2021年、2022年\n1-6月营业收入\n67.66亿元、31.61\n亿元，净利润\n14.78亿元、6.06\n亿元"
    ],
    "优宁维": [
      "301166.SZ",
      "2021年12月",
      "以抗体为核心的生命科学试\n剂及相关仪器、耗材和综合\n技术服务",
      "2021年、2022年\n1-6月营业收入\n11.10亿元、5.03\n亿元，净利润1.09\n亿元、0.41亿元"
    ],
    "菲鹏生物": [
      "未上市",
      "未上市",
      "体外诊断试剂原料、体外诊\n断仪器解决方案（主要产品\n为仪器）、体外诊断试剂解\n决方案（主要产品为试剂半\n成品即试剂核心组分）",
      "2021年营业收入\n23.32亿元，净利\n润15.03亿元"
    ]
  },
  "264-1.xlsx": {
    "诺禾致源": [
      42.21,
      42.89,
      35.12,
      39.15
    ],
    "华大基因": [
      54.08,
      58.09,
      60.07,
      53.56
    ],
    "优宁维": [
      22.6,
      23.19,
      22.77,
      22.27
    ],
    "菲鹏生物": [
      "未披露",
      88.5,
      93.95,
      92.7
    ],
    "可比公司均值": [
      39.63,
      53.17,
      52.98,
      51.92
    ],
    "景杰生物": [
      76.87,
      83.21,
      82.13,
      79.65
    ]
  },
  "264-2_265-1.xlsx": {
    "销售费用": [
      "金额",
      1923.74,
      4107.24,
      3221.94,
      3431.33
    ],
    "": [
      "占营业收入比例",
      "59.58%",
      "53.13%",
      "55.79%",
      "57.70%"
    ],
    "管理费用": [
      "金额",
      2408.69,
      4619.2,
      3131.89,
      1948.31
    ],
    "研发费用": [
      "金额",
      1281.96,
      3563.65,
      2223.38,
      1230.59
    ],
    "财务费用": [
      "金额",
      -292.78,
      -546.71,
      -14.84,
      79.8
    ],
    "项目": [
      "",
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "合计": [
      "金额",
      5321.62,
      11743.38,
      8562.36,
      6690.04
    ]
  },
  "265-2_266-1.xlsx": {
    "": [
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "职工薪酬": [
      1550.35,
      80.59,
      3537.72,
      86.13,
      2717.21,
      84.33,
      2806.65,
      81.8
    ],
    "货样赠品": [
      110.81,
      5.76,
      5.51,
      0.13,
      0.61,
      0.02,
      "",
      ""
    ],
    "办公、差旅费": [
      64.36,
      3.35,
      203.32,
      4.95,
      188.68,
      5.86,
      242.89,
      7.08
    ],
    "业务宣传费": [
      52.62,
      2.74,
      116.98,
      2.85,
      105.58,
      3.28,
      143.19,
      4.17
    ],
    "租赁费": [
      33.54,
      1.74,
      86.79,
      2.11,
      114.97,
      3.57,
      114.08,
      3.32
    ],
    "股份支付": [
      20.4,
      1.06,
      59.48,
      1.45,
      52.36,
      1.63,
      "",
      ""
    ],
    "折旧与摊销": [
      50.74,
      2.64,
      39.03,
      0.95,
      3.87,
      0.12,
      2.17,
      0.06
    ],
    "项目": [
      "2022年1-6月",
      "",
      "2021年度",
      "",
      "2020年度",
      "",
      "2019年",
      ""
    ],
    "外部服务费": [
      20.72,
      1.08,
      27.91,
      0.68,
      16.15,
      0.5,
      12.1,
      0.35
    ],
    "运杂费": [
      "",
      "",
      "",
      "",
      "",
      "",
      91.05,
      2.65
    ],
    "其他": [
      20.2,
      1.05,
      30.5,
      0.74,
      22.51,
      0.7,
      19.19,
      0.56
    ],
    "合计": [
      1923.74,
      100.0,
      4107.24,
      100.0,
      3221.94,
      100.0,
      3431.33,
      100.0
    ]
  },
  "266-2.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "销售职工薪酬（万元）": [
      "",
      "",
      1550.35,
      "",
      "",
      "/",
      "",
      "",
      3537.72,
      "",
      "",
      "30.20%",
      "",
      "",
      2717.21,
      "",
      "",
      "-3.19%",
      "",
      "",
      2806.65,
      ""
    ],
    "全年销售平均人数（人）": [
      "",
      "",
      120.67,
      "",
      "",
      "/",
      "",
      "",
      114.75,
      "",
      "",
      "3.85%",
      "",
      "",
      110.5,
      "",
      "",
      "-1.05%",
      "",
      "",
      111.67,
      ""
    ],
    "销售人均薪酬（万元）": [
      "",
      "",
      12.85,
      "",
      "",
      "/",
      "",
      "",
      30.83,
      "",
      "",
      "25.37%",
      "",
      "",
      24.59,
      "",
      "",
      "-2.16%",
      "",
      "",
      25.13,
      ""
    ]
  },
  "268-1.xlsx": {
    "诺禾致源": [
      18.61,
      14.7,
      15.81,
      14.97
    ],
    "华大基因": [
      19.49,
      18.3,
      12.84,
      22.09
    ],
    "优宁维": [
      9.22,
      6.94,
      7.94,
      8.42
    ],
    "菲鹏生物": [
      "未披露",
      5.58,
      5.43,
      12.82
    ],
    "可比公司平均值": [
      15.77,
      11.38,
      10.51,
      14.57
    ],
    "景杰生物": [
      21.54,
      18.58,
      20.99,
      29.59
    ]
  },
  "269-1.xlsx": {
    "": [
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比"
    ],
    "职工薪酬": [
      1519.81,
      "63.10%",
      2256.09,
      "48.84%",
      1528.51,
      "48.80%",
      1030.25,
      "52.88%"
    ],
    "股份支付": [
      229.36,
      "9.52%",
      965.95,
      "20.91%",
      262.72,
      "8.39%",
      "",
      "0.00%"
    ],
    "折旧与摊销": [
      272.77,
      "11.32%",
      453.63,
      "9.82%",
      51.99,
      "1.66%",
      17.64,
      "0.91%"
    ],
    "外部服务费": [
      140.6,
      "5.84%",
      346.88,
      "7.51%",
      281.02,
      "8.97%",
      330.94,
      "16.99%"
    ],
    "办公、差旅费": [
      104.73,
      "4.35%",
      210.49,
      "4.56%",
      195.91,
      "6.26%",
      105.32,
      "5.41%"
    ],
    "招聘费": [
      28.95,
      "1.20%",
      173.27,
      "3.75%",
      161.61,
      "5.16%",
      153.51,
      "7.88%"
    ],
    "租赁费": [
      29.62,
      "1.23%",
      43.34,
      "0.94%",
      505.99,
      "16.16%",
      220.01,
      "11.29%"
    ],
    "税费": [
      19.12,
      "0.79%",
      27.92,
      "0.60%",
      21.64,
      "0.69%",
      12.53,
      "0.64%"
    ],
    "其他": [
      63.73,
      "2.65%",
      141.64,
      "3.07%",
      122.49,
      "3.91%",
      78.11,
      "4.01%"
    ],
    "合计": [
      2408.69,
      "100.00%",
      4619.2,
      "100.00%",
      3131.89,
      "100.00%",
      1948.31,
      "100.00%"
    ]
  },
  "27-1.xlsx": {
    "联系地址：": [
      "浙江省杭州市钱塘新区杭州经济技术开发区乔新路 500 号和科\n科技中心1幢一层"
    ],
    "联系电话：": [
      "0571-28833567"
    ],
    "传真号码：": [
      "0571-28833567"
    ],
    "联系人：": [
      "谢俊"
    ]
  },
  "27-2.xlsx": {
    "住所：": [
      "广东省深圳市福田区中心三路8号卓越时代广场（二期）北座"
    ],
    "联系地址：": [
      "北京市朝阳区亮马桥路48号中信证券大厦25层"
    ],
    "联系电话：": [
      "010-60833001"
    ],
    "传真：": [
      "010-60833083"
    ],
    "保荐代表人：": [
      "焦延延、黄可"
    ],
    "项目协办人：": [
      "杜雨林"
    ],
    "项目其他经办人：": [
      "赖亦然、胡宇杰、唐浩然、李铮、高望"
    ]
  },
  "27-3.xlsx": {
    "联系地址：": [
      "上海市石门一路288号兴业太古汇香港兴业中心一座26楼"
    ],
    "联系电话：": [
      "021-52985488"
    ],
    "传真号码：": [
      "021-52985492"
    ],
    "经办律师：": [
      "邵春阳、黄维佳"
    ]
  },
  "27-4.xlsx": {
    "住所：": [
      "浙江省杭州市西湖区西溪路128号6楼"
    ],
    "联系电话：": [
      "0571-88216888"
    ],
    "传真：": [
      "0571-88216999"
    ],
    "经办注册会计师：": [
      "王建甫、易耀冬"
    ]
  },
  "270-1.xlsx": {
    "职工薪酬（万元）": [
      1182.83,
      2029.07,
      1295.96,
      975.61
    ],
    "全年平均人数（人）": [
      55.17,
      48.25,
      33.08,
      29.33
    ],
    "人均薪酬（万元）": [
      21.44,
      42.05,
      39.18,
      33.26
    ]
  },
  "271-1.xlsx": {
    "中介服务费": [
      52.23,
      203.55,
      180.44,
      201.79
    ],
    "顾问费": [
      37.58,
      42.63,
      29.45,
      44.42
    ],
    "保安、保洁服务费": [
      17.75,
      28.96,
      9.04,
      0.29
    ],
    "信息系统服务费": [
      21.27,
      26.97,
      26.23,
      60.02
    ],
    "其他": [
      11.76,
      44.76,
      35.86,
      24.42
    ],
    "合计": [
      140.6,
      346.88,
      281.02,
      330.94
    ]
  },
  "271-2.xlsx": {
    "诺禾致源": [
      "未披露",
      37.14,
      31.61,
      26.29
    ],
    "华大基因": [
      "未披露",
      30.66,
      68.51,
      19.86
    ],
    "优宁维": [
      "未披露",
      24.65,
      19.71,
      18.75
    ],
    "菲鹏生物": [
      "未披露",
      35.15,
      32.23,
      28.75
    ],
    "可比公司均值": [
      "未披露",
      31.9,
      38.02,
      23.41
    ],
    "景杰生物": [
      21.44,
      42.05,
      39.18,
      33.26
    ]
  },
  "272-1.xlsx": {
    "诺禾致源": [
      10.59,
      8.0,
      8.48,
      8.17
    ],
    "华大基因": [
      5.55,
      5.72,
      6.47,
      7.05
    ],
    "优宁维": [
      2.93,
      2.85,
      2.8,
      2.95
    ],
    "菲鹏生物": [
      "未披露",
      4.75,
      5.79,
      18.42
    ],
    "可比上市公司平均值": [
      6.36,
      5.33,
      5.89,
      9.15
    ],
    "景杰生物": [
      26.97,
      20.9,
      20.41,
      16.8
    ]
  },
  "273-1.xlsx": {
    "": [
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比"
    ],
    "职工薪酬": [
      724.82,
      "56.54%",
      1532.15,
      "42.99%",
      926.43,
      "41.67%",
      724.09,
      "58.84%"
    ],
    "外部服务费": [
      349.84,
      "27.29%",
      857.16,
      "24.05%",
      473.18,
      "21.28%",
      113.1,
      "9.19%"
    ],
    "直接材料": [
      99.88,
      "7.79%",
      392.22,
      "11.01%",
      408.98,
      "18.39%",
      151.54,
      "12.31%"
    ],
    "折旧与摊销": [
      209.02,
      "16.30%",
      448.68,
      "12.59%",
      268.11,
      "12.06%",
      188.69,
      "15.33%"
    ],
    "股份支付": [
      -146.03,
      "-11.39%",
      228.12,
      "6.40%",
      60.11,
      "2.70%",
      "",
      ""
    ],
    "其他": [
      44.44,
      "3.47%",
      105.32,
      "2.96%",
      86.59,
      "3.89%",
      53.17,
      "4.32%"
    ],
    "合计": [
      1281.96,
      "100.00%",
      3563.65,
      "100.00%",
      2223.38,
      "100.00%",
      1230.59,
      "100.00%"
    ]
  },
  "274-1.xlsx": {
    "引物合成、DNA合成及DNA测序": [
      145.97,
      231.87,
      60.64,
      0.84
    ],
    "多肽合成": [
      44.75,
      97.22,
      158.75,
      30.36
    ],
    "实验动物费": [
      75.77,
      157.49,
      170.28,
      79.32
    ],
    "质谱仪租赁费": [
      82.6,
      370.51,
      72.27,
      ""
    ],
    "其他": [
      0.75,
      0.06,
      11.23,
      2.58
    ],
    "合计": [
      349.84,
      857.16,
      473.18,
      113.1
    ]
  },
  "275-1_276-1.xlsx": {
    "基于生物质谱的蛋白质巴豆酰化高通量鉴定相关检测方法开发": [
      460.0,
      "",
      "",
      "",
      35.96,
      "已完成"
    ],
    "快速高灵敏度组蛋白H4修饰多重同时检测试剂盒的研制": [
      500.0,
      "",
      "",
      27.68,
      147.73,
      "已完成"
    ],
    "蛋白质翻译后修饰相关亲和试剂研发": [
      1625.0,
      "",
      104.81,
      811.06,
      433.2,
      "已完成"
    ],
    "基于数据非依赖型采集质谱技术的临床蛋白质组学高通量分析": [
      625.0,
      "",
      "",
      223.93,
      288.02,
      "已完成"
    ],
    "高通量宏蛋白质组学技术体系的开发": [
      465.0,
      "",
      "",
      164.55,
      269.42,
      "已完成"
    ],
    "生物大分子药物表征方法研发": [
      145.0,
      "",
      "",
      73.13,
      56.26,
      "已完成"
    ],
    "大队列临床样本的制备及质谱分析体系的开发": [
      180.0,
      "",
      "",
      152.53,
      "",
      "已完成"
    ],
    "信号转导通路相关亲和试剂研发": [
      485.0,
      "",
      "",
      458.8,
      "",
      "已完成"
    ],
    "基于蛋白质组学方法的局部进展期胃腺癌的药敏生物标志物的鉴定": [
      468.0,
      172.12,
      358.02,
      37.61,
      "",
      "执行中"
    ],
    "表观遗传学和肿瘤免疫学等科学研究前沿抗体开发": [
      1715.0,
      371.0,
      1435.01,
      73.47,
      "",
      "已完成"
    ],
    "高精准、多色标记免疫组化病理诊断抗体开发": [
      394.0,
      129.98,
      265.93,
      42.09,
      "",
      "已完成"
    ],
    "调控癌症和炎症等疾病的全新组蛋白乳酸化修饰兔单抗及试剂盒的开发和鉴定": [
      509.0,
      132.5,
      301.52,
      19.29,
      "",
      "执行中"
    ],
    "用于肠道微生物中大规模修饰位点鉴定的宏修饰组学技术方法开发": [
      390.0,
      59.47,
      201.84,
      30.88,
      "",
      "执行中"
    ],
    "用于临床组织和体液样本中完整N-糖基化修饰鉴定和定量的技术方法开发": [
      357.0,
      64.13,
      125.99,
      20.94,
      "",
      "执行中"
    ],
    "用于临床组织中翻译后修饰": [
      444.0,
      110.38,
      232.48,
      26.36,
      "",
      "执行中"
    ],
    "项目名称": [
      "预算",
      "2022年\n1-6月",
      "2021 \n年度",
      "2020 \n年度",
      "2019 \n年度",
      "进度"
    ],
    "位点精准靶向定量的PRM修饰组学技术方法开发": [
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "用于组织和细胞中大规模SUMO化修饰位点鉴定和定量的新技术开发": [
      344.0,
      73.29,
      197.29,
      26.51,
      "",
      "执行中"
    ],
    "肿瘤早期发现标志物伴随诊断抗体开发": [
      511.0,
      169.1,
      340.77,
      34.55,
      "",
      "执行中"
    ],
    "合计": [
      9617.0,
      1281.96,
      3563.65,
      2223.38,
      1230.59,
      ""
    ]
  },
  "276-2_277-1.xlsx": {
    "诺禾致源": [
      5.81,
      7.78,
      7.54,
      8.19
    ],
    "公司名称": [
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "华大基因": [
      8.22,
      7.2,
      7.38,
      11.33
    ],
    "优宁维": [
      2.17,
      1.51,
      1.03,
      1.1
    ],
    "菲鹏生物": [
      "未披露",
      7.95,
      10.51,
      35.92
    ],
    "可比公司均值": [
      5.4,
      6.11,
      6.62,
      14.14
    ],
    "景杰生物": [
      14.35,
      16.12,
      14.49,
      10.61
    ]
  },
  "277-2.xlsx": {
    "利息收入": [
      -351.9,
      -706.86,
      -58.02,
      -15.81
    ],
    "利息支出": [
      87.71,
      135.24,
      "",
      84.72
    ],
    "银行手续费": [
      4.0,
      6.11,
      7.21,
      4.46
    ],
    "汇兑损益": [
      -32.58,
      18.79,
      35.97,
      6.44
    ],
    "合计": [
      -292.78,
      -546.71,
      -14.84,
      79.8
    ]
  },
  "278-1.xlsx": {
    "与资产相关的政府补助": [
      62.97,
      125.93,
      76.72,
      ""
    ],
    "与收益相关的政府补助": [
      40.44,
      1430.46,
      574.99,
      184.16
    ],
    "增值税进项税加计抵减": [
      27.07,
      145.71,
      12.89,
      25.83
    ],
    "代扣代缴个税手续费返还": [
      13.12,
      4.34,
      9.54,
      0.04
    ],
    "合计": [
      143.6,
      1706.44,
      674.14,
      210.03
    ]
  },
  "279-1.xlsx": {
    "杭州市及钱塘区生物医药政策资金": [
      62.97,
      180.01,
      102.76,
      "",
      "与资产相关/\n与收益相关"
    ],
    "国家高新补助": [
      20.0,
      "",
      "",
      "",
      "与收益相关"
    ],
    "钱塘区送奖励行动奖金": [
      5.0,
      "",
      "",
      "",
      "与收益相关"
    ],
    "杭州市市级专利补贴": [
      0.7,
      "",
      "",
      "",
      "与收益相关"
    ],
    "省级专利授权财政补贴": [
      0.42,
      "",
      "",
      "",
      "与收益相关"
    ],
    "研发补助": [
      "",
      695.2,
      61.17,
      82.57,
      "与收益相关"
    ],
    "房租补助": [
      "",
      392.8,
      362.62,
      "",
      "与收益相关"
    ],
    "股改奖励": [
      "",
      165.0,
      "",
      "",
      "与收益相关"
    ],
    "科技创新创业补贴": [
      "",
      100.0,
      "",
      "",
      "与收益相关"
    ],
    "首届钱塘新区重才爱才先进单位奖励": [
      "",
      10.0,
      "",
      "",
      "与收益相关"
    ],
    "以工代训补助": [
      "",
      6.45,
      "",
      "",
      "与收益相关"
    ],
    "稳岗就业补贴": [
      14.32,
      6.93,
      22.51,
      "",
      "与收益相关"
    ],
    "新认定省级研发中心和知识产权运用补助": [
      "",
      "",
      60.0,
      "",
      "与收益相关"
    ],
    "2019 年度钱塘新区创新券奖励资助": [
      "",
      "",
      20.0,
      "",
      "与收益相关"
    ],
    "杭州市专利示范企业资助": [
      "",
      "",
      10.0,
      "",
      "与收益相关"
    ],
    "钱塘新区服务企业主营业务收入进档奖励": [
      "",
      "",
      3.0,
      "",
      "与收益相关"
    ],
    "杭州钱塘新区人才晋级晋升奖励": [
      "",
      "",
      2.0,
      "",
      "与收益相关"
    ],
    "企业复工复产补助": [
      "",
      "",
      0.9,
      "",
      "与收益相关"
    ],
    "钱塘新区财政局专利资助": [
      "",
      "",
      0.44,
      "",
      "与收益相关"
    ],
    "杭州就业服务中心奖补": [
      "",
      "",
      6.31,
      "",
      "与收益相关"
    ],
    "北京蛋白质组研究中心蛋白质组临床级定量和创新试剂研发经费拨付": [
      "",
      "",
      "",
      86.79,
      "与收益相关"
    ],
    "杭州经济技术开发区财政局创新券和创新创业人才补贴": [
      "",
      "",
      "",
      14.8,
      "与收益相关"
    ]
  },
  "28-1.xlsx": {
    "联系地址：": [
      "上海市浦东新区沈家弄路738号8楼"
    ],
    "联系电话：": [
      "021-68877288"
    ],
    "传真号码：": [
      "021-68877020"
    ],
    "经办注册评估师：": [
      "金燕、徐萍"
    ]
  },
  "28-2.xlsx": {
    "邮编：": [
      518038.0
    ],
    "联系电话：": [
      "0755-21899999"
    ],
    "传真号码：": [
      "0755-21899000"
    ]
  },
  "28-3.xlsx": {},
  "28-4.xlsx": {
    "电话：": [
      "0755-88668888"
    ],
    "传真": [
      "0755-82083947"
    ]
  },
  "28-5.xlsx": {
    "刊登发行公告日期": [
      "【】年【】月【】日"
    ],
    "开始询价推介日期": [
      "【】年【】月【】日"
    ],
    "刊登定价公告日期": [
      "【】年【】月【】日"
    ],
    "申购日期和缴款日期": [
      "【】年【】月【】日"
    ],
    "股票上市日期": [
      "【】年【】月【】日"
    ]
  },
  "280-1.xlsx": {
    "营业外收入": [
      3.4,
      3.9,
      4.8,
      4.16
    ],
    "违约金收入": [
      3.3,
      3.9,
      4.8,
      1.5
    ],
    "其他": [
      0.17,
      "",
      "",
      ""
    ],
    "营业外支出": [
      10.38,
      10.44,
      0.62,
      15.01
    ],
    "对外捐赠": [
      10.0,
      5.0,
      "",
      15.0
    ],
    "税收滞纳金": [
      "",
      4.28,
      "",
      ""
    ],
    "赔款支出": [
      "",
      0.9,
      "",
      ""
    ],
    "固定资产报废损失": [
      0.21,
      0.26,
      0.62,
      0.01
    ]
  },
  "280-2.xlsx": {
    "当期所得税费用": [
      153.12,
      1159.18,
      386.52,
      ""
    ],
    "递延所得税费用": [
      -85.9,
      -104.22,
      160.43,
      295.44
    ],
    "所得税费用合计": [
      67.22,
      1054.96,
      546.95,
      295.44
    ],
    "所得税费用/利润总额（%）": [
      6.64,
      13.4,
      11.69,
      11.31
    ]
  },
  "281-1.xlsx": {
    "期初未交": [
      -48.31,
      -92.15,
      120.78,
      73.1
    ],
    "本期应交": [
      -232.18,
      504.51,
      45.78,
      633.53
    ],
    "本期已交": [
      -127.5,
      460.67,
      258.72,
      585.85
    ],
    "期末未交": [
      -152.99,
      -48.31,
      -92.15,
      120.78
    ]
  },
  "282-1.xlsx": {
    "期初未交": [
      -232.32,
      -839.23,
      -633.86,
      -272.38
    ],
    "本期应交": [
      153.12,
      1687.15,
      386.52,
      ""
    ],
    "本期已交": [
      265.14,
      1080.24,
      591.88,
      361.48
    ],
    "期末未交": [
      -344.35,
      -232.32,
      -839.23,
      -633.86
    ]
  },
  "282-2.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）"
    ],
    "流动资产": [
      50187.69,
      74.17,
      53895.3,
      79.97,
      49251.63,
      88.55,
      16314.45,
      89.15
    ],
    "非流动资产": [
      17474.28,
      25.83,
      13503.16,
      20.03,
      6370.51,
      11.45,
      1985.0,
      10.85
    ],
    "合计": [
      67661.97,
      100.0,
      67398.46,
      100.0,
      55622.15,
      100.0,
      18299.44,
      100.0
    ]
  },
  "283-1.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）"
    ],
    "货币资金": [
      36110.0,
      71.95,
      43446.74,
      80.61,
      13416.12,
      27.24,
      5507.89,
      33.76
    ],
    "交易性金融资产": [
      "",
      "",
      "",
      "",
      29548.85,
      60.0,
      8001.29,
      49.04
    ],
    "应收账款": [
      9518.9,
      18.97,
      7241.71,
      13.44,
      4141.69,
      8.41,
      1458.51,
      8.94
    ],
    "预付账款": [
      194.83,
      0.39,
      186.44,
      0.35,
      277.73,
      0.56,
      33.47,
      0.21
    ],
    "其他应收款": [
      197.46,
      0.39,
      178.58,
      0.33,
      204.17,
      0.41,
      241.78,
      1.48
    ],
    "存货": [
      2742.96,
      5.47,
      2312.06,
      4.29,
      713.44,
      1.45,
      425.37,
      2.61
    ],
    "其他流动资产": [
      1423.54,
      2.84,
      529.76,
      0.98,
      949.63,
      1.93,
      646.13,
      3.96
    ],
    "合计": [
      50187.69,
      100.0,
      53895.3,
      100.0,
      49251.63,
      100.0,
      16314.45,
      100.0
    ]
  },
  "283-2.xlsx": {
    "库存现金": [
      2.81,
      2.81,
      2.81,
      2.01
    ],
    "银行存款": [
      36050.47,
      42520.7,
      13248.46,
      5205.88
    ],
    "其他货币资金": [
      56.72,
      923.24,
      164.85,
      300.0
    ],
    "合计": [
      36110.0,
      43446.74,
      13416.12,
      5507.89
    ]
  },
  "284-1.xlsx": {
    "账面余额": [
      10675.65,
      7900.3,
      4459.22,
      1591.6
    ],
    "坏账准备": [
      1156.74,
      658.58,
      317.53,
      133.09
    ],
    "账面价值": [
      9518.9,
      7241.71,
      4141.69,
      1458.51
    ]
  },
  "285-1.xlsx": {
    "": [
      "账面余额",
      "应收占比",
      "账面余额",
      "应收占比"
    ],
    "医院客户": [
      2477.57,
      "55.56%",
      613.53,
      "38.55%"
    ],
    "基础科研客户": [
      1751.69,
      "39.28%",
      914.48,
      "57.46%"
    ],
    "工业客户": [
      229.96,
      "5.16%",
      63.59,
      "4.00%"
    ],
    "合计": [
      4459.22,
      "100.00%",
      1591.6,
      "100.00%"
    ],
    "客户类别": [
      "2020.12.31",
      "",
      "2019.12.31",
      ""
    ]
  },
  "285-2.xlsx": {
    "": [
      "收入占比",
      "应收占比",
      "收入占比",
      "应收占比"
    ],
    "医院客户": [
      "39.58%",
      "55.56%",
      "30.31%",
      "38.55%"
    ],
    "基础科研客户": [
      "52.55%",
      "39.28%",
      "66.32%",
      "57.46%"
    ],
    "工业客户": [
      "7.86%",
      "5.16%",
      "3.37%",
      "4.00%"
    ],
    "合计": [
      "100.00%",
      "100.00%",
      "100.00%",
      "100.00%"
    ],
    "客户类别": [
      "2020年度/2020年12月31日",
      "",
      "2019年度/2019年12月31日",
      ""
    ]
  },
  "286-1_287-1.xlsx": {
    "2022年6月末": [
      1.0,
      "中国人民解放军海军军医大学第一附属医院",
      348.91,
      3.27
    ],
    "": [
      "合计",
      "",
      202.68,
      12.73
    ],
    "2021年末": [
      1.0,
      "华中科技大学同济医学院附属同济医院",
      288.69,
      3.65
    ],
    "时点": [
      "序\n号",
      "单位名称",
      "金额（万元）",
      "占比（%）"
    ],
    "2020年末": [
      1.0,
      "四川大学华西医院",
      211.17,
      4.74
    ],
    "2019年末": [
      1.0,
      "沈阳农业大学",
      48.82,
      3.07
    ]
  },
  "287-2_288-1.xlsx": {
    "": [
      "金额",
      "比例（%）",
      "坏账准备",
      "计提比例（%）",
      "净额"
    ],
    "1年以内": [
      1420.06,
      89.22,
      71.0,
      5.0,
      1349.06
    ],
    "1-2年": [
      123.16,
      7.74,
      24.63,
      20.0,
      98.53
    ],
    "2-3年": [
      18.2,
      1.14,
      7.28,
      40.0,
      10.92
    ],
    "3年以上": [
      30.18,
      1.9,
      30.18,
      100.0,
      ""
    ],
    "合计": [
      1591.6,
      100.0,
      133.09,
      8.36,
      1458.51
    ],
    "账龄": [
      "2019.12.31",
      "",
      "",
      "",
      ""
    ]
  },
  "288-2_289-1.xlsx": {
    "": [
      "1年以内",
      "1-2年",
      "2-3年",
      "3-4年",
      "4-5年",
      "5年以上"
    ],
    "华大基因 （医学板块）": [
      6.0,
      30.0,
      60.0,
      90.0,
      "",
      ""
    ],
    "公司": [
      5.0,
      20.0,
      40.0,
      100.0,
      "",
      ""
    ],
    "华大基因 （科服板块）": [
      20.0,
      50.0,
      80.0,
      100.0,
      "",
      ""
    ],
    "诺禾致源": [
      2.5,
      10.0,
      "19.00/17.00/15.00",
      "40.00/30.00",
      100.0,
      ""
    ],
    "菲鹏生物": [
      5.0,
      10.0,
      20.0,
      30.0,
      50.0,
      100.0
    ],
    "优宁维": [
      "公司在计量应收款项预期信用损失时参照历史信用损失经验，并考虑前瞻性\n信息，使用逾期天数与违约损失率对照表确定该应收账款组合的预期信用损\n失。",
      "",
      "",
      "",
      "",
      ""
    ]
  },
  "289-2.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "1年以内": [
      185.08,
      94.99,
      178.33,
      95.65,
      277.38,
      99.87,
      31.18,
      93.14
    ],
    "1-2年": [
      9.23,
      4.74,
      8.11,
      4.35,
      0.33,
      0.12,
      2.3,
      6.86
    ],
    "2-3年": [
      0.52,
      0.27,
      "",
      "",
      0.03,
      0.01,
      "",
      ""
    ],
    "合计": [
      194.83,
      100.0,
      186.44,
      100.0,
      277.73,
      100.0,
      33.47,
      100.0
    ]
  },
  "289-3_290-1.xlsx": {
    "2022.6.30": [
      1.0,
      "天术生物科技（上海）有限公司",
      124.95,
      64.13,
      "货款"
    ],
    "": [
      "合计",
      "",
      18.42,
      55.03,
      ""
    ],
    "时点": [
      "序号",
      "单位名称",
      "金额",
      "占比\n（%）",
      "性质"
    ],
    "2021.12.31": [
      1.0,
      "天术生物科技（上海）有限公司",
      78.13,
      41.9,
      "货款"
    ],
    "2020.12.31": [
      1.0,
      "天术生物科技（上海）有限公司",
      207.93,
      74.87,
      "货款"
    ],
    "2019.12.31": [
      1.0,
      "杭州龙湖房地产开发有限公司第一分公\n司",
      6.08,
      18.16,
      "福利费"
    ]
  },
  "291-1_292-1.xlsx": {
    "2022.6.30": [
      1.0,
      "杭州万海投资管理有限公司",
      91.84,
      46.31,
      "2-3年",
      "房租保证金"
    ],
    "": [
      "合计",
      "",
      203.46,
      82.68,
      "",
      ""
    ],
    "2021.12.31": [
      1.0,
      "杭州万海投资管理有限公司",
      91.84,
      51.35,
      "2-3年",
      "房租保证金"
    ],
    "2020.12.31": [
      1.0,
      "杭州万海投资管理有限公司",
      92.1,
      44.99,
      "1年以内、\n1-2年",
      "房租保证金"
    ],
    "时点": [
      "序\n号",
      "单位名称",
      "金额",
      "占比\n（%）",
      "账龄",
      "性质"
    ],
    "2019.12.31": [
      1.0,
      "杭州万海投资管理有限公司",
      91.84,
      37.32,
      "1年以内",
      "房租保证金"
    ]
  },
  "292-2.xlsx": {
    "": [
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比",
      "金额",
      "占比"
    ],
    "1年以内": [
      44.21,
      "22.29%",
      21.92,
      "12.25%",
      65.31,
      "31.90%",
      200.64,
      "81.52%"
    ],
    "1-2年": [
      35.93,
      "18.12%",
      36.4,
      "20.35%",
      102.6,
      "50.12%",
      26.65,
      "10.83%"
    ],
    "2-3年": [
      95.55,
      "48.18%",
      100.0,
      "55.91%",
      20.4,
      "9.97%",
      5.1,
      "2.07%"
    ],
    "3年以上": [
      22.64,
      "11.41%",
      20.55,
      "11.49%",
      16.4,
      "8.01%",
      13.73,
      "5.58%"
    ],
    "合计": [
      198.33,
      "100.00%",
      178.86,
      "100.00%",
      204.71,
      "100.00%",
      246.12,
      "100.00%"
    ],
    "坏账准备": [
      0.88,
      "",
      0.28,
      "",
      0.54,
      "",
      4.34,
      ""
    ],
    "账面价值": [
      197.46,
      "",
      178.58,
      "",
      204.17,
      "",
      241.78,
      ""
    ]
  },
  "292-3_293-1.xlsx": {
    "": [
      "账面余额",
      "跌价准备",
      "账面价值"
    ],
    "原材料": [
      141.53,
      7.89,
      133.65
    ],
    "库存商品": [
      76.88,
      16.63,
      60.25
    ],
    "在产品": [
      64.94,
      16.01,
      48.93
    ],
    "合同履约成本": [
      "",
      "",
      ""
    ],
    "未完成劳务": [
      182.54,
      "",
      182.54
    ],
    "合计": [
      465.9,
      40.53,
      425.37
    ],
    "项目": [
      "2019年12月31日",
      "",
      ""
    ]
  },
  "294-1.xlsx": {
    "抗体试剂产品原材料": [
      928.55,
      989.24,
      367.75,
      28.19
    ],
    "库存商品": [
      1281.23,
      823.27,
      180.31,
      76.88
    ],
    "在产品": [
      558.78,
      434.4,
      152.21,
      64.94
    ],
    "抗体试剂产品存货": [
      2768.56,
      2246.91,
      700.27,
      170.01
    ],
    "存货账面余额": [
      3161.64,
      2603.38,
      840.73,
      465.9
    ],
    "抗体试剂产品存货占比": [
      "87.57%",
      "86.31%",
      "83.29%",
      "36.49%"
    ]
  },
  "295-1.xlsx": {
    "预缴所得税": [
      344.35,
      232.34,
      839.23,
      633.86
    ],
    "上市中介服务费": [
      880.54,
      192.8,
      "",
      ""
    ],
    "待摊费用": [
      43.97,
      56.31,
      18.25,
      12.27
    ],
    "增值税留抵税额": [
      154.68,
      48.31,
      92.15,
      ""
    ],
    "合计": [
      1423.54,
      529.76,
      949.63,
      646.13
    ]
  },
  "295-2_296-1.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）"
    ],
    "固定资产": [
      4142.16,
      23.7,
      3739.26,
      27.69,
      4013.96,
      63.01,
      1481.16,
      74.62
    ],
    "在建工程": [
      4806.41,
      27.51,
      857.67,
      6.35,
      "",
      "",
      76.53,
      3.86
    ],
    "使用权资产": [
      3635.01,
      20.8,
      3724.03,
      27.58,
      "",
      "",
      "",
      ""
    ],
    "无形资产": [
      2237.88,
      12.81,
      2197.4,
      16.27,
      182.65,
      2.87,
      90.03,
      4.54
    ],
    "长期待摊费用": [
      2062.81,
      11.8,
      1943.42,
      14.39,
      1832.3,
      28.76,
      "",
      ""
    ],
    "项目": [
      "2022.6.30",
      "",
      "2021.12.31",
      "",
      "2020.12.31",
      "",
      "2019.12.31",
      ""
    ],
    "递延所得税资产": [
      366.97,
      2.1,
      281.07,
      2.08,
      176.85,
      2.78,
      337.28,
      16.99
    ],
    "其他非流动资产": [
      223.03,
      1.28,
      760.32,
      5.63,
      164.75,
      2.59,
      "",
      ""
    ],
    "合计": [
      17474.28,
      100.0,
      13503.16,
      100.0,
      6370.51,
      100.0,
      1985.0,
      100.0
    ]
  },
  "296-2.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）"
    ],
    "通用设备": [
      547.22,
      13.21,
      597.3,
      15.97,
      651.86,
      16.24,
      73.24,
      4.94
    ],
    "专用设备": [
      3594.37,
      86.78,
      3141.39,
      84.01,
      3361.53,
      83.75,
      1407.35,
      95.02
    ],
    "运输工具": [
      0.57,
      0.01,
      0.57,
      0.02,
      0.57,
      0.01,
      0.57,
      0.04
    ],
    "账面原值合计": [
      8105.85,
      100.0,
      7014.69,
      100.0,
      6412.23,
      100.0,
      3272.29,
      100.0
    ],
    "累计折旧合计": [
      3963.69,
      100.0,
      3275.44,
      100.0,
      2398.27,
      100.0,
      1791.13,
      100.0
    ],
    "账面价值合计": [
      4142.16,
      100.0,
      3739.26,
      100.0,
      4013.96,
      100.0,
      1481.16,
      100.0
    ]
  },
  "297-1.xlsx": {
    "通用设备": [
      "年限平均法",
      "3-10",
      3.0,
      "9.70-32.33"
    ],
    "专用设备": [
      "年限平均法",
      "3-5",
      3.0,
      "19.40-32.33"
    ],
    "运输工具": [
      "年限平均法",
      4.0,
      3.0,
      24.25
    ]
  },
  "297-2.xlsx": {
    "办公设备及其他": [
      "年限平均法",
      "3-5",
      5.0,
      "19-32"
    ],
    "运输设备": [
      "年限平均法",
      4.0,
      5.0,
      24.0
    ],
    "机器设备": [
      "年限平均法",
      5.0,
      5.0,
      19.0
    ],
    "房屋建筑物": [
      "年限平均法",
      "20-50",
      5.0,
      "1.9-4.75"
    ]
  },
  "297-3.xlsx": {
    "房屋及建筑物": [
      "年限平均法",
      30.0,
      5.0,
      3.17
    ],
    "通用设备": [
      "年限平均法",
      5.0,
      5.0,
      19.0
    ],
    "专用设备": [
      "年限平均法",
      10.0,
      5.0,
      9.5
    ],
    "运输工具": [
      "年限平均法",
      "5-10",
      5.0,
      "9.50-19.00"
    ],
    "其他设备": [
      "年限平均法",
      "3-5",
      5.0,
      "19.00-31.67"
    ]
  },
  "297-4_298-1.xlsx": {
    "生产设备": [
      "年限平均法",
      "5-10",
      5.0,
      "9.5-19"
    ],
    "类别": [
      "折旧方法",
      "折旧年限（年）",
      "预计残值率\n（%）",
      "年折旧率（%）"
    ],
    "房屋及建筑物": [
      "年限平均法",
      "20-50",
      5.0,
      "1.9-4.8"
    ],
    "运输工具": [
      "年限平均法",
      "4-6",
      5.0,
      "15.8-23.8"
    ],
    "办公及电子设备": [
      "年限平均法",
      "3-10",
      5.0,
      "9.5-31.7"
    ]
  },
  "298-2.xlsx": {
    "房屋及建筑物": [
      "年限平均法",
      20.0,
      5.0,
      4.75
    ],
    "机器设备": [
      "年限平均法",
      5.0,
      5.0,
      19.0
    ],
    "运输工具": [
      "年限平均法",
      5.0,
      5.0,
      19.0
    ],
    "办公设备及其他": [
      "年限平均法",
      "3-5",
      5.0,
      "19.00-31.67"
    ]
  },
  "298-3_299-1.xlsx": {
    "在安装设备": [
      885.54,
      462.41,
      "",
      ""
    ],
    "新厂房建设工程": [
      3920.87,
      269.76,
      "",
      ""
    ],
    "项目": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ],
    "医药港小镇办公楼四楼医学实验室洁净车间装修工程": [
      "",
      125.5,
      "",
      ""
    ],
    "医药港小镇办公楼装修工程": [
      "",
      "",
      "",
      76.53
    ],
    "合计": [
      4806.41,
      857.67,
      "",
      76.53
    ]
  },
  "299-2.xlsx": {
    "房屋及建筑物": [
      4322.56,
      687.56,
      "",
      3635.01
    ]
  },
  "299-3.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）"
    ],
    "土地使用权": [
      1951.46,
      87.2,
      1971.24,
      89.71,
      "",
      "",
      "",
      ""
    ],
    "办公软件": [
      286.42,
      12.8,
      226.16,
      10.29,
      182.65,
      100.0,
      90.03,
      100.0
    ],
    "账面原值合计": [
      2444.82,
      100.0,
      2331.58,
      100.0,
      235.81,
      100.0,
      107.17,
      100.0
    ],
    "累计摊销合计": [
      206.94,
      100.0,
      134.18,
      100.0,
      53.16,
      100.0,
      17.14,
      100.0
    ],
    "账面价值合计": [
      2237.88,
      100.0,
      2197.4,
      100.0,
      182.65,
      100.0,
      90.03,
      100.0
    ]
  },
  "300-1.xlsx": {
    "医药港小镇办公楼装修工程": [
      1552.17,
      1644.72,
      1832.3,
      ""
    ],
    "医药港小镇办公楼三楼体外诊断试剂洁净车间装修工程": [
      266.69,
      282.69,
      "",
      ""
    ],
    "医药港小镇办公楼西侧楼梯通道维修和食堂排污管道改造工程": [
      7.54,
      7.99,
      "",
      ""
    ],
    "医药港小镇办公楼RT-PCR实验室改造工程": [
      7.56,
      8.02,
      "",
      ""
    ],
    "医药港小镇办公楼抗体制备实验室改造工程": [
      9.01,
      "",
      "",
      ""
    ],
    "医药港小镇办公楼四楼医学实验室洁净车间装修工程": [
      219.84,
      "",
      "",
      ""
    ],
    "合计": [
      2062.81,
      1943.42,
      1832.3,
      ""
    ]
  },
  "300-2_301-1.xlsx": {
    "科目": [
      "项目",
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ],
    "递延所得税资产": [
      "资产减值准备",
      232.78,
      140.1,
      65.81,
      23.9
    ],
    "": [
      "小计",
      366.97,
      281.07,
      184.18,
      337.48
    ],
    "递延所得税负债": [
      "交易性金融资产\n公允价值变动",
      "",
      "",
      7.33,
      0.19
    ],
    "以净额列示的递延所得税资产": [
      "合计",
      366.97,
      281.07,
      176.85,
      337.28
    ]
  },
  "301-2.xlsx": {
    "待验收无形资产": [
      200.91,
      220.86,
      14.15,
      ""
    ],
    "预付设备款": [
      22.12,
      539.46,
      150.6,
      ""
    ],
    "合计": [
      223.03,
      760.32,
      164.75,
      ""
    ]
  },
  "302-1.xlsx": {
    "": [
      "金额",
      "占比 \n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "流动负债": [
      7516.52,
      68.3,
      8137.51,
      68.9,
      9889.9,
      96.61,
      15444.79,
      100.0
    ],
    "非流动负债": [
      3489.33,
      31.7,
      3672.47,
      31.1,
      347.48,
      3.39,
      "",
      ""
    ],
    "合计": [
      11005.84,
      100.0,
      11809.98,
      100.0,
      10237.38,
      100.0,
      15444.79,
      100.0
    ]
  },
  "302-2.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）",
      "金额",
      "占比 \n（%）"
    ],
    "应付账款": [
      1373.61,
      18.27,
      929.79,
      11.43,
      1782.09,
      18.02,
      452.22,
      2.93
    ],
    "预收款项": [
      "",
      "",
      "",
      "",
      "",
      "",
      5733.7,
      37.12
    ],
    "合同负债": [
      4129.04,
      54.93,
      4821.39,
      59.25,
      6504.51,
      65.77,
      "",
      ""
    ],
    "应付职工薪酬": [
      1320.92,
      17.57,
      1845.81,
      22.68,
      1414.61,
      14.3,
      985.64,
      6.38
    ],
    "应交税费": [
      44.86,
      0.6,
      31.62,
      0.39,
      40.11,
      0.41,
      164.83,
      1.07
    ],
    "其他应付款": [
      231.55,
      3.08,
      149.26,
      1.83,
      148.57,
      1.5,
      8108.41,
      52.5
    ],
    "一年内到期的非流动负债": [
      416.54,
      5.54,
      359.64,
      4.42,
      "",
      "",
      "",
      ""
    ],
    "合计": [
      7516.52,
      100.0,
      8137.51,
      100.0,
      9889.9,
      100.0,
      15444.79,
      100.0
    ]
  },
  "303-1.xlsx": {
    "设备工程款": [
      758.6,
      442.24,
      852.17,
      26.26
    ],
    "货款": [
      478.43,
      357.65,
      401.51,
      203.82
    ],
    "费用": [
      136.59,
      129.9,
      528.41,
      222.14
    ],
    "合计": [
      1373.61,
      929.79,
      1782.09,
      452.22
    ]
  },
  "303-2_304-1.xlsx": {
    "2022.6.30": [
      1.0,
      "杭州国成建设工程有限公司",
      "设备工程款",
      "装修工程",
      481.33,
      35.04
    ],
    "": [
      "合计",
      "",
      "/",
      "/",
      208.06,
      46.01
    ],
    "2021.12.31": [
      1.0,
      "苏州安捷信环境技术工程有\n限公司",
      "设备工程款",
      "装修工程",
      126.7,
      13.63
    ],
    "年度": [
      "序\n号",
      "单位名称",
      "性质",
      "主要采购内容",
      "金额",
      "占比\n（%）"
    ],
    "2020.12.31": [
      1.0,
      "浙江悦容建设集团有限公司",
      "设备工程款",
      "装修工程",
      495.41,
      27.8
    ],
    "2019.12.31": [
      1.0,
      "立信会计师事务所（特殊普通\n合伙）",
      "费用",
      "中介服务",
      75.47,
      16.69
    ]
  },
  "305-1.xlsx": {
    "2022.6.30": [
      1.0,
      "昆明医科大学第一附属医院",
      152.0,
      3.68
    ],
    "": [
      "合计",
      "",
      624.87,
      10.9
    ],
    "2021.12.31": [
      1.0,
      "山东第一医科大学",
      145.85,
      3.03
    ],
    "2020.12.31": [
      1.0,
      "山东第一医科大学",
      152.26,
      2.34
    ],
    "2019.12.31": [
      1.0,
      "华中科技大学同济医学院附属同济医院",
      227.13,
      3.96
    ]
  },
  "306-1.xlsx": {
    "短期薪酬：": [
      "",
      "",
      "",
      ""
    ],
    "工资、奖金、津贴和补贴": [
      813.77,
      1516.26,
      1187.92,
      909.86
    ],
    "职工福利费": [
      "",
      "",
      "",
      ""
    ],
    "社会保险费": [
      26.4,
      29.13,
      10.57,
      17.82
    ],
    "住房公积金": [
      1.23,
      1.38,
      "",
      0.17
    ],
    "工会经费和职工教育经费": [
      1.2,
      1.3,
      4.1,
      2.76
    ],
    "小计": [
      41.8,
      42.94,
      12.92,
      22.34
    ],
    "离职后福利（设定提存计划）：": [
      "",
      "",
      "",
      ""
    ],
    "基本养老保险": [
      40.5,
      41.5,
      12.48,
      21.59
    ],
    "失业保险费": [
      1.3,
      1.44,
      0.44,
      0.75
    ],
    "辞退福利": [
      436.51,
      254.8,
      199.1,
      32.68
    ],
    "合计": [
      1320.92,
      1845.81,
      1414.61,
      985.64
    ]
  },
  "306-2_307-1.xlsx": {
    "增值税": [
      1.69,
      "",
      "",
      120.78
    ],
    "企业所得税": [
      "",
      0.02,
      "",
      ""
    ],
    "代扣代缴个人所得税": [
      18.75,
      31.2,
      39.68,
      28.8
    ],
    "城市维护建设税": [
      0.04,
      "",
      "",
      8.57
    ],
    "土地使用税": [
      5.01,
      "",
      "",
      ""
    ],
    "教育费附加": [
      0.03,
      "",
      "",
      3.67
    ],
    "地方教育附加": [
      0.02,
      "",
      "",
      2.45
    ],
    "印花税": [
      0.2,
      0.4,
      0.43,
      0.55
    ],
    "项目": [
      "2022.6.30",
      "2021.12.31",
      "2020.12.31",
      "2019.12.31"
    ],
    "残疾人就业保障金": [
      19.12,
      "",
      "",
      ""
    ],
    "合计": [
      44.86,
      31.62,
      40.11,
      164.83
    ]
  },
  "307-2.xlsx": {
    "押金保证金": [
      127.03,
      127.16,
      129.05,
      89.58
    ],
    "投资款": [
      "",
      "",
      "",
      8000.0
    ],
    "应付暂收款": [
      85.37,
      5.08,
      2.21,
      8.72
    ],
    "费用款": [
      19.15,
      17.02,
      17.31,
      10.11
    ],
    "合计": [
      231.55,
      149.26,
      148.57,
      8108.41
    ]
  },
  "308-1.xlsx": {
    "": [
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金额",
      "占比\n（%）",
      "金\n额",
      "占比\n（%）"
    ],
    "租赁负债": [
      3330.74,
      95.46,
      3450.92,
      93.97,
      "",
      "",
      "",
      ""
    ],
    "递延收益": [
      158.59,
      4.54,
      221.55,
      6.03,
      347.48,
      100.0,
      "",
      ""
    ],
    "合计": [
      3489.33,
      100.0,
      3672.47,
      100.0,
      347.48,
      100.0,
      "",
      ""
    ]
  },
  "308-2.xlsx": {
    "股本": [
      36000.0,
      36000.0,
      36000.0,
      1500.0
    ],
    "资本公积": [
      12361.0,
      12223.51,
      7939.88,
      950.74
    ],
    "盈余公积": [
      849.68,
      849.68,
      156.37,
      48.69
    ],
    "其他综合收益": [
      -21.94,
      -7.4,
      -12.03,
      -20.02
    ],
    "未分配利润": [
      7467.39,
      6522.68,
      1300.54,
      375.25
    ],
    "归属于母公司股东权益": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ],
    "少数股东权益": [
      "",
      "",
      "",
      ""
    ],
    "股东权益合计": [
      56656.13,
      55588.47,
      45384.77,
      2854.65
    ]
  },
  "309-1.xlsx": {
    "期初未分配利润": [
      6522.68,
      1300.54,
      375.25,
      -1893.73
    ],
    "加：本期归属于母公司股东的净利润": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "减：提取法定盈余公积": [
      "",
      693.31,
      156.37,
      48.69
    ],
    "整体变更设立股份公司": [
      "",
      "",
      3051.11,
      ""
    ],
    "应付普通股股利": [
      "",
      900.0,
      "",
      ""
    ],
    "期末未分配利润": [
      7467.39,
      6522.68,
      1300.54,
      375.25
    ]
  },
  "309-2_310-1.xlsx": {
    "流动比率（倍）": [
      6.68,
      6.62,
      4.98,
      1.06
    ],
    "指标": [
      "2022年 \n6月30日",
      "2021年 \n12月31日",
      "2020年 \n12月31日",
      "2019年 \n12月31日"
    ],
    "速动比率（倍）": [
      6.31,
      6.34,
      4.91,
      1.03
    ],
    "资产负债率": [
      "16.27%",
      "17.52%",
      "18.41%",
      "84.40%"
    ],
    "息税折旧摊销前利润 （万元）": [
      2238.44,
      9875.12,
      5378.21,
      3171.57
    ],
    "利息保障倍数": [
      12.54,
      59.2,
      "/",
      31.85
    ]
  },
  "310-2.xlsx": {
    "诺禾致源": [
      "流动比率",
      1.91,
      1.87,
      1.34,
      1.29
    ],
    "": [
      "资产负债率",
      "16.27%",
      "17.52%",
      "18.41%",
      "84.40%"
    ],
    "菲鹏生物": [
      "流动比率",
      "未披露",
      4.05,
      2.47,
      2.55
    ],
    "华大基因": [
      "流动比率",
      3.65,
      3.26,
      2.21,
      2.82
    ],
    "优宁维": [
      "流动比率",
      10.67,
      10.33,
      2.97,
      2.65
    ],
    "可比公司均值": [
      "流动比率",
      5.41,
      4.88,
      2.25,
      2.33
    ],
    "景杰生物": [
      "流动比率",
      6.68,
      6.62,
      4.98,
      1.06
    ]
  },
  "311-1.xlsx": {
    "存货周转率": [
      0.82,
      2.45,
      4.82,
      4.73
    ],
    "应收账款周转率": [
      1.07,
      3.88,
      5.48,
      10.85
    ]
  },
  "311-2_312-1.xlsx": {
    "诺禾致源": [
      "存货周转率",
      2.17,
      4.93,
      4.84,
      5.43
    ],
    "项目": [
      "",
      "2022年1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "": [
      "应收账款周转率",
      1.07,
      3.88,
      5.48,
      10.85
    ],
    "菲鹏生物": [
      "存货周转率",
      "未披露",
      1.76,
      1.07,
      0.68
    ],
    "华大基因": [
      "存货周转率",
      1.53,
      3.0,
      4.96,
      4.45
    ],
    "优宁维": [
      "存货周转率",
      3.79,
      13.98,
      15.14,
      17.1
    ],
    "可比公司均值": [
      "存货周转率",
      2.5,
      5.92,
      6.5,
      6.92
    ],
    "景杰生物": [
      "存货周转率",
      0.82,
      2.45,
      4.82,
      4.73
    ]
  },
  "313-1.xlsx": {
    "一、经营活动产生的现金流量": [
      "",
      "",
      "",
      ""
    ],
    "经营活动现金流入小计": [
      6516.16,
      20715.13,
      15348.25,
      13808.33
    ],
    "经营活动现金流出小计": [
      7948.97,
      16804.09,
      11219.96,
      9487.08
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ],
    "二、投资活动产生的现金流量": [
      "",
      "",
      "",
      ""
    ],
    "投资活动现金流入小计": [
      867.06,
      29676.47,
      56529.88,
      8020.04
    ],
    "投资活动现金流出小计": [
      4922.2,
      6248.66,
      82597.61,
      17497.69
    ],
    "投资活动产生的现金流量净额": [
      -4055.14,
      23427.82,
      -26067.73,
      -9477.64
    ],
    "三、筹资活动产生的现金流量": [
      "",
      "",
      "",
      ""
    ],
    "筹资活动现金流入小计": [
      "",
      3519.77,
      30000.0,
      8000.0
    ],
    "筹资活动现金流出小计": [
      999.45,
      1579.32,
      "",
      1386.11
    ],
    "筹资活动产生的现金流量净额": [
      -999.45,
      1940.45,
      30000.0,
      6613.9
    ],
    "四、汇率变动对现金及现金等价物的影响": [
      17.18,
      -7.07,
      -17.18,
      4.2
    ],
    "五、现金及现金等价物净增加额": [
      -6470.22,
      29272.23,
      8043.38,
      1461.7
    ],
    "加：期初现金及现金等价物余额": [
      42523.51,
      13251.27,
      5207.89,
      3746.19
    ],
    "六、期末现金及现金等价物余额": [
      36053.28,
      42523.51,
      13251.27,
      5207.89
    ]
  },
  "314-1.xlsx": {
    "销售商品、提供劳务收到的现金": [
      5890.82,
      18512.12,
      14151.38,
      13593.97
    ],
    "收到的税费返还": [
      127.5,
      23.9,
      "",
      ""
    ],
    "收到其他与经营活动有关的现金": [
      497.84,
      2179.11,
      1196.87,
      214.36
    ],
    "经营活动现金流入小计": [
      6516.16,
      20715.13,
      15348.25,
      13808.33
    ],
    "购买商品、接受劳务支付的现金": [
      1287.85,
      3374.98,
      2086.82,
      1099.44
    ],
    "支付给职工以及为职工支付的现金": [
      5381.42,
      8829.69,
      6018.32,
      5671.71
    ],
    "支付的各项税费": [
      267.49,
      1630.4,
      914.09,
      1035.35
    ],
    "支付其他与经营活动有关的现金": [
      1012.21,
      2969.02,
      2200.73,
      1680.59
    ],
    "经营活动现金流出小计": [
      7948.97,
      16804.09,
      11219.96,
      9487.08
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ]
  },
  "314-2_315-1.xlsx": {
    "净利润": [
      944.71,
      6815.45,
      4132.78,
      2317.67
    ],
    "加：资产减值准备": [
      662.88,
      527.65,
      291.79,
      72.49
    ],
    "固定资产折旧、油气资产折耗、生产性生物资产折旧": [
      693.11,
      1162.45,
      615.56,
      459.5
    ],
    "使用权资产折旧": [
      249.75,
      437.81,
      "",
      ""
    ],
    "无形资产摊销": [
      72.76,
      81.02,
      36.02,
      14.25
    ],
    "项目": [
      "2022年 \n1-6月",
      "2021年度",
      "2020年度",
      "2019年度"
    ],
    "长期待摊费用摊销": [
      123.19,
      188.18,
      46.9,
      ""
    ],
    "处置固定资产、无形资产和其他长期资产的损失（收益以“－”号填列）": [
      "",
      -62.28,
      -7.55,
      ""
    ],
    "固定资产报废损失（收益以“－”号填列）": [
      0.21,
      0.26,
      0.62,
      0.01
    ],
    "公允价值变动损失（收益以“－”号填列）": [
      "",
      "",
      -47.56,
      -1.29
    ],
    "财务费用（收益以“－”号填列）": [
      86.94,
      135.75,
      2.2,
      85.87
    ],
    "投资损失（收益以“－”号填列）": [
      "",
      -47.58,
      -222.33,
      -20.04
    ],
    "递延所得税资产减少（增加以“－”号填列）": [
      -85.9,
      -104.22,
      160.43,
      295.44
    ],
    "递延所得税负债增加（减少以“－”号填列）": [
      "",
      "",
      "",
      ""
    ],
    "存货的减少（增加以“－”号填列）": [
      -587.22,
      -1787.85,
      -401.71,
      134.81
    ],
    "经营性应收项目的减少（增加以“－”号填列）": [
      -3008.47,
      -2710.52,
      -3393.91,
      -1267.52
    ],
    "经营性应付项目的增加（减少以“－”号填列）": [
      -722.25,
      -1488.95,
      2525.7,
      2197.67
    ],
    "其他": [
      137.48,
      763.86,
      389.35,
      32.41
    ],
    "经营活动产生的现金流量净额": [
      -1432.81,
      3911.04,
      4128.29,
      4321.25
    ]
  },
  "316-1.xlsx": {
    "收回投资收到的现金": [
      "",
      29500.0,
      56000.0,
      8000.0
    ],
    "取得投资收益收到的现金": [
      "",
      96.43,
      222.33,
      20.04
    ],
    "处置固定资产、无形资产和其他长期资产收回的现金净额": [
      0.06,
      80.04,
      7.55,
      ""
    ],
    "处置子公司及其他营业单位收到的现金净额": [
      "",
      "",
      "",
      ""
    ],
    "收到其他与投资活动有关的现金": [
      867.0,
      "",
      300.0,
      ""
    ],
    "投资活动现金流入小计": [
      867.06,
      29676.47,
      56529.88,
      8020.04
    ],
    "购建固定资产、无形资产和其他长期资产支付的现金": [
      4922.2,
      5488.66,
      4947.61,
      1197.69
    ],
    "投资支付的现金": [
      "",
      "",
      77500.0,
      16000.0
    ],
    "取得子公司及其他营业单位支付的现金净额": [
      "",
      "",
      "",
      ""
    ],
    "支付其他与投资活动有关的现金": [
      "",
      760.0,
      150.0,
      300.0
    ],
    "投资活动现金流出小计": [
      4922.2,
      6248.66,
      82597.61,
      17497.69
    ],
    "投资活动产生的现金流量净额": [
      -4055.14,
      23427.82,
      -26067.73,
      -9477.64
    ]
  },
  "317-1.xlsx": {
    "吸收投资收到的现金": [
      "",
      "",
      30000.0,
      8000.0
    ],
    "取得借款收到的现金": [
      "",
      "",
      "",
      ""
    ],
    "收到其他与筹资活动有关的现金": [
      "",
      3519.77,
      "",
      ""
    ],
    "筹资活动现金流入小计": [
      "",
      3519.77,
      30000.0,
      8000.0
    ],
    "偿还债务支付的现金": [
      "",
      "",
      "",
      500.0
    ],
    "分配股利、利润或偿付利息支付的现金": [
      "",
      900.0,
      "",
      36.11
    ],
    "支付其他与筹资活动有关的现金": [
      999.45,
      679.32,
      "",
      850.0
    ],
    "筹资活动现金流出小计": [
      999.45,
      1579.32,
      "",
      1386.11
    ],
    "筹资活动产生的现金流量净额": [
      -999.45,
      1940.45,
      30000.0,
      6613.9
    ]
  },
  "319-1.xlsx": {
    "1": [
      "蛋白质组学科技服务\n平台升级项目",
      20229.41,
      20229.41,
      "杭政工出\n[2021]37\n号",
      "杭环钱环\n评批\n[2022]27\n号"
    ],
    "2": [
      "高端科研及诊断抗体\n试剂生产项目",
      13430.19,
      13430.19,
      "",
      ""
    ],
    "3": [
      "基于蛋白质组学技术\n的综合研发平台项目",
      17785.57,
      17785.57,
      "",
      ""
    ],
    "合计": [
      "",
      51445.17,
      51445.17,
      "",
      ""
    ]
  },
  "323-1_324-1.xlsx": {
    "1": [
      "建筑工程费用",
      5505.54,
      "27.22%"
    ],
    "序号": [
      "项目",
      "投资金额（万元）",
      "占比"
    ],
    "2": [
      "设备购置费用",
      8880.17,
      "43.90%"
    ],
    "3": [
      "设备安装费用",
      407.39,
      "2.01%"
    ],
    "4": [
      "工程建设其他费用",
      1604.3,
      "7.93%"
    ],
    "5": [
      "预备费用",
      468.34,
      "2.32%"
    ],
    "6": [
      "铺底流动资金",
      3363.69,
      "16.63%"
    ],
    "总投资金额": [
      "",
      20229.41,
      "100.00%"
    ]
  },
  "324-2.xlsx": {
    "1": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "1.1": [
      "蛋白组学科技服\n务平台综合楼",
      "",
      "",
      "",
      "",
      "",
      "",
      "新建"
    ],
    "1.1.1": [
      "实验室",
      "",
      "",
      "",
      "",
      "",
      "",
      "新建"
    ],
    "1.1.1.1": [
      "特级实验室",
      "",
      "",
      2250.0,
      1500.0,
      3000.0,
      1012.5,
      "新建"
    ],
    "1.1.1.2": [
      "常规实验室",
      "",
      "",
      6250.0,
      1500.0,
      2000.0,
      2187.5,
      "新建"
    ],
    "1.1.2": [
      "办公区",
      "",
      "",
      4000.0,
      1500.0,
      1500.0,
      1200.0,
      "新建"
    ],
    "1.2": [
      "地下建筑",
      "",
      "",
      2800.0,
      2500.0,
      1000.0,
      980.0,
      "新建"
    ],
    "小计": [
      "",
      "",
      "",
      "",
      "",
      "",
      125.54,
      ""
    ],
    "2": [
      "总图工程",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "2.1": [
      "道路广场",
      "",
      "",
      910.23,
      300.0,
      "",
      27.31,
      ""
    ],
    "2.2": [
      "绿化",
      "",
      "",
      3508.15,
      280.0,
      "",
      98.23,
      ""
    ],
    "合计": [
      "",
      "",
      "",
      "",
      "",
      "",
      5505.54,
      ""
    ]
  },
  "325-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "*"
    ],
    "1": [
      "项目前期准备 \n（含设计）",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "2": [
      "土建工程",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "3": [
      "装修改造",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "4": [
      "设备购置、安装及调试",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "5": [
      "人员招聘与培训",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "6": [
      "竣工验收",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ]
  },
  "330-1.xlsx": {
    "1": [
      "建筑工程费",
      4150.79,
      "30.91%"
    ],
    "2": [
      "设备购置费",
      5542.58,
      "41.27%"
    ],
    "3": [
      "安装工程费",
      274.38,
      "2.04%"
    ],
    "4": [
      "工程建设其他费用",
      919.13,
      "6.84%"
    ],
    "5": [
      "预备费",
      308.54,
      "2.30%"
    ],
    "6": [
      "铺底流动资金",
      2234.77,
      "16.64%"
    ],
    "总投资金额": [
      "",
      13430.19,
      "100.00%"
    ]
  },
  "330-2_331-1.xlsx": {
    "1": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "1.1": [
      "抗体厂房",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "1.1.1": [
      "洁净厂房",
      "",
      "",
      2500.0,
      1500.0,
      2500.0,
      1000.0,
      "新建"
    ],
    "1.1.2": [
      "普通厂房",
      "",
      "",
      7500.0,
      1500.0,
      1500.0,
      2250.0,
      "新建"
    ],
    "1.2": [
      "地下建筑",
      "",
      "",
      2200.0,
      2500.0,
      1000.0,
      770.0,
      "新建"
    ],
    "小计": [
      "",
      "",
      "",
      "",
      130.79,
      "",
      "",
      ""
    ],
    "2": [
      "总图工程",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "序号": [
      "名称",
      "工程量（m2）",
      "土建单价 \n（元/m2）",
      "装修单价 \n（元/m2）",
      "投资额 \n（万元）",
      "备注",
      "",
      ""
    ],
    "2.1": [
      "道路广场",
      1660.56,
      300.0,
      "",
      49.82,
      "",
      "",
      ""
    ],
    "2.2": [
      "绿化",
      2891.85,
      280.0,
      "",
      80.97,
      "",
      "",
      ""
    ],
    "合计": [
      "",
      "",
      "",
      "",
      4150.79,
      "",
      "",
      ""
    ]
  },
  "332-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "*"
    ],
    "1": [
      "项目前期准备",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "2": [
      "勘察设计",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "3": [
      "土建施工",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "4": [
      "设备采购、安装及调试",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "5": [
      "人员招聘与培训",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "6": [
      "竣工验收",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "7": [
      "试运营",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ]
  },
  "336-1_337-1.xlsx": {
    "1": [
      "建筑工程费",
      9272.5,
      "52.13%"
    ],
    "2": [
      "设备购置费",
      5983.87,
      "33.64%"
    ],
    "3": [
      "安装工程费",
      192.91,
      "1.08%"
    ],
    "序号": [
      "项  目",
      "投资额（万元）",
      "比例"
    ],
    "4": [
      "工程建设其他费用",
      1842.13,
      "10.36%"
    ],
    "5": [
      "预备费",
      494.15,
      "2.78%"
    ],
    "总投资金额": [
      "",
      17785.57,
      "100.00%"
    ]
  },
  "337-2.xlsx": {
    "1.1": [
      "研发中心",
      17500.0,
      1500.0,
      2000.0,
      6125.0
    ],
    "1.2": [
      "专家楼",
      4000.0,
      1500.0,
      3000.0,
      1800.0
    ],
    "1.3": [
      "地下建筑",
      4300.0,
      2500.0,
      1000.0,
      1347.5
    ],
    "合计": [
      "",
      25350.0,
      "",
      "",
      9272.5
    ]
  },
  "338-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "*"
    ],
    "1": [
      "项目前期准备",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "2": [
      "勘察设计",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "3": [
      "土建施工",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "4": [
      "设备采购、安装及调试",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "5": [
      "人员招聘与培训",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "6": [
      "竣工验收",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "7": [
      "试运营",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ]
  },
  "350-1.xlsx": {
    "1": [
      "首钢医院\n有限公司",
      "景杰\n生物",
      "技术服\n务（委\n托）合同",
      "蛋白质组学研究/\n蛋白质修饰组学\n研究/生物信息学\n分析等",
      1680000.0,
      "2022/3/21",
      "履行\n完毕"
    ],
    "2": [
      "上海交通\n大学医学\n院附属新\n华医院",
      "景杰\n生物",
      "服务合\n同",
      "蛋白质组学和代\n谢组学研究服务",
      1800000.0,
      "2021/2/1",
      "正在\n履行"
    ],
    "3": [
      "广州呼吸\n健康研究\n院",
      "景杰\n生物",
      "技术服\n务（委\n托）合同",
      "512例诱导痰上清\n样本高通量蛋白质\n组学和靶向蛋白质\n组学分析",
      2500000.0,
      "2021/6/1-2023/6/1",
      "履行\n完毕"
    ],
    "4": [
      "河南农业\n大学",
      "景杰\n有限",
      "技术服\n务（委\n托）合同",
      "60个白花泡桐组\n织样本TMT标记\n定量磷酸化组学、\n乙酰化组学、巴豆\n酰化修饰组学及全\n蛋组学研究项目",
      1597800.0,
      "2018/7/20-2020/7/20",
      "履行\n完毕"
    ],
    "5": [
      "上海绿谷\n制药有限\n公司",
      "景杰\n有限",
      "技术服\n务（委\n托）合同",
      "256个血浆样本全\n蛋白Blood+定量\n蛋白质组学研究",
      1024000.0,
      "2020/12/8-2021/12/8",
      "履行\n完毕"
    ],
    "6": [
      "中国科学\n技术大学",
      "景杰\n有限",
      "技术服\n务（委\n托）合同",
      "24个组织样本全\n蛋白、磷酸化、乙\n酰化、琥珀酰化、\n巴豆酰化及乳酸化\n修饰4D Label Free\n定量研究",
      929510.0,
      "2019/12/26-2022/12/25",
      "履行\n完毕"
    ],
    "7": [
      "百济神州\n（北京）生\n物科技有\n限公司",
      "景杰\n有限",
      "主要服\n务合同",
      "蛋白质组学服务及\n抗体研发",
      "框架协议",
      "2019/7/30",
      "正在\n履行"
    ]
  },
  "351-1.xlsx": {
    "1": [
      "产品采购合同",
      "杭州力翔医疗设\n备有限公司",
      "激光显微切割系统",
      1850000.0,
      "2022/6/22",
      "正在\n履行"
    ],
    "2": [
      "合同",
      "布鲁克科学仪器\n香港有限公司",
      "质谱仪仪器",
      "665000美元",
      "2022/1/6",
      "正在\n履行"
    ],
    "3": [
      "销售合同",
      "天术智能（上海）\n科技有限公司",
      "原料一批",
      1150000.0,
      "2021/12/17",
      "正在\n履行"
    ],
    "4": [
      "销售合同",
      "天术智能（上海）\n科技有限公司",
      "原料一批",
      1130000.0,
      "2021/12/16",
      "正在\n履行"
    ],
    "5": [
      "合同",
      "布鲁克科学仪器香\n港有限公司",
      "质谱仪仪器",
      "665000美元",
      "2021/11/18",
      "履行\n完毕"
    ],
    "6": [
      "买卖合同",
      "赛默飞世尔科技\n（中国）有限公司",
      "质谱仪仪器",
      5989923.0,
      "2021/11/10",
      "履行\n完毕"
    ],
    "7": [
      "买卖合同",
      "赛默飞世尔科技\n（中国）有限公司",
      "质谱仪仪器",
      "725000美元",
      "2021/9/10",
      "正在\n履行"
    ],
    "8": [
      "销售合同",
      "布鲁克（北京）科\n技有限公司",
      "质谱仪仪器",
      4049750.0,
      "2021/5/17",
      "履行\n完毕"
    ],
    "9": [
      "销售合同",
      "英潍捷基（上海）\n贸易有限公司",
      "Tandem Mass TagTM",
      2063776.0,
      "2021/4/12",
      "履行\n完毕"
    ],
    "10": [
      "销售合同",
      "天术智能（上海）\n科技有限公司",
      "原料一批",
      1173860.0,
      "2020/12/30",
      "履行\n完毕"
    ],
    "11": [
      "销售合同",
      "天术智能（上海）\n科技有限公司",
      "原料一批",
      1088515.0,
      "2020/12/30",
      "履行\n完毕"
    ],
    "12": [
      "产品采购合同",
      "杭州乐乾科学仪器\n有限公司",
      "流式细胞仪",
      1324000.0,
      "2020/12/11",
      "履行\n完毕"
    ],
    "13": [
      "销售合同",
      "赛默飞世尔科技\n（中国）有限公司",
      "质谱仪仪器",
      "720000美元",
      "2020/9/22",
      "履行\n完毕"
    ],
    "14": [
      "销售合同",
      "布鲁克科学仪器香\n港有限公司",
      "2台质谱仪仪器",
      "1100000美元",
      "2020/9/16",
      "履行\n完毕"
    ],
    "15": [
      "销售合同",
      "赛默飞世尔科技\n（中国）有限公司",
      "质谱仪仪器",
      "735000美元",
      "2020/8/21",
      "履行\n完毕"
    ],
    "16": [
      "销售合同",
      "英潍捷基（上海）\n贸易有限公司",
      "Tandem Mass TagTM",
      1451240.0,
      "2020/5/25",
      "履行\n完毕"
    ],
    "17": [
      "销售合同",
      "上海星庭进出口有\n限公司",
      "质谱仪仪器",
      5855690.0,
      "2019/12/14",
      "履行\n完毕"
    ]
  },
  "352-1.xlsx": {
    "1": [
      "建设工\n程委托\n监理合\n同",
      "宁波国\n际投资\n咨询有\n限公司",
      "杭州景杰生物科技股份有限公\n司蛋白质组学技术服务和抗体\n研发生产项目监理合同",
      "2100000（注\n1）",
      "2022/2/25",
      "正在\n履行"
    ],
    "2": [
      "建设工\n程造价\n咨询合\n同",
      "建银工\n程咨询\n有限责\n任公司",
      "杭州景杰生物科技股份有限公\n司蛋白质组学技术服务和抗体\n研发生产项目造价咨询合同",
      "1100000 \n（注2）",
      "2022/1/22",
      "正在\n履行"
    ],
    "3": [
      "建设工\n程施工\n合同及\n补充协\n议",
      "杭州国\n成建设\n工程有\n限公司",
      "杭州景杰生物科技股份有限公\n司蛋白质组学技术服务和抗体\n研发生产项目施工合同",
      163514707.0,
      "2022/2/24",
      "正在\n履行"
    ],
    "4": [
      "建设工\n程施工\n合同",
      "浙江悦\n容建设\n集团有\n限公司",
      "杭州景杰生物科技有限公司办\n公楼及实验室装修设计、采购施\n工EPC总承包工程",
      "20850000（暂\n定合同价）",
      "2019/8/9",
      "履行\n完毕"
    ]
  },
  "39-1.xlsx": {
    "公司英文名称：": [
      "Jingjie PTM BioLab （HangZhou） Co. Inc."
    ],
    "注册资本：": [
      "36000万元人民币"
    ],
    "法定代表人：": [
      "程仲毅"
    ],
    "成立日期：": [
      "2010年12月30日（2020年12月25日整体变更为股份有限公\n司）"
    ],
    "公司住所：": [
      "浙江省杭州市钱塘新区杭州经济技术开发区乔新路 500 号和科\n科技中心1幢一层"
    ],
    "邮政编码：": [
      310018.0
    ],
    "联系电话/传真：": [
      "0571-28833567"
    ],
    "公司网址：": [
      "http://www.ptm-biolab.com.cn"
    ],
    "电子信箱：": [
      "ir@ptm-biolab.com"
    ],
    "信息披露部门：": [
      "董事会办公室"
    ],
    "信息披露负责人：": [
      "谢俊"
    ],
    "信息披露部门联系电话：": [
      "0571-28925667"
    ]
  },
  "40-1.xlsx": {
    "1": [
      "蒋旦如",
      402.6,
      "61%"
    ],
    "2": [
      "程仲毅",
      92.4,
      "14%"
    ],
    "3": [
      "赵卫权",
      66.0,
      "10%"
    ],
    "4": [
      "张宝仙",
      66.0,
      "10%"
    ],
    "5": [
      "金晓东",
      33.0,
      "5%"
    ],
    "总计": [
      "",
      660.0,
      "100%"
    ]
  },
  "42-1_43-1.xlsx": {
    "1": [
      "蒋旦如",
      93223800.0,
      "25.8955%"
    ],
    "序号": [
      "发起人名称",
      "股份数量",
      "持股比例"
    ],
    "2": [
      "上海江村",
      88723080.0,
      "24.6453%"
    ],
    "3": [
      "国投创业基金",
      37409760.0,
      "10.3916%"
    ],
    "4": [
      "杭州哲驰",
      34853760.0,
      "9.6816%"
    ],
    "5": [
      "程仲毅",
      29317320.0,
      "8.1437%"
    ],
    "6": [
      "珠海瑛杰",
      25714440.0,
      "7.1429%"
    ],
    "7": [
      "成都博远",
      14142960.0,
      "3.9286%"
    ],
    "8": [
      "苏州隆门六号",
      6400440.0,
      "1.7779%"
    ],
    "9": [
      "达晨创鸿",
      6171480.0,
      "1.7143%"
    ],
    "10": [
      "姜绪荣",
      5142960.0,
      "1.4286%"
    ],
    "11": [
      "福州泰弘",
      3857040.0,
      "1.0714%"
    ],
    "12": [
      "西藏数联",
      3857040.0,
      "1.0714%"
    ],
    "13": [
      "青岛正永",
      3214440.0,
      "0.8929%"
    ],
    "14": [
      "浙江和信",
      2571480.0,
      "0.7143%"
    ],
    "15": [
      "珠海泰弘",
      2571480.0,
      "0.7143%"
    ],
    "16": [
      "财智创赢",
      1542960.0,
      "0.4286%"
    ],
    "17": [
      "海南华昆",
      1285560.0,
      "0.3571%"
    ],
    "合计": [
      "",
      360000000.0,
      "100%"
    ]
  },
  "43-2.xlsx": {
    "1": [
      "上海江村",
      615.0,
      "41%"
    ],
    "2": [
      "蒋旦如",
      600.0,
      "40%"
    ],
    "3": [
      "程仲毅",
      195.0,
      "13%"
    ],
    "4": [
      "丁健",
      75.0,
      "5%"
    ],
    "5": [
      "赵雷杰",
      15.0,
      "1%"
    ],
    "合计": [
      "",
      1500.0,
      "100%"
    ]
  },
  "44-1.xlsx": {
    "2020年 4月": [
      "股权转让\n及增资",
      "1、股权转让 \n蒋旦如、程仲毅、赵雷杰、丁健、上海江村分别将其\n持有公司4.58%、1.49%、0.12%、0.57%、5.24%股\n权以1元/股的价格转让给杭州哲驰； \n上海江村将其持有公司3.00%股权以1元/股的价格\n转让给杭州哲康； \n蒋旦如、程仲毅、丁健、上海江村分别将其持有公司\n1.11%、0.44%、1.11%、2.21%股权以50元/股的价\n格转让给成都博远； \n赵雷杰将其持有公司0.89%股权以50元/股的价格转\n让给翱鹰实业。 \n2、增资 \n公司注册资本由1500万元增至1660万元，新增注\n册资本160万元由新股东国投创业基金以8000万元\n认缴。",
      "原股东转让\n给杭州哲驰\n及杭州哲康\n的价格为1元\n/股，转让给成\n都博远和翱\n鹰实业的价\n格为50元/\n股；增资价格\n为50元/股",
      1660.0
    ],
    "2020年 10月": [
      "股权转让\n及增资",
      "1、股权转让 \n程仲毅将其持有公司0.48%和0.40%股权分别转让给\n苏州隆门六号和海南华昆； \n蒋旦如将其持有公司1.00%和1.00%股权分别转让给\n苏州隆门六号和青岛正永； \n丁健将其持有公司1.92%、0.60%和0.48%股权分别\n转让给达晨创鸿、福州泰弘和财智创赢； \n杭州哲康将其持有公司0.80%、0.80%、0.60%和\n0.51%股权分别转让给国投创业基金、珠海泰弘、福\n州泰弘和苏州隆门六号； \n翱鹰实业将其持有公司0.80%股权转让给浙江和信。 \n2、增资 \n公司注册资本由1660万元增至1859.20万元，新增\n注册资本由新股东珠海瑛杰、西藏数联、姜绪荣及原\n股东国投创业基金以人民币30000万元认缴，其中\n人民币199.20万元计入公司注册资本，剩余金额计\n入公司资本公积。",
      "杭州哲康转\n让给福州泰\n弘的价格为\n150.69元/股，\n翱鹰实业转\n让给浙江和\n信的价格为\n150.59元/股，\n丁健转让给\n福州泰弘的\n价格为\n150.51元/股，\n其余股权转\n让及增资价\n格均为\n150.60元/股",
      1859.2
    ],
    "2020年 12月": [
      "整体变更\n为股份公\n司",
      "以截至2020年10月31日的净资产账面价值，按\n1:0.8241的比例折合为股份公司的股份总额\n36000.00万股，整体变更为股份有限公司，全体股\n东持股比例不变",
      "",
      36000.0
    ]
  },
  "44-2_45-1.xlsx": {
    "1": [
      "蒋旦如",
      93223800.0,
      "25.8955%"
    ],
    "序号": [
      "发起人名称",
      "股份数量",
      "持股比例"
    ],
    "2": [
      "上海江村",
      88723080.0,
      "24.6453%"
    ],
    "3": [
      "国投创业基金",
      37409760.0,
      "10.3916%"
    ],
    "4": [
      "杭州哲驰",
      34853760.0,
      "9.6816%"
    ],
    "5": [
      "程仲毅",
      29317320.0,
      "8.1437%"
    ],
    "6": [
      "珠海瑛杰",
      25714440.0,
      "7.1429%"
    ],
    "7": [
      "成都博远",
      14142960.0,
      "3.9286%"
    ],
    "8": [
      "苏州隆门六号",
      6400440.0,
      "1.7779%"
    ],
    "9": [
      "达晨创鸿",
      6171480.0,
      "1.7143%"
    ],
    "10": [
      "姜绪荣",
      5142960.0,
      "1.4286%"
    ],
    "11": [
      "福州泰弘",
      3857040.0,
      "1.0714%"
    ],
    "12": [
      "西藏数联",
      3857040.0,
      "1.0714%"
    ],
    "13": [
      "青岛正永",
      3214440.0,
      "0.8929%"
    ],
    "14": [
      "浙江和信",
      2571480.0,
      "0.7143%"
    ],
    "15": [
      "珠海泰弘",
      2571480.0,
      "0.7143%"
    ],
    "16": [
      "财智创赢",
      1542960.0,
      "0.4286%"
    ],
    "17": [
      "海南华昆",
      1285560.0,
      "0.3571%"
    ],
    "合计": [
      "",
      360000000.0,
      "100%"
    ]
  },
  "48-1_49-1.xlsx": {
    "统一社会信用代码": [
      "91330100MA2KGT6G4G",
      ""
    ],
    "住所": [
      "浙江省杭州市钱塘新区下沙街道乔新路500号和科科技中心 1幢4\n层401室",
      ""
    ],
    "法定代表人": [
      "程仲毅",
      ""
    ],
    "注册资本": [
      "人民币500万元",
      ""
    ],
    "企业类型": [
      "有限责任公司（自然人投资或控股的法人独资）",
      ""
    ],
    "成立日期": [
      "2021年6月1日",
      ""
    ],
    "经营期限": [
      "2021年6月1日至长期",
      ""
    ],
    "经营范围": [
      "许可项目：医疗服务；技术进出口（依法须经批准的项目，经相关\n部门批准后方可开展经营活动，具体经营项目以审批结果为准）。\n一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、\n技术推广（除依法须经批准的项目外，凭营业执照依法自主开展经\n营活动）。",
      ""
    ],
    "股东构成及控制情况": [
      "发行人持有其100%股权",
      ""
    ],
    "主营业务": [
      "医学检验",
      ""
    ],
    "主营业务与发行人主营业务的关系": [
      "公司发展医学检验业务的全资子公司",
      ""
    ],
    "主要财务数据": [
      "项目",
      "2022.6.30/2022年1-6月"
    ],
    "": [
      "净利润（万元）",
      -33.99
    ]
  },
  "49-2.xlsx": {
    "统一社会信用代码": [
      "91310115MA7B1AT90G",
      ""
    ],
    "住所": [
      "中国（上海）自由贸易试验区张江路665号三层",
      ""
    ],
    "法定代表人": [
      "程仲毅",
      ""
    ],
    "注册资本": [
      "人民币200万元",
      ""
    ],
    "企业类型": [
      "有限责任公司（自然人投资或控股的法人独资）",
      ""
    ],
    "成立日期": [
      "2021年8月23日",
      ""
    ],
    "经营期限": [
      "2021年8月23日至长期",
      ""
    ],
    "经营范围": [
      "一般项目：从事生物科技领域内的技术开发、技术服务：专用化学\n产品销售（不含危险化学品），货物进出口。（除依法须经批准的项\n目外，凭营业执照依法自主开展经营活动）",
      ""
    ],
    "股东构成及控制情况": [
      "发行人持有其100%股权",
      ""
    ],
    "主营业务": [
      "蛋白质组学技术服务",
      ""
    ],
    "主营业务与发行人主营业务的关系": [
      "与发行人主营业务相同，定位为公司的区域业务中心",
      ""
    ],
    "主要财务数据": [
      "项目",
      "2022.6.30/2022年1-6月"
    ],
    "": [
      "净利润（万元）",
      -82.66
    ]
  },
  "50-1.xlsx": {
    "投资总额": [
      "80万美元",
      ""
    ],
    "经理": [
      "程仲毅",
      ""
    ],
    "成立日期": [
      "2016年1月13日",
      ""
    ],
    "住所": [
      "2021 W Campbell Park Drive Suite 305 Chicago IL 60612.",
      ""
    ],
    "主要生产经营地": [
      "2021 W Campbell Park Drive Suite 305 Chicago IL 60612.",
      ""
    ],
    "股东构成及控制情况": [
      "发行人持有其100%股权",
      ""
    ],
    "主营业务": [
      "国际抗体市场的商业拓展业务",
      ""
    ],
    "主营业务与发行人主营业务的关系": [
      "发行人全资子公司，主要负责发行人国际抗体市场的商业拓展业务",
      ""
    ],
    "主要财务数据": [
      "项目",
      "2022.6.30/2022年1-6月"
    ],
    "": [
      "净利润（万元）",
      -68.83
    ]
  },
  "50-2_51-1.xlsx": {
    "统一社会信用代码": [
      "91110108MA01WCQ94A"
    ],
    "住所": [
      "北京市海淀区紫金数码园3号楼9层0908"
    ],
    "负责人": [
      "程仲毅"
    ],
    "企业类型": [
      "其他股份有限公司分公司（非上市）"
    ],
    "成立日期": [
      "2020年10月12日"
    ],
    "经营期限": [
      "2020年10月12日至无固定期限"
    ],
    "经营范围": [
      "检测服务；技术开发、技术服务；货物进出口。（市场主体依法自\n主选择经营项目，开展经营活动；依法须经批准的项目，经相关部\n门批准后依批准的内容开展经营活动；不得从事国家和本市产业政"
    ],
    "": [
      "策禁止和限制类项目的经营活动。）"
    ]
  },
  "51-2.xlsx": {
    "性别": [
      "女"
    ],
    "国籍": [
      "中国"
    ],
    "身份证号": [
      "3307261978********"
    ],
    "是否取得其他国家或者地区的居留权": [
      "具有美国永久居留权"
    ]
  },
  "52-1.xlsx": {
    "性别": [
      "男"
    ],
    "国籍": [
      "中国"
    ],
    "身份证号": [
      "3402231974********"
    ],
    "是否取得其他国家或者地区的居留权": [
      "无境外永久居留权"
    ]
  },
  "55-1.xlsx": {
    "性别": [
      "男"
    ],
    "国籍": [
      "美国"
    ],
    "护照号": [
      "599994***"
    ]
  },
  "56-1.xlsx": {
    "统一社会信用代码": [
      "91330101MA2H0FJU3T"
    ],
    "执行事务合伙人": [
      "杭州承鼎企业管理有限公司"
    ],
    "经营场所": [
      "浙江省杭州经济技术开发区白杨街道6号大街452号2幢C1609\n号房"
    ],
    "企业类型": [
      "有限合伙企业"
    ],
    "注册资本": [
      "人民币180万元"
    ],
    "实收资本": [
      "人民币180万元"
    ],
    "成立日期": [
      "2019年11月11日"
    ],
    "经营范围": [
      "技术开发、技术服务、技术咨询、成果转让：网络信息技术，计\n算机软硬件，生物技术。（依法须经批准的项目，经相关部门批\n准后方可开展经营活动）"
    ],
    "主营业务及其与发行人主营业务的关系": [
      "杭州哲驰为员工持股平台，除持有发行人9.6816%股份外，无投资\n或参与经营其他经营性实体的情形"
    ]
  },
  "56-2.xlsx": {
    "统一社会信用代码": [
      "91330100MA2GLE5F24"
    ],
    "法定代表人": [
      "Yingming Zhao"
    ],
    "经营场所": [
      "浙江省杭州市钱塘新区18号大街795号1幢6层611室"
    ],
    "企业类型": [
      "有限责任公司（外国自然人独资）"
    ],
    "成立日期": [
      "2019年4月9日"
    ],
    "经营范围": [
      "服务：企业管理咨询，经济信息咨询（除商品中介），企业形象策\n划，商务信息咨询（除商品中介），市场营销策划，图文设计（涉\n及国家规定实施准入特别管理措施的除外）。"
    ],
    "主营业务及其与发行人主营业务的关系": [
      "杭州承鼎为杭州哲驰的执行事务合伙人"
    ]
  },
  "57-1.xlsx": {
    "1": [
      "Yingming Zhao",
      10.0,
      "100%"
    ],
    "合计": [
      "",
      10.0,
      "100%"
    ]
  },
  "57-2.xlsx": {
    "统一社会信用代码": [
      "91330101MA2H0FLW24"
    ],
    "执行事务合伙人": [
      "杭州承鼎企业管理有限公司"
    ],
    "经营场所": [
      "浙江省杭州经济技术开发区白杨街道6号大街452号2幢C1606\n号房"
    ],
    "企业类型": [
      "有限合伙企业"
    ],
    "成立日期": [
      "2019年11月11日"
    ],
    "经营范围": [
      "技术开发、技术服务、技术咨询、成果转让：网络信息技术，计\n算机软硬件，生物技术。（涉及国家规定实施准入特别管理措施\n的除外）。（依法须经批准的项目，经相关部门批准后方可开展\n经营活动）"
    ],
    "主营业务及其与发行人主营业务的关系": [
      "杭州哲康无投资或参与经营其他经营性实体的情形"
    ]
  },
  "57-3.xlsx": {
    "1": [
      "吕松涛",
      "有限合伙人",
      44.55,
      "99 %"
    ],
    "2": [
      "杭州承鼎企业管理有限公司",
      "普通合伙人",
      0.45,
      "1%"
    ],
    "合计": [
      "",
      "",
      45.0,
      "100%"
    ]
  },
  "58-1.xlsx": {
    "统一社会信用代码": [
      "91310000312386811Y"
    ],
    "法定代表人": [
      "吕松涛"
    ],
    "经营场所": [
      "中国（上海）自由贸易试验区牛顿路421号6幢103部位312室"
    ],
    "企业类型": [
      "有限责任公司（自然人投资或控股）"
    ],
    "注册资本": [
      "人民币27000万元"
    ],
    "实收资本": [
      "人民币27000万元"
    ],
    "成立日期": [
      "2014年9月10日"
    ],
    "经营范围": [
      "实业投资，投资管理，企业管理咨询，中医文化传播，健康咨询，企业形\n象策划，市场营销策划，市场信息咨询与调查（不得从事社会调查、社会\n调研、民意调查、民意测验），文化艺术活动策划，广告的设计、制作、\n代理与发布，医疗设备、医药产品、保健品的研发及相关领域内的技术开\n发、技术转让、技术咨询、技术服务，中医教学仪器设备、实验室试剂（除\n危险品）及设备的研究、开发与销售，计算机软硬件、系统集成领域内的\n技术开发、技术服务，网页设计，网络工程设计与维护，玩具、文教用品、\n电子产品、化妆品的开发、销售，工艺礼品、办公用品、教学模具、健身\n器械、食用农产品销售。（依法须经批准的项目，经相关部门批准后方可\n开展经营活动）"
    ],
    "主营业务及其与发行人主营业务的关系": [
      "上海江村的主营业务是股权投资，与发行人主营业务无关"
    ]
  },
  "58-2.xlsx": {
    "1": [
      "吕松涛",
      24300.0,
      "90.0000%"
    ],
    "2": [
      "张晓霞",
      1080.0,
      "4.0000%"
    ],
    "3": [
      "赵纯梅",
      810.0,
      "3.0000%"
    ],
    "4": [
      "樊祥林",
      810.0,
      "3.0000%"
    ],
    "合计": [
      "",
      27000.0,
      "100.0000%"
    ]
  },
  "58-3_59-1.xlsx": {
    "统一社会信用代码": [
      "91310000MA1FL1TP95"
    ],
    "执行事务合伙人": [
      "国投（上海）创业投资管理有限公司"
    ],
    "经营场所": [
      "上海市杨浦区控江路1142号23幢4064-31室"
    ],
    "企业类型": [
      "有限合伙企业"
    ],
    "注册资本": [
      "人民币100亿元"
    ],
    "实收资本": [
      "不适用"
    ],
    "成立日期": [
      "2016年3月4日"
    ],
    "经营范围": [
      "创业投资，投资管理，创业投资管理，投资咨询。（依法须经批\n准的项目，经相关部门批准后方可开展经营活动）"
    ],
    "主营业务与发行人主营业务的关系": [
      "国投创业基金的主营业务是股权投资，与发行人主营业务无关"
    ]
  },
  "59-2.xlsx": {
    "1": [
      "国家开发投资集团有限公司",
      "有限合伙人",
      268516.16,
      "26.85%"
    ],
    "2": [
      "宁波梅山保税港区乾平涌顺投资\n管理合伙企业（有限合伙）",
      "有限合伙人",
      193602.96,
      "19.36%"
    ],
    "3": [
      "宁波梅山保税港区珞佳熙明投资\n管理合伙企业（有限合伙）",
      "有限合伙人",
      144375.0,
      "14.44%"
    ],
    "4": [
      "上海科技创业投资（集团）有限公\n司",
      "有限合伙人",
      127864.84,
      "12.79%"
    ],
    "5": [
      "中国人寿保险股份有限公司",
      "有限合伙人",
      102291.87,
      "10.23%"
    ],
    "6": [
      "长江养老保险股份有限公司",
      "有限合伙人",
      77000.0,
      "7.70%"
    ],
    "7": [
      "西藏藏财投资合伙企业（有限合\n伙）",
      "有限合伙人",
      38500.0,
      "3.85%"
    ],
    "8": [
      "中国太平洋人寿保险股份有限公\n司",
      "有限合伙人",
      21455.93,
      "2.15%"
    ],
    "9": [
      "上海双创孵化投资中心（有限合\n伙）",
      "有限合伙人",
      20000.0,
      "2.00%"
    ],
    "10": [
      "国投（上海）创业投资管理有限公\n司",
      "普通合伙人",
      6393.24,
      "0.64%"
    ],
    "合计": [
      "",
      "",
      1000000.0,
      "100.00%"
    ]
  },
  "60-1.xlsx": {
    "统一社会信用代码": [
      "91440400MA55C41R48"
    ],
    "执行事务合伙人": [
      "深圳精创智造企业管理合伙企业（有限合伙）"
    ],
    "经营场所": [
      "珠海市横琴新区宝华路6号105室-71565（集中办公区）"
    ],
    "企业类型": [
      "有限合伙企业"
    ],
    "注册资本": [
      "人民币20100万元"
    ],
    "实收资本": [
      "人民币20000万元"
    ],
    "成立日期": [
      "2020年9月27日"
    ],
    "经营范围": [
      "一般项目：信息咨询服务（不含许可类信息咨询服务）；社会经济\n咨询服务；信息技术咨询服务。（除依法须经批准的项目外，凭营\n业执照依法自主开展经营活动）"
    ],
    "主营业务及其与发行人主营业务的关系": [
      "珠海瑛杰的主营业务是咨询服务，与发行人主营业务无关"
    ]
  },
  "60-2.xlsx": {
    "1": [
      "深圳和谐成长三期科技发展股权\n投资基金合伙企业（有限合伙）",
      "有限合伙人",
      20000.0,
      "99.5025%"
    ],
    "2": [
      "深圳精创智造企业管理合伙企业\n（有限合伙）",
      "普通合伙人",
      100.0,
      "0.4975%"
    ],
    "合计": [
      "",
      "",
      20100.0,
      "100.0000%"
    ]
  },
  "61-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ],
    "1": [
      "",
      "",
      "蒋旦如",
      "",
      "",
      9322.38,
      "",
      "",
      "25.8955%",
      "",
      "",
      9322.38,
      "",
      "",
      "23.3001%",
      ""
    ],
    "2": [
      "",
      "",
      "上海江村",
      "",
      "",
      8872.308,
      "",
      "",
      "24.6453%",
      "",
      "",
      8872.308,
      "",
      "",
      "22.1752%",
      ""
    ],
    "3": [
      "",
      "",
      "国投创业基金",
      "",
      "",
      3740.976,
      "",
      "",
      "10.3916%",
      "",
      "",
      3740.976,
      "",
      "",
      "9.3501%",
      ""
    ],
    "4": [
      "",
      "",
      "杭州哲驰",
      "",
      "",
      3485.376,
      "",
      "",
      "9.6816%",
      "",
      "",
      3485.376,
      "",
      "",
      "8.7113%",
      ""
    ],
    "5": [
      "",
      "",
      "程仲毅",
      "",
      "",
      2931.732,
      "",
      "",
      "8.1437%",
      "",
      "",
      2931.732,
      "",
      "",
      "7.3275%",
      ""
    ],
    "6": [
      "",
      "",
      "珠海瑛杰",
      "",
      "",
      2571.444,
      "",
      "",
      "7.1429%",
      "",
      "",
      2571.444,
      "",
      "",
      "6.4270%",
      ""
    ],
    "7": [
      "",
      "",
      "成都博远",
      "",
      "",
      1414.296,
      "",
      "",
      "3.9286%",
      "",
      "",
      1414.296,
      "",
      "",
      "3.5349%",
      ""
    ],
    "8": [
      "",
      "",
      "苏州隆门六号",
      "",
      "",
      640.044,
      "",
      "",
      "1.7779%",
      "",
      "",
      640.044,
      "",
      "",
      "1.5997%",
      ""
    ],
    "9": [
      "",
      "",
      "达晨创鸿",
      "",
      "",
      617.148,
      "",
      "",
      "1.7143%",
      "",
      "",
      617.148,
      "",
      "",
      "1.5425%",
      ""
    ],
    "10": [
      "",
      "",
      "姜绪荣",
      "",
      "",
      514.296,
      "",
      "",
      "1.4286%",
      "",
      "",
      514.296,
      "",
      "",
      "1.2854%",
      ""
    ],
    "11": [
      "",
      "",
      "福州泰弘",
      "",
      "",
      385.704,
      "",
      "",
      "1.0714%",
      "",
      "",
      385.704,
      "",
      "",
      "0.9640%",
      ""
    ],
    "12": [
      "",
      "",
      "西藏数联",
      "",
      "",
      385.704,
      "",
      "",
      "1.0714%",
      "",
      "",
      385.704,
      "",
      "",
      "0.9640%",
      ""
    ],
    "13": [
      "",
      "",
      "青岛正永",
      "",
      "",
      321.444,
      "",
      "",
      "0.8929%",
      "",
      "",
      321.444,
      "",
      "",
      "0.8034%",
      ""
    ],
    "14": [
      "",
      "",
      "浙江和信",
      "",
      "",
      257.148,
      "",
      "",
      "0.7143%",
      "",
      "",
      257.148,
      "",
      "",
      "0.6427%",
      ""
    ],
    "15": [
      "",
      "",
      "珠海泰弘",
      "",
      "",
      257.148,
      "",
      "",
      "0.7143%",
      "",
      "",
      257.148,
      "",
      "",
      "0.6427%",
      ""
    ],
    "16": [
      "",
      "",
      "财智创赢",
      "",
      "",
      154.296,
      "",
      "",
      "0.4286%",
      "",
      "",
      154.296,
      "",
      "",
      "0.3856%",
      ""
    ],
    "17": [
      "",
      "",
      "海南华昆",
      "",
      "",
      128.556,
      "",
      "",
      "0.3571%",
      "",
      "",
      128.556,
      "",
      "",
      "0.3213%",
      ""
    ],
    "18": [
      "",
      "",
      "本次公开发行股份",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      4010.0,
      "",
      "",
      "10.0225%",
      ""
    ],
    "总计": [
      "",
      "",
      "",
      "",
      "",
      36000.0,
      "",
      "",
      "100.00%",
      "",
      "",
      40010.0,
      "",
      "",
      "100.0000%",
      ""
    ]
  },
  "62-1.xlsx": {
    "1": [
      "蒋旦如",
      93223800.0,
      "25.8955%"
    ],
    "2": [
      "上海江村",
      88723080.0,
      "24.6453%"
    ],
    "3": [
      "国投创业基金",
      37409760.0,
      "10.3916%"
    ],
    "4": [
      "杭州哲驰",
      34853760.0,
      "9.6816%"
    ],
    "5": [
      "程仲毅",
      29317320.0,
      "8.1437%"
    ],
    "6": [
      "珠海瑛杰",
      25714440.0,
      "7.1429%"
    ],
    "7": [
      "成都博远",
      14142960.0,
      "3.9286%"
    ],
    "8": [
      "苏州隆门六号",
      6400440.0,
      "1.7779%"
    ],
    "9": [
      "达晨创鸿",
      6171480.0,
      "1.7143%"
    ],
    "10": [
      "姜绪荣",
      5142960.0,
      "1.4286%"
    ],
    "合计": [
      "",
      341100000.0,
      "94.7500%"
    ]
  },
  "62-2.xlsx": {
    "1": [
      "蒋旦如",
      "董事",
      9322.38,
      "25.8955%"
    ],
    "2": [
      "程仲毅",
      "董事、总经理",
      2931.732,
      "8.1437%"
    ],
    "3": [
      "姜绪荣",
      "无",
      514.296,
      "1.4286%"
    ]
  },
  "62-3_63-1.xlsx": {
    "1": [
      "达晨创鸿",
      "1.7143%",
      "达晨创鸿和财智创赢的执行事务合伙人、私募基金管理人均"
    ],
    "序号": [
      "关联股东\n姓名/名称",
      "本次发行前\n持有发行人\n的股份比例",
      "关联关系"
    ],
    "": [
      "珠海泰弘",
      "0.7143%",
      ""
    ],
    "2": [
      "福州泰弘",
      "1.0714%",
      "福州泰弘的执行事务合伙人为赣州朝晖投资管理合伙企业\n（有限合伙），珠海泰弘的执行事务合伙人为赣州御晖投资\n管理合伙企业（有限合伙）；赣州朝晖投资管理合伙企业（有\n限合伙）与赣州御晖投资管理合伙企业（有限合伙）的执行\n事务合伙人均为上海合弘景晖股权投资管理有限公司。\nWang Stephen Hui持有上海合弘景晖股权投资管理有限公\n司50%的股权，为控股股东及实际控制人。福州泰弘与珠\n海泰弘具有一致行动关系。"
    ]
  },
  "64-1_65-1.xlsx": {
    "": [
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "估值调整",
      "",
      "",
      "",
      ""
    ]
  },
  "65-2_66-1.xlsx": {
    "1": [
      "蒋旦如",
      1.0,
      "1名自然人"
    ],
    "2": [
      "上海江村",
      4.0,
      "4名自然人"
    ],
    "3": [
      "国投创业基金",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "4": [
      "杭州哲驰",
      3.0,
      "公司持股平台，合伙人为33名自然\n人（除蒋旦如外均为公司员工）及1\n家有限责任公司（穿透后股东为1名\n自然人）"
    ],
    "5": [
      "程仲毅",
      1.0,
      "1名自然人"
    ],
    "6": [
      "珠海瑛杰",
      5.0,
      "1名已完成私募投资基金备案的合伙\n企业按1名股东计算，4名自然人"
    ],
    "7": [
      "成都博远",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "8": [
      "苏州隆门六号",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "9": [
      "达晨创鸿",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "10": [
      "姜绪荣",
      1.0,
      "1名自然人"
    ],
    "序号": [
      "股东名称",
      "穿透计算股东数（名）",
      "穿透后主体情况"
    ],
    "11": [
      "福州泰弘",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "12": [
      "西藏数联",
      2.0,
      "2名自然人"
    ],
    "13": [
      "青岛正永",
      5.0,
      "5名自然人"
    ],
    "14": [
      "珠海泰弘",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "15": [
      "浙江和信",
      3.0,
      "3名自然人"
    ],
    "16": [
      "财智创赢",
      1.0,
      "已完成私募投资基金备案，按1名股\n东计算"
    ],
    "17": [
      "海南华昆",
      2.0,
      "2名自然人"
    ],
    "合计": [
      "",
      34.0,
      ""
    ]
  },
  "66-2.xlsx": {
    "": [
      "廖冠民",
      "",
      "",
      "独立董事",
      "",
      "",
      "2022.08.28-2023.12.24",
      "",
      "",
      "董事会"
    ]
  },
  "68-1.xlsx": {
    "": [
      "施苏君",
      "",
      "",
      "职工代表监事",
      "",
      "",
      "2020.12.25-2023.12.24",
      "",
      "",
      "职工代表"
    ]
  },
  "69-1.xlsx": {
    "": [
      "",
      "",
      "",
      "董事会秘书",
      "",
      "2021.03.26-2023.12.24",
      ""
    ]
  },
  "70-1.xlsx": {
    "": [
      "高翔",
      "",
      "",
      "研发总监"
    ]
  },
  "70-2_71-1_72-1.xlsx": {
    "": [
      "高翔",
      "",
      "",
      "研发总监",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      "",
      ""
    ]
  },
  "73-1.xlsx": {
    "2020.01.01- 2020.03.19": [
      "Yingming Zhao、吕松涛、金洪\n元、丁健",
      ""
    ],
    "2020.03.20- 2020.10.19": [
      "Yingming Zhao、吕松涛、万津",
      "股东会选举蒋旦如提名的Yingming \nZhao、上海江村提名的吕松涛、国投创\n业基金提名的万津担任景杰有限董事"
    ],
    "2020.10.20- 2020.12.22": [
      "Yingming Zhao、程仲毅、吕松\n涛、万津、庞紫璇、缪伟",
      "股东会选举蒋旦如提名的Yingming \nZhao、程仲毅、缪伟，选举上海江村提\n名的吕松涛，选举国投创业基金提名的\n万津，选举珠海瑛杰提名的庞紫璇担任\n景杰有限董事"
    ],
    "2020.12.23- 2021.04.15": [
      "Yingming Zhao、程仲毅、吕松\n涛、万津、庞紫璇、Wang \nStephen Hui、Hongtao Yu、郭\n坤坤、江苏",
      "创立大会暨第一次股东大会选举董事和\n独立董事"
    ],
    "2021.04.16- 2022.04.29": [
      "Yingming Zhao、程仲毅、蒋旦\n如、吕松涛、万津、庞紫璇、\nHongtao Yu、郭坤坤、江苏",
      "Wang Stephen Hui因个人发展原因辞去\n董事职务，公司2020年年度股东大会选\n举蒋旦如为董事"
    ],
    "2022.04.30-2022.8.27": [
      "Yingming Zhao、程仲毅、吕松\n涛、万津、庞紫璇、蒋旦如、\nHongtao Yu、郭坤坤、王艳侠",
      "独立董事江苏因个人原因辞去独立董事\n职位，2021年度股东大会选举王艳侠担\n任发行人独立董事"
    ],
    "2022.8.28至今": [
      "Yingming Zhao、程仲毅、吕\n松涛、万津、庞紫璇、蒋旦如、\nHongtao Yu、郭坤坤、廖冠民",
      "独立董事王艳侠因个人原因辞去独立董\n事职位，2022年第三次临时股东大会选\n举廖冠民担任发行人独立董事"
    ]
  },
  "73-2_74-1.xlsx": {
    "2020.01.01- 2020.03.19": [
      "赵纯梅、赵雷杰、贺铁明",
      ""
    ],
    "2020.03.20- 2020.12.22": [
      "赵纯梅、龚淑英、朱俊",
      "股东会选举赵纯梅、龚淑英担任景杰有限\n监事，职工代表大会选举朱俊为职工代表\n监事"
    ],
    "日期": [
      "监事会成员变化情况",
      "具体情况"
    ],
    "2020.12.23至今": [
      "朱俊、吕锐、施苏君",
      "创立大会暨第一次股东大会选举朱俊、吕\n锐为股东代表监事； \n职工代表大会选举施苏君为职工代表监事"
    ]
  },
  "74-2.xlsx": {
    "": [
      "谢俊",
      "财务总监、董事\n会秘书",
      ""
    ],
    "2020.01.01- 2020.12.22": [
      "程仲毅",
      "经理",
      ""
    ],
    "2020.12.23- 2020.12.24": [
      "程仲毅",
      "总经理、董事会\n秘书",
      "公司第一届董事会第一次\n会议聘任"
    ],
    "2020.12.25- 2021.03.25": [
      "程仲毅",
      "总经理",
      "程仲毅因职位调整不再担\n任董事会秘书，公司第一届\n董事会第二次会议聘任杨\n利所为董事会秘书"
    ],
    "2021.03.26- 2022.01.06": [
      "程仲毅",
      "总经理",
      "杨利所因个人发展原因辞\n去董事会秘书职务，公司第\n一届董事会第三次会议聘\n任谢俊为董事会秘书"
    ],
    "2022.01.07- 2022.03.17": [
      "程仲毅",
      "总经理",
      "栾巍因个人原因辞去副总\n经理职务"
    ],
    "2022.03.18至今": [
      "程仲毅",
      "总经理",
      "潘红阳因个人原因辞去副\n总经理职务"
    ]
  },
  "74-3.xlsx": {
    "2020.01.01": [
      "高翔",
      "未发生变动"
    ]
  },
  "75-1.xlsx": {
    "程仲毅": [
      "董事、总经理",
      2931.732,
      "8.1437%",
      "直接"
    ],
    "蒋旦如": [
      "董事",
      9322.38,
      "25.8955%",
      "直接"
    ],
    "合计": [
      "",
      12254.112,
      "34.0392%",
      ""
    ]
  },
  "75-2_76-1.xlsx": {
    "Yingming Zhao": [
      "董事长",
      "通过杭州承鼎间接持股0.0968%（杭州承鼎持有杭州哲驰1%股权）"
    ],
    "程仲毅": [
      "董事、总\n经理",
      "通过杭州哲驰间接持股4.4650%（持有杭州哲驰46.1186%股份）"
    ],
    "蒋旦如": [
      "董事",
      "通过杭州哲驰间接持股3.6010%（持有杭州哲驰37.1944%股份）"
    ],
    "吕松涛": [
      "董事",
      "通过上海江村间接持股22.1808%（持有上海江村90.0000%股份）"
    ],
    "朱俊": [
      "监事",
      "通过杭州哲驰间接持股0.0723%（持有杭州哲驰0.7470%股份）"
    ],
    "施苏君": [
      "监事",
      "通过杭州哲驰间接持股0.0268%（持有杭州哲驰0.2767%股份）"
    ],
    "姓名": [
      "职务",
      "间接持有公司股份比例及持股方式"
    ],
    "谢俊": [
      "财务总\n监、董事\n会秘书",
      "通过杭州哲驰间接持股0.2678%（持有杭州哲驰2.7667%股份）"
    ],
    "高翔": [
      "其他核心 \n人员",
      "通过杭州哲驰间接持股0.0714%（持有杭州哲驰0.7378%股份）"
    ]
  },
  "76-2_77-1.xlsx": {
    "Yingming Zhao": [
      "杭州承鼎企业管理有限公司",
      10.0,
      "100.00%"
    ],
    "": [
      "上海睿纳基因科技有限公司",
      100.0,
      "100.00%"
    ],
    "吕松涛": [
      "上海顾隐脉磨瑞生命科技有限公司",
      10.0,
      "83.00%"
    ],
    "姓名": [
      "对外投资企业名称",
      "注册资本",
      "直接持股比例"
    ],
    "万津": [
      "北京元昇咨询管理有限公司",
      100.0,
      "99.00%"
    ],
    "Hongtao Yu": [
      "西湖制药（杭州）有限公司",
      1000.0,
      "25.20%"
    ]
  },
  "78-1.xlsx": {
    "1": [
      "Yingming Zhao",
      "董事长",
      13.09,
      38.02,
      "否",
      "公司董事长Yingming \nZhao先生未与公司签\n订劳动合同，领取的\n薪酬系劳务报酬"
    ],
    "2": [
      "程仲毅",
      "董事、总经理",
      25.28,
      54.2,
      "否",
      ""
    ],
    "3": [
      "蒋旦如",
      "董事",
      "",
      "",
      "否",
      ""
    ],
    "4": [
      "吕松涛",
      "董事",
      "",
      "",
      "是",
      "担任上海绿谷制药有\n限公司董事长兼总经\n理，并领取薪酬"
    ],
    "5": [
      "万津",
      "董事",
      "",
      "",
      "否",
      ""
    ],
    "6": [
      "庞紫璇",
      "董事",
      "",
      "",
      "否",
      ""
    ],
    "7": [
      "Hongtao Yu",
      "独立董事",
      6.0,
      12.0,
      "否",
      ""
    ],
    "8": [
      "郭坤坤",
      "独立董事",
      6.0,
      12.0,
      "是",
      "担任杭州四时餐饮管\n理有限公司执行董事\n兼总经理，并领取薪\n酬"
    ],
    "9": [
      "廖冠民",
      "独立董事",
      "",
      "",
      "否",
      "2022年8月入职"
    ],
    "10": [
      "朱俊",
      "股东代表监事、 \n监事会主席",
      34.85,
      70.11,
      "否",
      ""
    ],
    "11": [
      "吕锐",
      "监事",
      "",
      "",
      "是",
      "2021年1-3月担任上\n海绿谷制药有限公司\n人力资源副总监，并\n领取薪酬"
    ],
    "12": [
      "施苏君",
      "职工代表监事",
      24.14,
      34.19,
      "否",
      ""
    ],
    "13": [
      "谢俊",
      "财务总监、董事\n会秘书",
      73.14,
      116.72,
      "否",
      ""
    ],
    "14": [
      "高翔",
      "研发总监",
      27.34,
      52.73,
      "否",
      ""
    ],
    "合计": [
      "",
      "",
      209.84,
      389.96,
      "",
      ""
    ]
  },
  "79-1.xlsx": {
    "薪酬总额": [
      209.284,
      389.96,
      428.45,
      192.62
    ],
    "利润总额": [
      1011.93,
      7917.32,
      4840.46,
      2614.73
    ],
    "占比": [
      "20.68%",
      "4.93%",
      "8.85%",
      "7.37%"
    ]
  },
  "80-1_81-1_82-1.xlsx": {
    "1": [
      "杭州承鼎",
      "",
      "普通合伙人",
      1.8,
      "1.0000%"
    ],
    "序号": [
      "合伙人名称",
      "职能",
      "合伙人类别",
      "出资额",
      "出资比例"
    ],
    "2": [
      "程仲毅",
      "管理人员",
      "有限合伙人",
      83.0134,
      "46.1186%"
    ],
    "3": [
      "蒋旦如",
      "董事",
      "有限合伙人",
      66.95,
      "37.1944%"
    ],
    "4": [
      "李军民",
      "管理人员",
      "有限合伙人",
      4.98,
      "2.7667%"
    ],
    "5": [
      "谢俊",
      "管理人员",
      "有限合伙人",
      4.98,
      "2.7667%"
    ],
    "6": [
      "顾宏博",
      "研发人员",
      "有限合伙人",
      3.32,
      "1.8444%"
    ],
    "7": [
      "王敏昆",
      "生产人员",
      "有限合伙人",
      1.992,
      "1.1067%"
    ],
    "8": [
      "荆振宇",
      "销售人员",
      "有限合伙人",
      1.66,
      "0.9222%"
    ],
    "9": [
      "陆巧渊",
      "管理人员",
      "有限合伙人",
      1.66,
      "0.9222%"
    ],
    "10": [
      "朱俊",
      "生产人员",
      "有限合伙人",
      1.3446,
      "0.7470%"
    ],
    "11": [
      "高翔",
      "研发人员",
      "有限合伙人",
      1.328,
      "0.7378%"
    ],
    "12": [
      "王云龙",
      "销售人员",
      "有限合伙人",
      1.0956,
      "0.6087%"
    ],
    "13": [
      "戚武林",
      "研发人员",
      "有限合伙人",
      0.5312,
      "0.2951%"
    ],
    "14": [
      "施苏君",
      "管理人员",
      "有限合伙人",
      0.498,
      "0.2767%"
    ],
    "15": [
      "翁叶靖",
      "销售人员",
      "有限合伙人",
      0.4482,
      "0.2490%"
    ],
    "16": [
      "曹玲玲",
      "销售人员",
      "有限合伙人",
      0.4316,
      "0.2398%"
    ],
    "17": [
      "万慧达",
      "研发人员",
      "有限合伙人",
      0.332,
      "0.1844%"
    ],
    "18": [
      "赵佳楠",
      "销售人员",
      "有限合伙人",
      0.332,
      "0.1844%"
    ],
    "19": [
      "马飞",
      "销售人员",
      "有限合伙人",
      0.332,
      "0.1844%"
    ],
    "20": [
      "贺铁明",
      "生产人员",
      "有限合伙人",
      0.3154,
      "0.1752%"
    ],
    "21": [
      "梁猛",
      "研发人员",
      "有限合伙人",
      0.2822,
      "0.1568%"
    ],
    "22": [
      "李晓鸣",
      "管理人员",
      "有限合伙人",
      0.2822,
      "0.1568%"
    ],
    "23": [
      "石润霖",
      "销售人员",
      "有限合伙人",
      0.249,
      "0.1383%"
    ],
    "24": [
      "李治海",
      "销售人员",
      "有限合伙人",
      0.249,
      "0.1383%"
    ],
    "25": [
      "陈庆",
      "研发人员",
      "有限合伙人",
      0.2158,
      "0.1199%"
    ],
    "26": [
      "耿兆明",
      "销售人员",
      "有限合伙人",
      0.1992,
      "0.1107%"
    ],
    "27": [
      "桑元东",
      "研发人员",
      "有限合伙人",
      0.1992,
      "0.1107%"
    ],
    "28": [
      "卓娅",
      "生产人员",
      "有限合伙人",
      0.1826,
      "0.1014%"
    ],
    "29": [
      "沈碧秋",
      "研发人员",
      "有限合伙人",
      0.1826,
      "0.1014%"
    ],
    "30": [
      "殷玉贤",
      "管理人员",
      "有限合伙人",
      0.166,
      "0.0922%"
    ],
    "31": [
      "程大龙",
      "销售人员",
      "有限合伙人",
      0.166,
      "0.0922%"
    ],
    "32": [
      "张晓丽",
      "管理人员",
      "有限合伙人",
      0.1162,
      "0.0646%"
    ],
    "33": [
      "金鑫",
      "研发人员",
      "有限合伙人",
      0.083,
      "0.0461%"
    ],
    "34": [
      "吴佳欢",
      "研发人员",
      "有限合伙人",
      0.083,
      "0.0461%"
    ],
    "合计": [
      "",
      "",
      "",
      180.0,
      "100.0000%"
    ]
  },
  "83-1.xlsx": {
    "": [
      "一类（注3）",
      "二类（注4）",
      "三类（注5）"
    ],
    "第一年": [
      "0%",
      "0%",
      "0%"
    ],
    "第二年": [
      "0%",
      "0%",
      "0%"
    ],
    "第三年": [
      "0%",
      "0%",
      "0%"
    ],
    "第四年": [
      "28%",
      "42%",
      "60%"
    ],
    "第五年": [
      "10%",
      "12%",
      "20%"
    ],
    "第六年": [
      "10%",
      "14%",
      "20%"
    ],
    "第七年": [
      "12%",
      "16%",
      ""
    ],
    "第八年": [
      "12%",
      "16%",
      ""
    ],
    "第九年": [
      "14%",
      "",
      ""
    ],
    "第十年": [
      "14%",
      "",
      ""
    ],
    "合计": [
      "100%",
      "100%",
      "100%"
    ]
  },
  "85-1.xlsx": {
    "2019年": [
      "",
      ""
    ],
    "2020年": [
      389.35,
      "9.42%"
    ],
    "2021年": [
      1291.82,
      "18.95%"
    ],
    "2022年1-6月": [
      137.48,
      "14.55%"
    ]
  },
  "86-1.xlsx": {
    "员工人数": [
      310.0,
      326.0,
      269.0,
      217.0
    ]
  },
  "86-2.xlsx": {
    "1": [
      "研发人员",
      38.0,
      "12.26%"
    ],
    "2": [
      "生产人员",
      95.0,
      "30.65%"
    ],
    "3": [
      "销售人员",
      125.0,
      "40.32%"
    ],
    "4": [
      "管理人员",
      52.0,
      "16.77%"
    ],
    "合 计": [
      "",
      310.0,
      "100%"
    ]
  },
  "86-3.xlsx": {
    "1": [
      "博士",
      27.0,
      "8.71%"
    ],
    "2": [
      "硕士",
      198.0,
      "63.87%"
    ],
    "3": [
      "本科",
      76.0,
      "24.52%"
    ],
    "4": [
      "大专及以下",
      9.0,
      "2.90%"
    ],
    "合计": [
      "",
      310.0,
      "100.00%"
    ]
  },
  "87-1.xlsx": {
    "1": [
      "50岁以上（含50岁）",
      1.0,
      "0.32%"
    ],
    "2": [
      "40-49岁",
      11.0,
      "3.55%"
    ],
    "3": [
      "30-39岁",
      102.0,
      "30.90%"
    ],
    "4": [
      "30岁以下（不含30岁）",
      196.0,
      "63.23%"
    ],
    "合计": [
      "",
      310.0,
      "100.00%"
    ]
  },
  "87-2.xlsx": {
    "发行人境内主体员工总人数": [
      "",
      308.0,
      324.0,
      268.0,
      215.0
    ],
    "基本养老保险": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "": [
      "实际参保比例",
      "95.45%",
      "99.38%",
      "98.51%",
      "99.53%"
    ],
    "基本医疗保险": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "工伤保险": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "失业保险": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "生育保险": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ],
    "住房公积金": [
      "实际参保人数",
      294.0,
      322.0,
      264.0,
      214.0
    ]
  },
  "88-1.xlsx": {
    "": [
      "合计",
      "",
      "",
      14.0
    ]
  },
  "92-1_93-1.xlsx": {
    "蛋白质组分析": [
      "标 记 定\n量 蛋 白\n质 组 分\n析",
      "样本中蛋白质组成\n及其在不同样本中\n含量变化的分析、\n蛋白质相互作用谱\n分析、蛋白质图谱\n分析",
      "利用含稳定同位素的试剂如\nTMT，对来自数个或十余种生物\n样本的蛋白肽段标记，用于分析\n不同样本或分析同一样本在处\n理前后的蛋白质种类含量的变\n化。该方法通量高，一次进样可\n以同时获得十余个样本中蛋白\n质的相关信息，灵敏度较高。缺\n点是需要用到昂贵的标记试剂，\n不大适合大规模的样本分析",
      "科学研究、疾病机\n制与药物作用机理\n研究、生物标志物\n筛选、药物作用靶\n点发现、新药开发\n等"
    ],
    "": [
      "其 他 蛋\n白 质 修\n饰 组 分\n析",
      "主要包括其他非基\n于质谱的蛋白质修\n饰组的定性定量分\n析",
      "通过对特异性蛋白质翻译后修\n饰的肽段进行检测，从而实现\n对目标蛋白修饰位点的鉴定",
      "对目的蛋白修饰位\n点进行验证。广泛\n应用于生物标志物\n的确证、疾病的诊\n断、药物作用靶点\n的确认以及靶向药\n物的药效评估"
    ],
    "大类": [
      "小类",
      "具体服务",
      "服务简介",
      "应用领域"
    ],
    "蛋白质修饰组分析": [
      "标 记 定\n量 蛋 白\n质 修 饰\n组分析",
      "样本中蛋白质修饰\n谱和修饰位点含量\n的变化分析",
      "利用含稳定同位素的试剂如\nTMT 对蛋白肽段标记，对样本\n进行标记，利用各类蛋白质修饰\n泛抗体、修饰类泛抗体富集技术\n和高灵敏度的生物质谱分析技\n术，可对样本中的各类修饰进\n行高深度鉴定和定量分析，如蛋\n白质磷酸化、乙酰化、乳酸化、\n磷酸化、丙二酰化、巴豆酰\n化、2-羟基异丁酰化等修饰",
      "科学研究、疾病机\n制与药物作用机理\n研究、生物标志物\n筛选、药物作用靶\n点发现、新药开发\n等"
    ]
  },
  "95-1.xlsx": {
    "磷酸化": [
      "",
      "调节包括细胞增殖、发育、分化、细胞骨架调控、细胞凋亡、\n神经活动、肌肉收缩、新陈代谢及肿瘤发生等生命活动的过程。\n调节磷酸化状态的激酶抑制剂是抗肿瘤药物开发的重要类型"
    ],
    "泛素化": [
      "",
      "在蛋白质降解、DNA 损伤修复、细胞自噬、胞吞作用、炎症\n反应等众多生物学过程中均发挥重要调控作用。调节泛素化状\n态的泛素连接酶抑制剂是抗肿瘤药物开发的重要类型"
    ],
    "乙酰化": [
      "",
      "参与转录、趋化作用、新陈代谢、细胞信号转导、应激反应、\n白质水解、细胞凋亡以及神经元的发育等多个过程。调节乙酰\n化状态的去乙酰化酶抑制剂是抗肿瘤药物开发的重要类型"
    ],
    "甲基化": [
      "",
      "通常涉及重金属修饰、基因表达的调控、蛋白质功能的调节以\n及核糖核酸（RNA）加工等。调节甲基化状态的去甲基化酶抑\n制剂是抗肿瘤药物开发的重要类型"
    ],
    "糖基化": [
      "",
      "在许多生物过程中起着重要的作用，如免疫保护、病毒的复制、\n细胞生长、细胞与细胞之间的黏附、炎症的产生等。多种疾病\n的药物开发与调节靶蛋白的糖基化状态密切相关"
    ],
    "新型酰化": [
      "",
      "包括蛋白质乳酸化、巴豆酰化、琥珀酰化、3-羟基丁酰化、2-\n羟基异丁酰化等十多种酰化修饰，参与众多生物学过程，如参\n与基因的表达调控、精子发生、DNA 损伤修复、免疫应答、\n肿瘤微环境和代谢应激。蛋白质酰化修饰调控是新药开发尚待\n发掘的巨大宝库"
    ]
  },
  "96-1_97-1.xlsx": {
    "抗体科研试剂": [
      2035.0,
      "表观遗传学",
      "Anti-Tri-methy\nl-Histone H3 \n（Lys23） \nRabbit mAb",
      "针对表观遗传学研究重要功能蛋白\n的检测与分析用抗体，用于表观遗\n传学基础研究"
    ],
    "": [
      "",
      "免疫学",
      "Anti-CD3 \nRabbit mAb",
      "针对免疫学研究中重要功能蛋白的\n检测与分析用抗体，用于免疫学基\n础研究"
    ],
    "抗体类别": [
      "在售产品数\n量（种）",
      "产品系列",
      "代表性产品",
      "产品用途"
    ]
  },
  "97-2.xlsx": {
    "": [
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）",
      "金额",
      "比例\n（%）"
    ],
    "蛋白质组学技术服务": [
      6754.56,
      75.63,
      17137.86,
      77.53,
      14308.07,
      93.22,
      11028.78,
      95.11
    ],
    "蛋白质组分析": [
      3683.44,
      41.24,
      8952.01,
      40.5,
      6459.71,
      42.09,
      5637.92,
      48.62
    ],
    "蛋白质修饰组分析": [
      3071.12,
      34.38,
      8185.85,
      37.03,
      7848.36,
      51.14,
      5390.87,
      46.49
    ],
    "抗体试剂产品": [
      2177.06,
      24.37,
      4966.32,
      22.47,
      1040.18,
      6.78,
      566.52,
      4.89
    ],
    "合计": [
      8931.62,
      100.0,
      22104.18,
      100.0,
      15348.24,
      100.0,
      11595.3,
      100.0
    ]
  },
  "99-1.xlsx": {},
  "99-2.xlsx": {},
  "99-3.xlsx": {},
  "99-4.xlsx": {},
  "99-5.xlsx": {},
  "99-6.xlsx": {}
}